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VABSTRACT
Interleukin-5 (IL-5) has gained increasing medical importance in 
recent years as the role of eosinophils in both chronic bronchial 
inflamm ation and the pathological damage characteristic of asthma has 
emerged. The function of IL-5 in humans is largley restricted to activity on 
the eosinophil lineage of granulocytes where it acts as the predom inant 
eosinophilopoietic  cytokine. Thus understand ing  the m echanism s 
controlling expression of this cytokine could have significant medical 
applications, particularly in the control of chronic asthma.
The aim of this thesis was to initiate the molecular characterisation of 
mIL-5 regulation. The mIL-5 gene was chosen because the only available 
tissue culture cell lines expressing IL-5 were derived from mice. Previous 
work in this laboratory had shown that the mIL-5 gene is transcriptionally 
regulated. The first objective was to identify functionally im portant 
region(s) of the m ouse IL-5 gene which harboured the main cis-ac ting  
control elements for cell type-specific induction of transcription. To this end 
the rem aining ~3.4 kb of the original 10 kb mIL-5 genomic X clone was 
sequenced and the extended sequence was searched by com puter for 
consensus DNA binding sites of characterised mammalian transcription 
factors and some of in terest w ere located. N onetheless com puter 
identification of consensus sites did not mean the sites would be active or 
important. This could only be established by functional analysis. Reporter 
genes were used as indicators of expression initiated from cloned mIL-5 
genom ic sequences. Plasm id constructs containing mIL-5 genomic 
sequences linked to reporter gene coding sequences were introduced into 
tissue culture cell lines which exhibited regulated expression of the 
endogenous mIL-5 gene. The initial assay procedure involved transient 
transfection of supercoiled plasmid DNA. The first mIL-5 reporter construct 
to be screened contained 547 bp of 5' flanking sequence. However, only 
constitutive expression was detected w ith this am ount of 5’ flanking 
sequence and so a construct containing the extended 5’ mIL-5 flanking 
sequence was prepared. This large construct, carrying 3859 bp of 5’ mIL-5 
sequence, was assayed by transient transfections in three different mIL-5 
producing  cell lines bu t show ed no sign of expression in either
VI
unstim ulated  or stim ulated cells. Loss of the constitutive expression 
observed for the -547 bp construct indicated that the -3859 bp construct may 
contain a silencer element between -547 and -3859.
In contrast to the transient transfection results, inducible expression 
was obtained when these same constructs were incorporated into the 
chromatin of a mouse Th 2 T cell clone and a mouse T cell line using stable 
transfection assays. Truncations of the -3859 bp reporter construct showed 
that constructs carrying at least 1016 bp of mIL-5 5’ flanking sequence 
retained comparable inducibility in the chromatin environment. Internal 
deletions and m utagenesis led to a more detailed characterisation of 
im portant cis-acting sequences. Inducible enhancer activity was found in 
the region -965 to -1016 with no clear cut-off in activity between truncation 
constructs in this region. One of the im portant motifs identified more 
exactly was a CTF/NFI site (-928 to -940) which is located in the extended 5' 
flanking sequence. The CTF/NFI site was shown to act as a silencer element 
which was an activity not previously  a ttribu ted  to this family of 
transcription factors and a possible mechanism for this novel action is 
discussed. A second site identified was a consensus site previously 
recognised as common to IL-5 and GM-CSF (-40 to -54) when the original 
sequence of the mIL-5 gene was determined. Mutation of the IL-5/GM-CSF 
conserved region abolished expression of the reporter construct.
Although further work is required to identify the exact sequences 
constituting the mIL-5 enhancer and the proteins which m ediate the 
activities at the CTF/N FI site and the IL-5/GM-CSF conserved region, a 
definite pattern for the arrangem ent of the mIL-5 ds-acting  regulatory  
sequences has emerged. There is a distal region in the mIL-5 gene which 
contains enhancer activity with a nearby silencer, and a proximal element 
which mediates the distal activities. This thesis also describes a method for 
the stable transfection of T cell clones which provides the best physiological 
model for the in vitro study of cytokine gene regulation.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Introduction
Most cells of a multicellular organism contain the same complement 
of genes and yet are capable of selectively expressing different genes or sets of 
genes. The mechanisms allowing this differential gene expression from one 
cell type to another are not completely clear. The packaging of genomic 
DNA is one obvious level at which gene expression could be regulated [for 
review see Goodbourn 1990]. If a gene is packaged into a highly condensed 
form, as in heterochrom atin, then access of the transcriptional apparatus 
will be prevented and the gene will remain silent throughout the life of that 
cell. On the other hand, a gene packaged into a more open chromatin 
dom ain (euchromatin) would be accessible to trans-acting transcription 
factors and may be transcribed.
Inducible gene expression requires more complicated regulation than 
just accessibility of a gene for transcription. Inducible transcription is 
m odulated by additional trans-acting factors that are not part of the basic 
transcriptional apparatus [for review see Maniatis et al. 1987]. Such factors 
m ay function by recru iting  com ponents of the basic transcriptional 
apparatus in order to enhance transcription, or by interfering with assembly 
of the basic transcriptional apparatus, and thus inhibit transcription. The 
involvem ent of these add itional trans-acting factors in inducible 
transcription provides another level at which tissue-specific gene expression 
may be regulated. For instance the activities of trans-acting factors 
themselves may be regulated. This may involve controlling their expression 
in a cell type-specific m anner; changing their DNA binding capacity by 
covalent modification of either the trans-acting factor itself or the DNA to 
which it binds; or by various protein-protein interactions which directly 
affect the functioning of trans-acting factors.
In principle, eukaryotic gene expression may be regulated at a number 
of levels including initiation, extension and term ination of transcription; 
processing of the prim ary transcript such as 5' capping, splicing of introns
3and polyadenylation; mRNA degradation; translocation of mRNA from the 
nucleus; various controls of translation; post-translational modifications; 
and ultimately protein degradation. Nonetheless, initiation of transcription 
is a major point of control for regulation of tissue-specific inducible genes 
and the response of T lymphocytes to activation is an im portant example 
and increasingly studied model of this process.
T lymphocytes coordinate the cellular immune response. Resting T 
lymphocytes are activated when their T cell receptor encounters foreign 
antigen presented in association with self-histocompatibility molecules on 
the surface of specialised antigen-presenting cells [Unanue and Allen 1987]. 
This specific activation via the T cell receptor in conjunction with other cell 
surface receptors leads to second messenger cytoplasmic activity which in 
turn ultim ately affects transcription of particular sets of genes in the T 
lym phocyte nucleus [Weiss et al. 1986]. The im m unoregulatory effector 
m olecules know n collectively as cytokines are a major class of genes 
switched on by this signalling event.
Cytokine gene expression is highly regulated. Tight control over the 
timing and cell type capable of expressing each cytokine is essential for each 
to perform their correct physiological function [Taniguchi 1988]. Aberrant 
expression of cytokines may lead to pathological consequences ranging from 
leukemia to hypersensitivity disease. Thus the cytokines are an important 
model system for the study of tissue-specific inducible gene expression.
IL-5 is one of the cytokines expressed by T lymphocytes and was 
originally identified through its activity on m urine B-cells. Subsequently 
IL-5 was identified as eosinophil differentiation factor and its central role in 
the regu lation  of eosinophils in hum ans and other m am m als was 
established. U nderstanding the regulation of this inducible cytokine may 
ultimately be valuable in treating certain pathological conditions in humans 
involving eosinophilia (for example, asthma). The field of investigation 
into transcriptional regulation of cytokine genes was just beginning at the
4commencement of this project and no publications were available relating 
to functional or m echanistic aspects of interleukin-5 transcrip tional 
regulation. Some work had been done on related cytokines such as 
interleukin-2, interleukin-3 and GM-CSF and the strategies employed are 
reviewed. Relevant literature published subsequently is addressed in the 
discussion sections of each chapter and in the final chapter.
1.2 IL-5 as a Member of the Cytokine Family
Cytokines are a group of highly potent soluble polypeptides produced 
by cells for the purpose of intercellular communication. In the immune 
system, cytokines communicate messages to various cells through their 
interaction with specific cell surface receptors and as a group are responsible 
for coordinating the multiple functions of a cellular immune reaction.
Cytokines of the immune system are generally classified on the basis 
of the cell type in which they are produced. For example, lymphokines are 
produced by lym phocytes and monokines are produced by monocytes. 
In terleukin-5  (IL-5, eosinophil d ifferen tia tion  factor) was initially- 
characterised as a lymphokine produced by T lymphocytes [Sanderson et al. 
1985]. More recently other immune cell types have been reported to produce 
IL-5. Hum an IL-5 has been detected in eosinophils in the intestinal mucosa 
of patients w ith coeliac disease [Desreumaux et al. 1992] and in Reed- 
Sternberg cells of Hodgkins disease [Samoszuk and Nansen 1990; Samoszuk 
1992]; while m urine IL-5 has been detected in mast cells [Plaut et al. 1989]. 
Nonetheless, T lymphocytes are still believed to be the predom inant source 
of IL-5 in vivo.
The identification and characterisation of IL-5 came from two 
convergent lines of research in mouse studies of T cell factors regulating B 
cells and of T cell factors regulating eosinophils. The term interleukin-5 was 
first proposed in 1986 when the m urine cDNA was cloned and sequenced 
from a m urine T cell clone [Kinashi et al. 1986]. The protein expressed from
this cDNA exhibited both T-cell replacing factor (TRF) activity and B-cell 
growth factor II (BCGF-II) activity. In the same year the human IL-5 cDNA 
was also isolated using the murine cDNA as a probe. This demonstrated 
that the two genes shared significant homology between these two species 
[Azuma et al. 1986].
Subsequently, this laboratory cloned, sequenced and expressed genes 
for human [Campbell et al. 1987] and murine [Campbell et al. 1988] 
eosinophil differentiation factor (EDF) and confirmed the suspected identity 
between EDF and BCGF-II (IL-5) [Sanderson et al 1985 and 1986].
1.3 Biological Activities of IL-5
The brief outline of the history of discovery of IL-5 illustrates the 
diverse nature of its biological activity. Pleiotropic activities are common 
for cytokines of the immune system [for review see Arai et al. 1990].
Human IL-5 (hIL-5) is mainly active on eosinophils, while murine IL- 
5 (mIL-5) is active on B-cells as well as eosinophils. In addition there are a 
few reports attributing other activities to IL-5. These include mIL-5 as a 
killer-helper factor (KHF) inducing thymocytes to differentiate into cytotoxic 
T lymphocytes [Takatsu et al. 1987] and a similar activity has been described 
for hIL-5 [Nagasawa et al. 1991]. hIL-5 also has basophil differentiation factor 
activity [Denburg et al. 1991; Denburg, 1992] and basophil activating factor 
activity [Hirai et al. 1990; Bischoff et al. 1990].
1.3.1 IL-5 activity on B-cells
The general features of murine IL-5 activity on B-cells may be 
summarised under three main categories:
I. Murine IL-5, previously known as B-cell growth factor II (BCGF-II), 
has growth promoting activity in vivo on Ly-1+ (CD5) B-cells. Two mouse
6models have provided experimental evidence for this activity. In one, 
lethally irradiated mice received bone marrow cells infected with a 
recombinant retrovirus bearing the IL-5 coding sequence. The only B-cell 
population to increase in these mice was the Ly-1 + B-cell lineage in the 
peritoneum, which increased by at least 10-fold [Vaux et al. 1990]. In the 
other model, transgenic mice expressing mIL-5 under the control of a mouse 
metallothionein promoter had elevated serum levels of mIL-5 and a distinct 
increase in the Ly-1+ B-cell population in the spleen [Tominaga et al. 1991].
Murine IL-5 also shows in vitro BCGF-II activity on the mouse B 
lymphoma cell line BCLi and on normal mouse spleen B-cells stimulated 
with dextran sulphate [Kinashi et al. 1986].
IL Murine IL-5 was also identified as T-cell replacing factor (TRF) . TRF 
induces IgM secretion by the BCLi tumour line and secondary induction of 
anti-dinitrophenol (DNP) IgG synthesis by DNP-primed B-cells [Kinashi et 
al. 1986]. Further evidence for IgM inducing activity was shown by 
M atsum oto et al. [1987], where normal B-cells stimulated with 
lipopolysaccharide (LPS) plus TRF showed an increase in p-chain mRNA 
production. Evidence for in vivo IgM enhancing activity of mIL-5 has been 
reported in IL-5 transgenic mice [Tominaga et al. 1991].
Murine IL-5 also induces IL-2 receptor expression on resting mouse B- 
cells, activated B-cells, antigen-stimulated thymocytes and T cells [Harada et 
al. 1987; Noma et al. 1987; Nakanishi et al. 1988]. Later reports showed that 
mIL-5 induces independent expression of the IL-2 receptor 55 kd a-chain in 
murine splenic B-cells [Loughnan et al. 1987 and 1988]. Further work 
showed IL-4 complemented the IL-5 activity by inducing expression of the 
IL-2 receptor 75 kd ß-chain, thus forming the high affinity IL-2 receptor on B- 
cells from spleens of Balb/c nu/nu mice [Loughnan and Nossal 1989].
IL-2 receptor inducing activity for hIL-5 on T- and B-cells has not been 
as widely reported. However a recent report has claimed hIL-5 can induce
high-affinity IL-2 receptor production by IL-2 stimulated hum an peripheral 
T-cells [Hara et al. 1991].
IK. IgA-enhancing factor activity has been attributed to mIL-5 [e.g., 
M urray et al. 1987; Coffman et al. 1987; Harriman et al. 1988; Eckmann et al. 
1992]. This activity is believed to reflect an increase in synthesis of IgA by 
cells already committed to IgA production rather than a class switching 
activity [M atsum oto et al. 1989]. Further, evidence for IgA-enhancing 
activity in  v ivo  was obtained in IL-5 transgenic mice [Tominaga et al. 1991].
Although activity of hIL-5 on hum an B-cells was reported in early 
studies [Azuma et al. 1986; Yokota et al. 1987], this activity rem ains 
controversial [Clutterbuck et al. 1987; Sanderson et al. 1988; McKenzie and 
Sanderson 1992]. Recent autoradiographic studies w ith radiolabelled 
recombinant hIL-5 (rhIL-5) detected receptors on hum an eosinophils but not 
on neutrophils, lymphocytes or a B cell line [Ingley and Young 1991].
1.3.2 IL-5 activity on eosinophils
Eosinophils are antibody-dependent cytotoxic granulocytes derived 
from bone marrow and perform an im portant physiological role in various 
pathological conditions. The selective expansion of the eosinophil 
population, known as eosinophilia, has long been associated with parasitic 
and allergic diseases [Gleich and Adolphson 1986]. The involvement of T- 
cell derived factors in the mechanism of eosinophilia was known from as 
early as 1970 [Basten and Beeson 1970]. A number of cytokines have since 
been cloned from T-cells, including IL-3, GM-CSF and IL-5 which all exhibit 
activity on eosinophils. H ow ever, IL-5 is the m ost specific for the 
eosinophilic lineage. To date the essential features of IL-5 activity on 
eosinophils may be summarised as follows:
I. M urine IL-5 [Sanderson et al. 1985; Campbell et al. 1988] and hIL-5 
[Cam pbell et al. 1987; C lutterbuck e t al. 1989] selectively induce the
production of and m aintenance of eosinophils in bone m arrow cultures. 
This is in contrast to IL-3 and GM-CSF which induce other cells in addition 
to eosinophils, notably neutrophils and macrophages.
IL Both hIL-5 [Clutterbuck et al. 1990] and mIL-5 [Yamaguchi et al. 1988a] 
function as late acting factors in the eosinophil differentiation pathw ay in 
vitro . However, at least three different experimental approaches have 
shown mIL-5 alone is sufficient for inducing eosinophilia in vivo:
i) Antibody to m urine IL-5 inhibited blood eosinophilia in parasitised 
mice [Coffman et al. 1989; Sher et al. 1990; Rennick et al. 1990; Korenaga et al. 
1991].
ii) The two different methods applied to produce mice with abnormally 
high levels of IL-5 expression have supported the view that IL-5 plays a 
major role in the development of eosinophilia. The IL-5 producing bone- 
m arrow  replacement m ethod (described above) [Vaux et al. 1990] and IL-5 
transgenic mice [Dent et al. 1990; Tominaga et al. 1991] each attain high 
serum  levels of IL-5 resulting in eosinophilia w ith no effect on other 
granulocytes. Conversely, analogous experiments with IL-3 [Chang et al. 
1989] result in mice with a greater increase in neutrophils than eosinophils, 
or with GM-CSF [Johnson et al. 1989; Metcalf and Moore 1988; Lang et al. 
1987] result in greater increases in neutrophils and m acrophages than 
eosinophils. Results from mice with high levels of IL-5 indicate the IL-5 
m ediated production of eosinophils in vivo is not necessarily limited by the 
num bers of comm itted eosinophil precursors as in vitro studies suggest 
[Clutterbuck and Sanderson 1990]. It has been suggested that in vitro culture 
c o n d itio n s  do n o t a ccu ra te ly  re p ro d u c e  the  bone m arrow  
m icroenvironm ent w here eosinophil p recurso r popu lations m ay be 
m aintained by cell-cell interactions in addition to cytokines [Sanderson 
1992b].
iii) A ntibody to m urine IL-5 receptor inhibits eosinophilia in IL-5
transgenic mice [Hitoshi et al. 1991].
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IK. In addition to eosinophil differentiation and maintenance, IL-5 is 
capable of activating eosinophils in a num ber of in vitro assays. 
Recom binant hum an IL-5 caused m orphological changes in norm al 
peripheral blood eosinophils such as cellular elongation, membrane ruffling 
and concentration of granules towards one end of the activated eosinophils. 
A num ber of eosinophil effector functions were also selectively stimulated 
by rhIL-5. These included killing of antibody-coated tum our cells, 
phagocytosing serum-opsonised baker's yeast and production of superoxide 
anion [Lopez et al. 1988].
Both hum an [Wang et a l 1989; Sehmi et al. 1992] and m urine 
[Yamaguchi et al. 1988b] IL-5 have been reported to have eosinophil 
chemotactic activity in in vitro assays. Evidence for eosinophil chemotactic 
activity for IL-5 in vivo is not as clear. Perhaps some insight is provided by 
the different tissue distribution of eosinophils in the two IL-5 transgenic 
mice models reported to date. Each model utilises a different IL-5 DNA 
construct to generate transgenic mice. In one a 10 kb mIL-5 genomic 
fragment was ligated to the hum an CD2 dominant control region restricting 
transgene expression to all T-cells [Dent et al. 1990]. The other IL-5 
transgenic construct had the mouse metallothionein prom oter controlling 
expression of a mIL-5 cDNA, resulting in more diverse tissue expression of 
the IL-5 transgene [Tominaga et al. 1991]. While both groups of mice 
exhibited splenomegaly and high eosinophil num bers in bone marrow and 
peripheral blood eosinophilia, there were some differences in eosinophil 
localisation. The CD2-IL-5 transgenic mice had no eosinophil infiltration in 
the liver or skeletal muscle whereas the metallothionein-IL-5 transgenic 
mice did, perhaps reflecting the ectopic production of IL-5 in the latter 
animals. A possible mechanism for IL-5 m ediated eosinophil localisation is 
upregulation of adhesion molecules [Lopez et al. 1986]. Walsh et al. [1990] 
have shown the IL-5 induced increase in expression of the integrin C D llb  
increases adhesion of eosinophils to endothelial cells.
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Hum an recombinant IL-5 enhances IgA and IgG induced eosinophil 
degranulation as m easured by release of eosinophil-derived neurotoxin 
[Fujisawa et al. 1990] and also by release of eosinophil cationic protein, 
eosinophil peroxidase and major basic protein [Kita et al. 1992]. It is 
interesting to compare this activity with the IgA-enhancing activity of mIL-5 
on m urine B-cells. Murine IL-5 may perform a coordinating role between 
the hum oral and cell-m ediated im m une responses on mucosal surfaces 
where IgA is the most abundant immunoglobulin.
Having considered the in vitro eosinophil activating properties of 
IL-5, it seems curious that mice w ith artificially induced constitutive 
expression of IL-5 [Vaux et al. 1990; Dent et al. 1990] endure long term or 
lifelong eosinophilia but do not appear to show ill effects from these 
potentially cytotoxic cells. In contrast, mice with artificially high titres of 
GM-CSF [Lang et al. 1987] or IL-3 [Chang et al. 1989] die from serious 
pathological disorders resulting from substantial increases in myeloid cell 
numbers. The IL-5 transgenic and bone marrow replacement experiments 
dem onstrate that IL-5 alone is sufficient to induce eosinophilia in vivo, 
although other or additional signals may be required to activate eosinophils 
in vivo [Sanderson 1992b], such as antigen-antibody (IgG, IgA or IgE) 
complexes.
1.4 IL-5, Eosinophils and Pathological Conditions
As already discussed, mice w ith artificially induced constitutive 
expression of IL-5 undergo both eosinophilia and selective expansion of the 
Ly-1 + B-cell lineage [Vaux et al. 1990; Tominaga et al. 1991]. The Ly-1+ 
subpopulation  of B-cells is particularly  notew orthy for production of 
au toantibodies [W etzel 1989] and IL-5 has been show n to increase 
autoantibody production [Herron et al. 1988]. However it seems unlikely 
that these observations have direct relevance for hum ans as hIL-5 appears 
not to act on hum an B-cells [Clutterbuck et al. 1987]. Therefore this section
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gives an overview of disease states where eosinophils, in association with 
IL-5, are involved in the pathological process.
Both hum an  and m urine stud ies link IL-5 expression w ith 
eosinophilia arising from various pathological conditions including some of 
unknown aetiology (e.g., IHES and EMS, see below). Previous mention has 
been m ade of experiments dem onstrating the essential role of mIL-5 in 
parasite induced eosinophilia in mice where anti-mIL-5 antibodies inhibited 
the developm ent of eosinophilia [Coffman et al. 1989; Sher et al. 1990; 
Rennick et al. 1990; Korenaga et al. 1991].
1.4.1 Eosinophils and IL-5 in human helminth infections
Helm inth infections in hum ans are known to elicit an eosinophilia 
[Gleich and Adolphson 1986] and association of IL-5 with the eosinophilic 
response has been reported [Limaye et al. 1990; Mahanty et al. 1992].
1.4.2 Human eosinophilia with concomitant IL-5 expression
In hum ans a wide variety of studies correlate IL-5 expression with 
selective eosinoph ilia . The serum  of p a tien ts  w ith  id iopath ic  
hypereosinophilic syndrom e (IHES) contained an activity capable of 
extending in  v i tr o  viability of eosinophils, augm enting their functional 
properties and converting norm odense eosinophils to the hypodense state 
characteristic of the m ajority of eosinophils from IHES patients. A 
monoclonal antibody against hum an IL-5 distinguished this cytokine from 
IL-3 and GM-CSF as the activity present in the serum  from IHES patients 
[Owen et al. 1989]. Another hum an eosinophilic condition, associated with 
the ingestion of L-tryptophan, is known as eosinophilia-myalgia syndrome 
(EMS). Anti-hIL-5 monoclonal antibody was also used to identify IL-5 as the 
predom inant eosinophilopoietic factor in the serum of EMS patients [Owen 
et al. 1990]. Messenger RNA for IL-5 has been detected in Reed-Sternberg 
cells of H odgkin's disease w ith eosinophilia by Samoszuk and Nanson
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[1990]. Inoue et al. [1990a] investigated IL-5 mRNA expression in a resected 
lym ph node from  a patien t w ith K im ura's disease (angiolym phoid 
hyperplasia with eosinophilia). Northern blot analysis revealed constitutive 
expression of IL-5 mRNA in the lymph node cells.
1.4.3 Eosinophils and IL-5 in tumours
Histological studies of cellular infiltration in resected tum ours from 
cancers such as operable prim ary lung cancers [Kolb and Muller 1979], 
colonic carcinoma [Pretlow et al. 1983], cervical carcinoma [Pastrnak and 
Jansa 1984] and gastric carcinoma [Iwasaki et al. 1986] have revealed a 
positive  correlation  betw een eosinophil in filtra tion  and im proved 
prognosis. However Sanderson [1992a] points out that the correlation is not 
absolute because instances of tumour-associated blood eosinophilia without 
tum our infiltration are indicative of a poor prognosis, and further, that the 
presence of eosinophils in a tum our does not prove their involvement in 
tum our rejection.
Recently Baumann et al. [1992] reported a curious effect of rhIL-5 on 
freshly isolated M4Eo blasts from a patien t w ith acute m yelogenous 
leukem ia (AML). After short term  incubation w ith rhIL-5 the cells 
differentiated into m acrophages. In contrast, the response of another 
variant of AML to rhIL-5 was vigorous proliferation.
In a mouse model, Wu et al. [1992] dem onstrated an anti-tum our 
effect for rmIL-4 and rmIL-5 on a transplantable B cell lymphoma. Local 
adm in istra tion  of rmIL-4 or rmIL-5 inh ib ited  tum our grow th  and 
histopathological examination revealed necrotic changes due to infiltration 
of eosinophils, macrophages and lymphocytes.
1.4.4 Eosinophils and IL-5 in graft rejection
Eosinophil infiltration has been reported to be a specific indicator of
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adverse prognosis in renal [Weir et al. 1986; Kormendi and Amend 1988], 
liver [Foster et al. 1989] and lung [Kondo et al. 1991] transplantation. More 
recently Martinez et al. [1992] demonstrated IL-5 expression in biopsies from 
hum an liver allografts show ing histopathological evidence of acute 
rejection. The m odulation of IL-5 gene expression may therefore be of great 
relevance in transplantation biology.
1.4.5 Eosinophils and IL-5 in hypersensitivity diseases
Eosinophils are known to be involved in hypersensitivity diseases 
such as atopic dermatitis, hayfever and asthma. Atopic subjects were studied 
for the cytokine mRNA profile in allergen-induced late-phase cutaneous 
reactions [Kay et a l  1991]. The predom inant cytokines were IL-3, IL-4, IL-5 
and GM-CSF. IL-5 expression was most closely associated with eosinophilic 
infiltration at the site of inflammation. In a recent study of hayfever 
sufferers, Durham  et al. [1992] showed that eosinophil infiltration during 
allergen-provoked rhinitis is associated with an increase in mRNA levels of 
the cytokines, IL-3, IL-4, IL-5 amd GM-CSF. In particular, IL-5 mRNA was 
shown to have the closest association with eosinophil infiltration.
A prom inent feature of the histopathology of asthm a is the 
infiltration of the bronchial m ucosa with eosinophils, m acrophages and 
lymphocytes [Corrigan and Kay 1992]. Cytotoxic products of eosinophil 
degranulation such as major basic protein [Wardlaw et al. 1988], eosinophil 
cationic protein [DeMonchy et al. 1985] and eosinophil peroxidase [Gleich 
1990] have been detected in the airways of asthmatic patients. These findings 
suggest eosinophils are involved in the progressive tissue damage observed 
in the asthmatic lung.
The eosinophilia occuring with bronchial asthma prom pted a search 
for the presence of IL-5 in asthm atic subjects. H am id et al. [1991] 
demonstrated IL-5 mRNA in cells located beneath the bronchial epithelium 
basement membrane of asthmatic subjects by in s i tu  hybridisation, while no
IL-5 was detected in nonatopic norm al controls. Walker et al. [1991] 
identified IL-5 and GM-CSF, using neutralising antibodies, in the sera of 
allergic and nonallergic asthmatics and Robinson et al. [1992] have shown 
that the mRNAs for IL-4 and IL-5 are predom inantly expressed by T 
lymphocytes from bronchoalveolar-lavage (BAL) fluid of atopic asthmatics.
Walker et al. [1992] have reported a difference in the cytokine profile 
of allergic and nonallergic asthma. IL-4 and IL-5 were characteristic of 
allergic asthm a w here elevated IgE levels accom pany eosinophilia, 
consistent with the respective biological activities of each cytokine. In 
contrast, in nonallergic asthma, where IgE levels are not elevated although 
eosinophilia is still characteristic, increased levels of IL-2 and IL-5, but not 
IL-4 are observed. This finding may provide an im portant insight into 
regulation of cytokines in hum an T lymphocytes because it illustrates 
differential regulation. While IL-4 and IL-5 are often expressed together by T 
cell clones (see section 1.5.3), this important example shows that each may be 
expressed independently in vivo.
1.5 Molecular Biology of IL-5
1.5.1 IL-5 protein structure
The cDNA for murine IL-5 codes for a polypeptide of 133 amino acids 
including a 21 amino acid leader sequence [Kinashi et al 1986; Campbell et 
al. 1988]. The hum an IL-5 cDNA encodes 134 amino acids with 22 amino 
acid leader sequence [Azuma et al. 1986; Campbell et al. 1987]. Both the 
m ature mIL-5 (113 amino acids) and m ature hIL-5 (115 amino acids) have a 
predicted molecular weight of ~13kD. Initial empirical molecular weight 
estim ations of biologically active m urine IL-5 were between 45,000 and 
50,000 [Sanderson et al. 1985; Tominaga et al. 1988]. Upon reduction with ß- 
m ercaptoethanol, IL-5 m igrates w ith an apparent m olecular w eight of 
between 25,000 and 30,000 indicating the active form is a dimer [Tominaga et 
al. 1988]. Subsequent investigations showed that two conserved cysteine
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residues were responsible for cross-linking the IL-5 homodimer in an anti­
parallel configuration [Minamitake et al. 1990; Proudfoot et al. 1991; 
McKenzie et al. 1991a]. Mutation of the conserved cysteine residues to 
threonine showed that monomeric mIL-5 is biologically inactive [McKenzie 
et al. 1991a]. The discrepancy between the predicted and empirical molecular 
weight of IL-5 monomers is due to heterogeneous glycosylation. Murine IL- 
5 has three potential N-linked glycosylation sites of which the first and third 
are conserved in human IL-5 [Azuma et al. 1986]. Deglycosylated IL-5 retains 
biological activity [Tominaga et al. 1990; Proudfoot et al 1991].
The primary amino acid sequences of human and murine IL-5 share 
70% homology. Both proteins have equivalent specific activities in human 
HL60 assays [Plaetinck et al. 1990], although hIL-5 is 20 fold more active in 
human bone marrow assays than mIL-5 [Clutterbuck et al. 1987]. Human 
IL-5 cross-species activity is poor, being 50- to 100-fold less active than mIL-5 
in the murine eosinophil differentiation (mEDF) assay and on mouse B-cells 
[Clutterbuck et al. 1987; Plaetinck et al. 1990] and specific activity of purified 
rhIL-5 was high in a human peripheral eosinophil maintenance assay but 
lowT in mouse BCLj and mEDF assays [Ingley et al. 1991].
Two different approaches to structure-function analysis have 
identified 8 amino acids at the C-terminus as being important in conferring 
species specificity on IL-5. One method utilised interspecies hybrids between 
mIL-5 and hIL-5, replacement of the hIL-5 C-terminus with the mIL-5 C- 
terminus resulted in biological activity equivalent to wildtype mIL-5 
[McKenzie et al. 1991b]. Cyanogen bromide (CNBr) treatment of rhIL-5 
removed the eight C-terminus amino acids after methionine at position 107 
and the resulting truncated protein lost IgM-inducing activity on BCLi cells 
despite remaining a dimer [Kodama et al. 1991].
1.5.2 The IL-5 receptor (IL-5R)
Both hIL-5 and mIL-5 high affinity receptors consist of two subunits,
an a  chain and a ß chain. The IL-5R a  chain is only able to bind IL-5 ligand 
with low affinity in mouse but with relatively high affinity in human. 
While both the human and murine IL-5Ra chains also occur in a soluble 
form, the reason for this is not clear, although there may be a role for the 
soluble form in modulating the IL-5 ligand function. The IL-5R ß chain of 
each species is not able to bind IL-5 ligand alone, although when combined 
with the IL-5R a  chain it increases receptor affinity for IL-5 ligand binding. 
This effect is more significant in mouse than in human. The ß chain is also 
responsible for signal transduction from the IL-5 receptor. [For reviews see 
Nicola and Metcalf 1991; Takatsu 1992; Tominaga et al. 1992; Lopez et al. 
1992].
One further point of interest relating to the IL-5 receptor system is the 
discovery that the IL-5R ß chain is identical to the IL-3 receptor and GM-CSF 
receptor ß chains [reviewed by Lopez et al. 1992]. This common receptor 
component explains the cross-competition observed for these cytokines 
when binding to their receptors and may explain the redundancy of 
biological function observed for these three cytokines particularly on the 
eosinophil lineage.
1.5.3 IL-5 gene structure and chromosome location
The cloning and sequencing of the murine IL-5 gene [Campbell et al. 
1988; Mizuta et al 1988] and the human IL-5 gene [Campbell et al. 1987; 
Tanabe et al. 1987] allowed comparison with the respective cDNAs to reveal 
the exon/intron arrangement of each gene. The coding sequence of each 
gene is distributed over 4 exons which are separated by 3 introns each 
beginning with GT and ending with AG. This 4 exon/3 intron arrangement 
is common amongst cytokines including GM-CSF, IL-4, IFN-y and IL-2, 
although IL-3 is different having 5 exons and 4 introns. A comparison of the 
sizes of the murine and human IL-5 exons and introns is shown in table 1.1.
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Table 1.1 Sizes of the exons and introns in the m urine and hum an IL-5 
genes [data from Campbell et al. 1987 and 1988].______
Species exon 1 intron 1 exon 2 intron 2 exon 3 intron 3 exon 4
m ouse 184 bp 829 bp 33 bp 1875 bp 129 bp 79 bp 1188 bp
h u m an 189 bp 208 bp 33 bp 950 bp 129 bp 105 bp 466 bp
The first 3 exons of both genes are virtually identical in size although 
the fourth exon of the m urine gene has an additional 738 bp in the 3' 
un transla ted  region [Campbell et al. 1988]. The first 2 introns are also 
significantly larger in the mIL-5 gene compared to the hIL-5 gene, and this is 
due to additional repeat sequences in the mIL-5 gene [Campbell et al. 1988].
Alignment of the murine and hum an IL-5 genomic sequences shows 
the exons are highly conserved. In addition some homology was found in 
areas of each intron and extending up to approximately -300 from the CAP 
site [Campbell et al. 1988]. Comparison with other cytokine genes did not 
reveal any significant homology except for a short sequence immediately 5' 
of the TATA box. This sequence was highly conserved between murine and 
hum an IL-5 and GM-CSF, and to a lesser extent in hum an G-CSF, mouse 
IL-4 and murine IL-2 [Campbell et al. 1988; Mizuta et al. 1988]. The location 
of this short homologous sequence within the prom oter region of several 
cytokine genes suggested it may have a function in gene regulation. 
Subsequent work has shown this region is protected in DNase I footprinting 
analysis of the hGM-CSF gene [Nimer et al. 1988], and m utagenesis has 
shown this sequence is functionally im portant for transcriptional regulation 
of the hGM-CSF gene [Nimer et al. 1990]. M utagenesis combined with 
functional analysis and gel shift assays has determined the bases critical for 
binding to this site and dem onstrated the binding of two separate, but 
overlapping, proteins in the m urine GM-CSF gene [Miyatake et al. 1991]. 
This conserved site is discussed in more detail in Chapter 4.
The hum an IL-5 gene is found at 5q31 in a cluster with the related
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cytokines IL-3, GM-CSF and IL-4 [Sutherland et al. 1988; van Leeuwen et al. 
1989; Chandrasekharappa et al. 1990]. This cytokine cluster is deleted in 
patients with the 5q- syndrome [Sutherland et al. 1988] and deletion of the 5q 
region is frequently associated with myeloid leukemias [Le Beau et al. 1989]. 
The murine IL-5 gene is also localised close to the IL-3, GM-CSF and IL-4 
genes and the cluster is located on chromosome 11 [Lee et al. 1989; Webb et 
a l  1989].
1.5.4 The relationship between IL-3, GM-CSF, IL-4 and IL-5
Although the peptide and nucleotide primary sequences of IL-3, 
GM-CSF, IL-4 and IL-5 bear little significant homology their common 
features have led to them being classified as a gene family [Sanderson et al. 
1988; Boulay and Paul 1992]. These common features, as mentioned earlier, 
include:
- a redundancy in biological activity on eosinophils for IL-3, GM-CSF and 
IL-5.
- a common receptor component (ß chain) shared between IL-3, GM-CSF and 
IL-5.
- the a  chains of all four are part of the same superfamily of transmembrane 
proteins [Miyajima et al. 1992].
- structural similarities in the exon/intron arrangement and position in the 
genes for GM-CSF, IL-4 and IL-5.
- clustering of all four genes on both the human and mouse chromosomes.
- similarity in the regulation of expression of the genes for GM-CSF, IL-3, 
IL-4 and IL-5.
The last point, relating to similarity in the regulation, will be 
discussed further in the next section. In summary, these similarities have 
led to the postulate that these four genes may be ancestrally related, having 
diverged following ancient gene duplication events [Sanderson et al. 1988].
The IL-2 gene may also be related to the above group of cytokine genes
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even though it is located on a different chromosome (at 4q26-27 in human 
[HGM9, 1987] and 3B or 3C in mouse [Webb et al. 1990]). The IL-2 gene shares 
a similar exon/in tron  arrangement with the GM-CSF, IL-4 and IL-5 genes; 
the IL-2 receptor ß chain is part of the same superfam ily as the above 
m entioned group; IL-2 shows strict T cell-specific expression; and IL-2 
regulation shows some sim ilarities to the above m entioned group of 
cytokines.
1.6 Regulation of Cytokine Gene Expression
As already mentioned, the cytokines IL-2, IL-3, IL-4, GM-CSF and IL-5 
share common features in their regulation. Tight control over the 
appearance and disappearance of each cytokine is essential for each to 
perform  their correct physiological function. The expression of each 
cytokine is restricted to one or a few cell types; all show tightly regulated 
inducibility and a short half life for both the mRNA and cytokine. Up until 
now investigations into the m echanisms controlling cytokine regulation 
have focused primarily on characterising the processes involved in mRNA 
production and turnover. A major goal has been to locate the ds-acting  
DNA elements involved in induction of transcription and to characterise 
the cognate traws-acting factors which are ultim ately responsible for 
establishing a functional transcription complex at the promoter.
1.6.1 Differential expression of cytokines in ThI and Th2 CD4+
helper T cell clones
In mice, cloned CD4+ helper T cells have been classified into two 
subclasses, Th I and Th 2, on the basis of the different lymphokine profiles 
produced by different T cell clones [Mosmann et a l 1986; and reviewed in 
Mosmann and Coffman 1989]. The Th I class secrete IL-2 and y-IFN but not 
IL-4 and IL-5, whereas the Th 2 class secrete IL-4 and IL-5, but not IL-2 and 
y-IFN, and both classes can produce IL-3 and GM-CSF. While many murine 
T cell clones seem to fit into this classification [Cherwinski et al. 1987], not all
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conform [Kelso and Gough 1988; Firestein et al. 1989]. Nonetheless there is 
also some suggestion that the Th 1/T h2 classification may be applicable to 
normal murine T lymphocytes [Swain et al. 1988a and 1988b; Carding et al. 
1989].
A lymphokine secretion pattern has been less clear for human CD4+ 
helper T cell clones [Maggi et al. 1988; Paliard et al. 1988; Salmon et al. 1989]. 
However, many of the human T cell clones derived from allergic 
individuals have lymphokine profiles analogous to the murine Th2 subset 
[Umetsu et al. 1988; Parronchi et al 1991]. More recently Salgame et al. [1991] 
were able to demonstrate distinct human CD4+ T cell subsets based on the 
cytokine profiles of T cell clones derived from individuals responding to the 
infectious pathogen Mycobacterium leprae. The authors suggest that 
previous attempts to demonstrate both Th I and Th 2 subsets in humans 
failed because the T cell clones were not derived from hyperimmunised 
subjects as was the case with the mouse studies. It is also interesting to note, 
from the regulation perspective, that CD8+ suppressor T cell clones (i.e., 
representing the other major class of T lymphocyte) produced significant 
amounts of IL-4 with no IL-5, thus supporting the notion (see below) that 
these two genes are regulated independently [Salgame et al. 1991].
1.6.2 Are IL-3, IL-4, GM-CSF and IL-5 expressed coordinately or
independently in T lymphocytes?
The coordinated expression of IL-3, GM-CSF, IL-4 and IL-5 observed 
upon antigen or mitogen stimulation of the murine Th 2 class of CD4+ 
helper T cell clone [Cherwinski et al. 1987] may indicate common regulatory 
mechanisms for the induction of these cytokines. However, IL-3 and 
GM-CSF can also be expressed independently of IL-4 and IL-5, as in the Th I 
class of CD4+ helper T cell clone, and therefore each pair of cytokines must 
have different mechanisms of induction. There is further evidence 
suggesting IL-4 and IL-5 can be differentially regulated by lymphokines. In 
murine CD4+ helper T cell clones anti-CD3 antibody stimulated production
of GM-CSF, IL-4 and IL-5, whereas IL-2 or IL-4 were able to selectively 
stimulate expression of IL-5 and not IL-4 or GM-CSF [Bohjanen et al. 1990]. 
Further, Yamaguchi et al. [1990] demonstrated that IL-5 was responsible for 
the selective eosinophilia induced after injection of human IL-2 into mice by 
showing that an antibody to mIL-5 blocked the eosinophilia. This may 
explain observations of a similar effect of IL-2 injection in humans 
[Silberstein et al. 1989]. Human T cell clones showing differential regulation 
of IL-4 and IL-5 have also been characterised [Bacchetta et al. 1990] and there 
is in vivo evidence from allergic and nonallergic asthma patients indicating 
that IL-4 and IL-5 can be expressed independently [Walker et al. 1992; see 
section 1.3.6]. Finally, the fact that eosinophilia can occur without increases 
in other leukocytes (see sections 1.3.2 II and 1.4.2) quite clearly suggests that 
IL-5 can be expressed independently.
1.6.3 Cytokine messenger RNA expression in T lymphocytes
Messenger RNA for most cytokine genes is undetectable in T 
lymphocytes unless the cells have been stimulated in an appropriate 
manner. This stimulation is normally provided in vivo by antigen- 
presenting cells [Unanue and Allen 1987; Altman et al. 1990]. For many 
experiments investigating expression of cytokine genes in T cell clones, the 
antigen presenting cell is replaced by mitogenic lectins which act via the T 
cell receptor [Kanellopoulos et al 1985; Schmitt-Verhulst et al. 1987]. Lectins 
such as concanavalin A (Con A) or phytohemagglutinin (PHA), or 
antibodies to T cell receptor, CD3 complex or other cell surface antigens, are 
capable of triggering a second messenger cascade which ultimately leads to 
de novo transcriptional activity in the nucleus [Weiss et al. 1986]. An 
approach commonly used on continuous T cell lines has been to bypass the 
cell surface receptors and to directly stimulate second messengers such as 
protein kinase C [Nishizuka 1986] with the agent phorbol 12-myristate 13- 
acetate (PMA) [Rosenstreich and Mizel 1979] (also called 12-0- 
tetradecanoylphorbol-13-acetate, TPA), often in conjunction with a calcium 
ionophore [Truneh et al. 1985].
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Two m echanism s have been shown to control the transience of 
cytokine m essenger RNA [for review see Tanaguchi 1988]. One is the 
induction of transcription, and the other is posttranscriptional involving 
the rapid  and selective degradation of the cytokine messenger RNA. A 
repeated sequence in the 3' untranslated region (UTR) of the mRNA 
(AUUUA) has been identified as being involved in targeting transcripts for 
degradation [Shaw and Kamen 1986; Caput et al. 1986; W reschner and 
Rechavi 1988]. Although its function was not recognised at the time, this 
element was first identified as a motif present in several cytokine 3' UTRs 
[Campbell et al. 1985]. This regulatory mechanism has been shown for 
m urine GM-CSF [Bickel et al. 1990], hum an GM-CSF [Shaw and Kamen 
1986], murine IL-3 [Wodnar-Filipowicz et al. 1990] and some other cytokines 
and proto-oncogenes [reviewed in Reeves and Magnuson 1990]. The same 
m echanism  has not been dem onstra ted  for mIL-5 a lthough sim ilar 
sequences are present in the 3' UTR of the mIL-5 mRNA. Therefore the 
contribution of posttranscriptional mRNA degradation to regulation of 
mIL-5 levels is not known.
1.6.4 Initiation of transcription by RNA polymerase II
Initiation of transcription requires recognition by RNA polymerase II 
(pol II) of a specific complex at the promoter. One of the first prom oter 
elements to be identified in eukaryotic genes was the TATA box, which is 
generally located 25-30 bp upstream  from the transcription initiation site, 
although it should be noted that not all genes transcribed by pol II contain a 
TATA box. The complicated interactions between m ultiple transcription 
factors to form the initiation complex at this motif have been the subject of 
investigation for many years [reviewed by Sawadogo and Sentenac 1990]. 
The factor TFIID is the primary TATA binding protein and its binding is a 
prerequisite for the ordered and sequential binding of TFIIA, TFIIB, RNA 
polymerase II, TFIIF (also known as RAP30/74) and TFIIE [Buratowski et al. 
1989; Greenblatt 1991a and b; Roeder 1991], to form the complex known as
the preinitiation complex (although with further purification the number of 
these general factors is increasing [Weinmann 1992]). It is believed that the 
rate or efficiency of formation, and subsequent stability of the preinitiation 
complex at the prom oter can be influenced by trans-acting factors that bind 
to more distal cis-acting regions. Such factors may also control the efficiency 
of elongation [Greenblatt 1991b; Roeder 1991].
The trans-acting proteins that bind distal cis-acting DNA sequences 
may m odulate transcription in a positive or negative manner. If found 
close (<100 bp) to the transcription initiation site such sequences are 
considered to be part of the gene promoter. If found more distally (usually 
>100 bp), these sequences are classified as enhancers or maybe silencers 
[Serfling et al. 1985; Ptashne 1986]. There have been a number of models put 
forward to explain how DNA binding proteins such as enhancers can act 
over a sometimes considerable distance, e.g., ~20 kb for the dom inant 
control region of the globin genes [Evans et al. 1990]. The main models put 
forward for enhancer function generally propose a looping out of DNA in 
order to allow contact betw een proteins bound to the enhancer and 
prom oter elem ent(s) [Ptashne 1988; M itchell and Tjian 1989]. The 
interaction of these proteins is supposed to increase the likelihood of RNA 
polymerase II initiating or extending transcription by enhancing formation 
a n d /o r  stability of the preinitiation complex [Lewin 1990]. Analysis of 
cloned enhancer b inding proteins supports this model to some extent 
because most are m odular, w ith distinct DNA binding and functional 
domains [Johnson and McKnight 1989; Mitchell and Tjian 1989; Latchman 
1990]. Other models for enhancer function have been proposed [Atchison 
1988], for example the entry site model, where the enhancer provides access 
for transcrip tion factors to the DNA followed by tracking until they 
encounter specific prom oter elements; the chrom atin structure modifying 
model, where enhancers modify local chromatin structure to favour access 
for the transcriptional apparatus; and the nuclear address model, where 
enhancers direct chrom atin dom ains into transcriptionally active nuclear 
com partm ents.
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1.6.5 Characterisation of c i s -acting DNA elements in cytokine genes
The prom oter/enhancer region of both the mouse [Serfling et al. 1989; 
N ovak et al. 1990] and hum an [Siebenlist et al. 1986; Fujita et al. 1986; 
D urand et al. 1987 and 1988; Williams et al. 1988; Shaw et al. 1988; Nabel et  
al. 1988; Emmel et al. 1989] IL-2 genes were functionally characterised for 
c is-ac ting  DNA reg u la to ry  e lem ents using  the ch lo ram phen ico l 
acetyltransferase (CAT) reporter gene as a m arker for expression. This 
approach involved ligating IL-2 genomic DNA sequences to the CAT coding 
region in a bacterial plasm id followed by transient transfection into 
appropriate IL-2 expressing cells, usually the hum an Jurkat T cell leukemia 
line. This approach is discussed in more detail in Chapter 3 where it has 
been applied to m urine IL-5. A num ber of czs-acting sequences w ere 
identified within the hum an IL-2 5' flanking sequence and protein binding 
to these sites was confirmed by either gel shift assay [Durand et al. 1987; 
Shaw et al. 1988; Nabel et al. 1988] or DNase I footprinting experiments 
[Shaw et al. 1988; Serfling et al. 1989].
The expression obtained from IL-2CAT reporter constructs was 
generally inducible, cell type-specific and similar to that of the endogenous 
IL-2 gene expression in showing susceptibility to repression by cyclosporin A 
[Emmel et al. 1989] and the glucocorticoid dexamethasone [Vacca et al. 1989]. 
How ever a discrepancy has been observed betw een expression from a 
transiently transfected IL-2CAT reporter construct and endogenous IL-2 gene 
expression. A hum an IL-2CAT reporter construct expressed well in the 
m urine T cell lymphom a line (EL4) but poorly in the hum an Jurkat T cell 
leukemia line, yet both cell lines express high levels of endogenous IL-2. 
The addition of an SV40 enhancer element im proved expression of the 
same construct in Jurkat cells leading the authors to claim that the original 
construct may not have contained all hIL-2 enhancer sequences [Martensson 
and Leanderson 1989]. An alternative explanation could be that the hIL-2 
enhancer sequences were not functional in this transient transfection assay.
This result sheds some doubt on studies where the regulation of a cytokine 
from one species has been analysed in a cell line from another species even 
if the cross-species cell line expresses the analogous endogenous gene.
The same reporter gene/transient transfection technique was also 
used to identify cis-acting DNA elements for related genes. These included 
human GM-CSF [Chan et al 1986; Kaushansky 1989; Nimer et al 1988, 1989a 
and 1990], murine GM-CSF [Sugimoto et al. 1990] and human IL-3 [Mathey- 
Prevot et al. 1990; Shoemaker et al. 1990]. Although cis-acting sequences 
located by some of this work may not be physiologically relevant in the 
normal situation as the cells used for transfection were either cross-species 
[Nimer et al 1988, 1989a and 1990; Mathey-Prevot et al. 1990; Shoemaker et 
al. 1990] or infected by leukemia viruses [Chan et al. 1986; Mathey-Prevot et 
al. 1990]. Viral infection may be a problem because proteins from two 
leukemia viruses (e.g., the tax proteins of HTLV-I and -II) have been shown 
to have trans-activating properties on cytokine promoters [Miyatake et al. 
1988; Nimer et al 1989b]. Functional data for IL-4 were less clear, although 
Arai et al [1989] have shown expression from a human IL-4CAT construct 
with 2300 bp of 5' sequence. Finally, there were no publications on either 
the physical or functional characterisation of cis-acting DNA sequences 
involved in murine or human IL-5 gene expression at the beginning of this 
project.
1.7 Aims of the Thesis
Nuclear run-on assays have indicated that the major point of mIL-5 
gene regulation is the induction of transcription [Wang 1989; Wang et al 
1993]. Consequently, as a first step toward investigating the mechanisms of 
mIL-5 expression, it was decided to try to functionally identify important 
regions of the gene which were responsible for tissue-specific induction of 
transcription, and subsequently to characterise important cis-acting DNA 
element(s) within these regions. The approach taken here was to prepare 
mIL-5-reporter gene constructs and transfect them into murine cells able to
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express mIL-5, the objective being to identify sequences which conferred 
expression characteristics representative of the endogenous mIL-5 gene on 
the reporter construct, i.e., tightly regulated inducibility after appropriate cell 
stimulation, sensitivity to glucocorticoids, and cell type-specific expression. 
In doing so, a primary goal was to demonstrate the function of the czs-acting 
sequence element(s) in the most physiologically relevant model available. 
Murine T cell clones were the best in vitro model of T lymphocytes available 
for this work, however, T cell clones were also known to be difficult to 
transfect and so this technical problem had to be addressed. Two continuous 
m urine T cell lines, which were able to express IL-5 and had been 
successfully transfected previously, were also available for transfection 
experim ents. Chapter 2 describes the sequencing and analysis of the 
upstream  region of the mIL-5 gene, Chapter 3 presents analysis of mIL-5- 
reporter gene constructs using transient transfection assays, Chapter 4 
describes expression of mIL-5CAT constructs after stable integration into the 
transfected cell genome and Chapter 5 discusses the findings of this project.
CHAPTER 2
SEQUENCE AND ANALYSIS OF THE UPSTREAM REGION OF
THE MOUSE IL-5 GENE.
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2.1 Introduction
In previous work performed in this laboratory [Campbell et al, 1988] a 
10 kb genomic H im d ill fragm ent containing the m urine interleukin-5 
(mIL-5) gene was isolated by screening a mouse genomic lambda library 
with an mIL5 cDNA probe. Subsequently, 6727 bp of this fragment was 
sequenced yielding 547 bp of 5' flanking sequence. Since upstream  
enhancers involved in transcriptional regulation may be several kilobases 
away from their proximal promoter elements it was desirable to characterise 
add itional upstream  sequence prio r to detailed  analysis of mIL-5 
transcription. This section describes the sequencing and analysis of the 
rem aining 5' flanking sequence of the original 10 kb genomic H in d ill  
fragment, which gave a total of 3.9 kb of upstream  sequence of the mIL-5 
gene.
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2.2 Materials and Methods
The methods described from section 2.2.1 to section 2.2.4 were used in 
both the work described in this chapter and in work described in subsequent 
chapters.
2.2.1 Bacterial Transformations
The bacterial transformation procedure utilised in this Thesis was 
based on the method of Hanahan [1983]. The high efficiency method was 
utilised when transforming newly ligated vectors, while the colony 
transformation method was utilised for rapid transformation of purified 
plasmid. The E. coli bacterial hosts, TGI, DH5a, and JM110 are described in 
Sambrook et al. [1989].
2.2.1.1 High efficiency transformation
Fresh SOB + 20 mM Mg+2 was made up by adding 1 ml of 2 M MgCl2 
to 99 ml of SOB medium (20 g/1 bactotryptone; 5 g/1 yeast extract; 0.6 g/1 
NaCl; 0.2 g/1 KC1). This solution was filter sterilised through a 0.2 pm filter 
(Sartorius). Bacterial cultures were grown up to a Klett reading of 100 (Klett- 
Summerson Photoelectric Colorimeter) in 20 ml of SOB + 20 mM Mg+2 in a 
side-arm flask. The culture was then chilled on ice for 5 minutes before 
being transferred to a 50 ml polypropylene tube for a 5 minute centrifugation 
to pellet the cells in an MSE centrifuge (1750 g) at 4°C. The cell pellet was 
then resuspended in 6.7 ml of cold TFB (10 mM MES pH 6.3; 100 mM RbCl; 
45 mM MnCl2,‘ 10 mM CaC^; 3 mM [Co(NH3)6 ]Cl3) and incubated on ice for 
10 minutes. After a further 5 minute centrifugation at 4°C, the cells were 
resuspended in 1.6 ml of cold TFB, 56 pi of DMSO (DMF was an alternative) 
was added and the tube was left on ice. After 5 minutes, 56 pi of freshly 
prepared 2.25 M DTT was added to the mixture on ice. Ten minutes later a 
further 56 pi of DMSO (or DMF) was added and incubation continued for 5 
minutes on ice.
Two hundred and ten microlitres of the competent cells mixture was 
added to a pre-chilled 5 ml polystyrene tube (Falcon) containing 10 pi (2-10
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ng) of the DNA to be transformed. After 30 minutes incubation on ice the 
cells were heat shocked at 42°C for 2.5 minutes, then 800 \x\ of SOB + 20 mM 
Mg+2 (at RT) was added and the cells were incubated in a 37°C shaking water 
bath at 200 rpm  for 1 hr. A further 2 ml of SOB + 20 mM Mg+2 medium was 
added and the tubes were inverted to mix before centrifuging for 5 minutes 
in an MSE centrifuge at RT. Cell pellets were resuspended in 50 |il of SOB + 
20 mM Mg+2 medium before plating on appropriate selective plates.
2.2.1.2 Colony transformation
Two to four fresh colonies (2-3 mm diam eter from overnight 
incubation) were resuspended in 200 pi of cold TFB and incubated on ice for 
15-20 minutes. Approximately 100 ng of supercoiled plasm id DNA was 
added and the mixture was incubated on ice for a further 30 minutes before 
continuing with the above method from the 2.5 minute 42°C heat shock step 
until plating on appropriate selective plates.
2.2.2 Small Scale Preparation of Plasmid DNA
The following small scale procedures were used for screening plasmid 
constructs. The boiling m ethod was modified from Maniatis et al. [1982], 
and utilised for constructs requiring restriction enzyme digestion analysis 
a n d /o r  sequencing. The rapid screening method [Maniatis et al. 1982] was 
utilised for screening prim ary transform ants for constructs that were 
expected to have inserts or deletions w ith at least a 5% size difference 
compared to the parent construct.
2.2.2.1 Boiling method
A sterile 5 ml polystyrene tube (Falcon) was used for a 1.5 ml 
m iniculture of bacteria containing the plasmid of interest. The miniculture 
was grown up overnight in a 37°C air shaker or 37°C shaking water bath. 
Generally the m edium  was Superbroth (2.4% w /v  yeast extract, 1.2% w /v  
tryptone, 0.5% v /v  glycerol, 1 M potassium  phosphate, pH  7.5) although 
2xYT (1.0% w /v  yeast extract, 1.6% w /v  tryptone, 0.5% w /v  NaCl) gave 
sufficient plasm id DNA yields. The most commonly used antibiotic was
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ampicillin, at 100 |j.g/ml in the culture.
Minicultures were transferred to 1.5 ml Eppendorf tubes for 1 minute 
of centrifugation in an Eppendorf centrifuge. The m edium was thoroughly 
removed and the cell pellet was resuspended in 350 pi of STET (8% sucrose; 
0.5% Triton X-100; 50 mM EDTA, pH  8.0; 10 mM Tris/H Cl, pH 8.0), 25 pi of 
freshly dissolved (20 m g/m l) lysozyme (Sigma) was added and the tube 
contents mixed before boiling the tube for 40 seconds. After a 10 minute 
centrifugation the pellet of cellular debris was rem oved w ith a sterile 
toothpick. The plasm id DNA was precipitated from the supernatant by 
adding 40 pi of 3 M sodium acetate, pH 5.2, and 420 pi of isopropanol. The 
tube was centrifuged immediately for 15 minutes in an Eppendorf centrifuge 
at 4°C. The pellet was then washed with 1 ml of dry ether before drying in a 
Speedvac C oncentrator (Savant) for 5 m inutes. The dry pellet was 
resuspended in 100 pi of TioEo.i containing 100 p g /m l of bovine pancreatic 
RNase A (Sigma) and incubated at 37°C for 20-30 minutes.
The RNase and other remaining proteins were removed by adding 25 
pi of equilibrated phenol and 25 pi of chloroform : isoamyl alcohol (24:1), 
vortexing for 10 seconds and centrifuging for 2 minutes at RT. The 100 pi of 
supernatant was transferred to a new Eppendorf tube, 10 pi of 3M sodium 
acetate, pH 5.2, and 275 pi of absolute ethanol were added to precipitate the 
plasmid DNA. The tubes were centrifuged immediately for 15 minutes at 
4°C. The resulting pellet was washed with 1 ml of absolute ethanol before 
drying in a Speedvac Concentrator for 5 to 10 minutes. The pellet was 
redissolved in 50 pi of TioEo.i and 5 pi was used for restriction enzyme 
digests.
22.2.2 Rapid screening method for primary transformants
Colonies from prim ary transform ants were picked w ith a sterile 
toothpick and rep lated  in a sector of a m aster plate containing the 
appropriate selective antibiotic. Generally each m aster plate contained 16 
num bered sectors. These master plates were incubated at 37°C for at least 4 
hours (up to overnight).
32
A sterile toothpick was used to transfer a small amount of bacteria 
from the master plate to an Eppendorf tube, where it was resuspended in 30 
pi of cracking buffer (50 mM NaOH, 0.5% SDS, 5 mM EDTA and 0.025% 
bromocresol green). The tube was incubated at 65-68 °C for approximately 45 
m inutes before brief centrifugation to spin down condensation. Twenty 
microlitres was loaded onto a 0.7% agarose gel along with appropriate 
controls. Electrophoresis was continued until samples had migrated 2 /3  to 
3 /4  along the length of the gel. The gel was then stained with ethidium 
bromide (1 pg/m l) for 30 minutes.
2.2.3 Large Scale Preparations of CsCl Purified Plasmid DNA
The following large scale m ethod of plasmid preparation typically 
yielded approximately 1-2 mg of DNA per 500 ml of culture for plasmids 
containing the pBR322 origin of replication grown in the E. coli host strain 
D H 5a. This m ethod was also scaled down by half to allow more rapid 
preparation of plasmid DNA. The 500 ml culture method is outlined below; 
the 250 ml m ethod was identical except all volumes were halved and the 
ultracentrifugation step utilised a Beckman TL-100 (see below).
A 15 ml culture of the transform ed E .c o l i  host was grown up in 
appropriate selective antibiotic (usually 100 jig /m l ampicillin) for 3 hrs in a 
37°C shaking water bath. This inoculum was added to 500 ml of prewarmed 
LB culture m edium  (0.5% w /v  yeast extract, 1% w /v  tryptone, 0.5% w /v  
NaCl) containing 100 p g /m l ampicillin in a 2 L flask. This culture was 
incubated for approximately 3 hrs (reaching a Klett of 150-200) at 37°C in an 
air shaker. Spectinomycin (Upjohn) was added (100 pg /m l) to amplify the 
plasm id overnight.
The amplified overnight cultures were poured into two 250 ml GSA 
buckets and centrifuged for 10 minutes at 5,000 rpm  at 4°C (Sorvall RC-5). 
The supernatant was poured off and the bacterial pellet was resuspended in 
5 ml of STET, the two 5 ml STET volum es were pooled in a 50 ml 
Erlenmeyer flask, and 1 ml of freshly dissolved (20 m g/m l) lysozyme 
(Sigma) was added. The flask was heated over a bunsen burner until boiling 
then immediately held in a boiling water bath for 40 seconds. The contents
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were cooled on ice before transferring to a Beckman polyallomer centrifuge 
tube (14 x 89 mm). Tubes were balanced before centrifugation (Beckman L8- 
70 ultracentrifuge) in an SW-41 swing-out rotor (Beckman) for 30 minutes at 
25,000 rpm and 20°C. The supernatant was transferred to an SS34 tube 
(Sorvall) and the DNA was precipitated by adding 1 /10th the volume of 3 M 
sodium acetate (pH 5.2) and an equal volume of isopropanol. After brief 
mixing tubes were placed in an SS34 rotor (Sorvall) and centrifuged (Sorvall 
RC-5) for 20 minutes at 15,000 rpm and 4°C.
The supernatant was decanted and the pellet was washed with dry 
ether before adding 10 ml (4 ml for half-scale method) of TioEo.i. The pellet 
was soaked for up to 1 hr before vortexing to resuspend the pellet. Ten 
grams (4 g for half-scale method) of CsCl was gently dissolved in the DNA 
solution and 800 pi ( 350 pi for half-scale method) of ethidium bromide (10 
mg/ml) was added before transferring to a 16 x 76 mm (or 13 x 51 mm for 
half-scale method) Beckman Bell-top polyallomer Quick-Seal tube . Tubes 
were balanced and sealed without air bubbles before loading in a Beckman 
75Ti rotor for centrifugation in a Beckman L8-70 ultracentrifuge at 42,000 
rpm at 16-20°C for at least 36 hrs (or 13 x 51 mm Quick-Seal tubes were 
loaded into a TLA 100.4 Beckman rotor and centrifuged at 100,000 rpm at 
25°C for at least 15 hrs). Plasmid bands were recovered in 1-2 ml using a 
hypodermic syringe and needle [Maniatis et al. 1982] and ethidium bromide 
was removed in the upper phase by 6 extractions with isopropanol 
equilibrated with saturated CsCl in water. The DNA sample was then 
transferred to dialysis tubing (flat width of 10 mm from Selbys Scientific, 
type 453103), samples were dialysed at 4°C with stirring against 500 volumes 
of TioEo.i, with three changes of dialysis solution, allowing at least 6 hrs 
equilibration each time. PBS was used for the final dialysis; overall dilution 
of CsCl was 1 in ~6 x 1010. Absorbance readings were taken at 260 nm and 280 
nm. The 260/280 was generally around 1.8 and DNA concentration was 
determined on the basis that a solution with an OD260 of 1 contains 50 pg/m l 
[Maniatis et al. 1982].
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2.2.4 Isolation of High Molecular Weight DNA From Mammalian 
Cells in Tissue Culture
This procedure was developed by Dr B. van Leeuwen. Approximately 
1 x 108 tissue culture cells were centrifuged and the cell pellet was 
resuspended in 1 ml of suspension buffer (lOOmM EDTA, 30 mM Tris pH 
8.0), 1 ml of lysis buffer (100 mM EDTA, 30 mM Tris pH 8.0, 2% Sarcosyl) was 
added and the mixture was incubated at 37°C for at least 4 hrs and up to 
overnight in a 5 ml tube (Falcon). Two grams of CsCl was carefully 
dissolved in the DNA sample, increasing the volum e to 2.6 ml. The 
mixture was then transferred to a Beckman thick wall polyallomer open top 
centrifuge tube (13 x 51 mm). Tubes were balanced with a solution of 
suspension buffer containing 1 g /m l CsCl. Samples were centrifuged in a 
TLA 100.3 rotor in a Beckman TL100 ultracentrifuge at 50,000 rpm for 20 hrs 
at 15°C. The high molecular weight DNA was recovered from the base of 
the centrifuge tube by puncturing the bottom of the tube with an 18 gauge 
needle. The viscous DNA was collected in an Eppendorf tube as the needle 
was slowly w ithdraw n. Flow rate increases after the first 700-800 pi, 
indicating that the DNA had been recovered. The high molecular weight 
DNA was dialysed three times against 2 litres of TioEo.i with gentle stirring at 
4°C, each dialysis being allowed to equilibrate for a m inim um  of 6 hrs. 
Absorbance readings were taken at 260 nm and 280 nm and concentration 
was calculated on the basis that a solution with an OD260 of 1 contains 50 
pg /m l of DNA [Maniatis et al  1982].
2.2.5 Preparation of mIL-5 gene fragment carrying the upstream 
region
A 10 kb mouse genomic fragm ent, containing Hin d ill ends, was 
subcloned from a lam bda EMBL3A clone into pSV2neo (By Dr. H. D. 
Campbell). The region to be sequenced was removed from the vector and 
rem aining fragm ent on a LMP agarose gel after digestion w ith Hin d ill  
(Biolabs) and Eco47III (Amersham). The 5' Hindll l  overhang was blunt- 
ended with the Klenow fragment of DNA polymerase I (Pharmacia) in the 
presence of 0.5 mM dNTPs [Maniatis et al. 1982] and 3 \ig of the ~4 kb 
fragm ent was blunt-end ligated to itself (T4 DNA ligase, Pharmacia). A
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sample of the ligation product was analysed on a 0.8% agarose submarine 
minigel.
2.2.6 Random fragmentation of DNA by sonication
The concatemerised and/or circularised ~4 kb fragment ligation 
product was extracted with equilibrated phenol-chloroform, ethanol 
precipitated and desiccated before resuspending in a volume of 10 pi of 
T10E0.i. The DNA sample was then made up to a volume of 250 pi in 
sonication buffer (0.5 M NaCl, 0.1 M Tris pH 7.5, 5.0 mM EDTA). The short 
probe of the sonicator (Ystrom Sonic Pen)was tuned in 250 pi of sonication 
buffer at power setting 3. Six separate 5 second bursts of sonication were 
applied to the DNA sample with 60 seconds of cooling in ice/water between 
bursts. The sonicated DNA sample was then ethanol precipitated, desiccated 
and resuspended in a volume of 26 pi of sddH20  in preparation for end 
repair. The sample was made up to a volume of 40 pi containing T4 DNA 
polymerase buffer (67 mM Tris pH 8.0, 6.7 mM MgCl2), 1 mM DTT, 50 pM 4x 
dNTP mix, and 20 units of T4 DNA polymerase (Promega). After incubating 
for 2 hours at 15°C the sample was extracted once with equilibrated phenol- 
chloroform . The phenol-chloroform phase was washed once with 40 pi of 
T10E0.i and this was pooled with the DNA sample prior to one extraction 
with water saturated ether, then ethanol precipitation. After desiccating, the 
sonicated DNA pellet was resuspended in 20 pi of T10E0 1 before loading onto 
a LMP agarose gel.
2.2.7 LMP agarose gel isolation of sonicated fragments
The 20 pi sonicated DNA sample was loaded (without dye) onto a 1% 
LMP agarose gel (containing 1 pg/m l ethidium bromide). Lambda DNA 
and pBR322 DNA digested with Hindlll and Hinfl, respectively, were loaded 
(together with dye) as size standards three lanes clear of the sonicated 
sample. Fractions representing 200-500 bp and 500-1000 bp were isolated 
from the sonicated DNA smear visualized under UV light. The gel sections 
were transferred to Eppendorf tubes and heated at 65°C for 5 minutes to melt 
the gel prior to three extractions with equilibrated phenol. After two 
extractions with water saturated ether the sonicated DNA fractions were
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ethanol precipitated, desiccated and resuspended in 10 pi of T10E0i.
2.2.8 Ligation into sequencing vector and transfection into E.coli
The 10 pi ligation reaction was set up using 100 ng of sonication 
fraction with 10 ng of M13 mplO (Amersham commercial preparation, Smal 
linearised and phosphatased). The ligation buffer was 50 mM Tris, pH 7.5, 5 
mM M gCl2, 1 mM DTT and 1 mM ATP, 20 units of T4 DNA ligase 
(Pharmacia) was added and the reaction was incubated at 16°C overnight. 
The ligation product was transfected into E.coli strain TGI (see section 
2.2.1.1). X-Gal-IPTG blue/w hite  plaque discrimination [Messing 1983] was 
used to distinguish clones with insert DNA.
2.2.9 Single-strand template preparation
A total of 186 white plaques were picked using sterile pointed tooth 
picks. Each plaque was dipped into 1.5 ml (seeded with 0.5% v /v  of 
overnight TGI culture) of 2x YT medium in a 5 ml sterile polystyrene tube 
(Falcon). After 6 hours incubation in a shaking water bath (250 rpm) at 37°C, 
the 1.5 ml cultures were transferred to Eppendorf tubes and centrifuged for 
10 m inutes at RT. 1 ml of the supernatant was transferred to a new 
Eppendorf tube containing 270 pi of 20% PEG, 2.5 M NaCl, mixed and 
incubated at RT for 15 minutes (200 pi of the remaining supernatant was 
kept as phage stock at -20°C). Five minutes of centrifugation produced a 
phage pellet from which all traces of PEG solution were removed before 
resuspending in 100 pi of T10E0.i. A 50 pi extraction with equilibrated 
phenol rem oved the protein coat from the single-stranded phage and the 
supernatant after brief centrifugation was extracted with water saturated 
ether before ethanol precipitation and resuspension of the DNA in 20 pi, 
ready for sequencing reactions.
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2.2.10 Sequencing Procedure
2.2.10.1 Preparation of sequencing plates
The sequencing gel glass plate preparation involved pre-treatment of 
the plates so that the acrylamide gel could be covalently bound to the 
backing plate.
Briefly, the 390 mm x 200 mm backing plate was thoroughly cleaned 
by first soaking in 1 M KOH in ethanol then rinsing in hot water followed 
by a rinse with distilled water before standing to dry. A 'bind' silane mix 
was made up consisting of 5 ml of absolute ethanol, 25 pi of MATS (Sigma) 
and 165 pi of 10% acetic acid. This bind silane mix was spread evenly over 
the plate with one lint-free tissue. After 3 minutes drying in a fumehood 
the plate was rinsed with absolute ethanol and left standing to dry.
The notched front plate was pre-coated with 'repel' silane, 5% v /v  
dimethyldichlorosilane in trichloroethane. Briefly, the 390 mm x 200 mm 
notched glass plate was cleaned thoroughly with 7X detergent (Flow 
Laboratories) then rinsed with distilled water and left standing to dry. 
Approximately 5 ml of repel silane was spread evenly over the plate with a 
lint-free tissue, and when dry this siliconising step was repeated before 
rinsing the plate with distilled water. Once dry the plates were polished 
with lint-free tissue and taped together, separated by 0.3 mm spacers, with a 
suitable grade of tape (Gradient Laboratories).
2.2.10.2 Preparation of 6% acrylamide sequencing gels
A volume of 50 ml of 8 M urea-6 % acrylamide was made up for a gel 
365 mm x 200 mm x 0.3 mm. Briefly, 24 g of ultrapure urea was weighed out 
in a 200 ml beaker. This was made up to ~40 ml including 7.5 ml of 40% 
acrylamide solution (38 : 2 w /w  acrylamide : bisacrylamide), 5 ml of lOx TBE 
(0.89 M Tris, 0.89 M boric acid, 0.025 M EDTA) and distilled water. The urea 
was dissolved at between 37°C - 50°C prior to making the volume up to 50 
ml in a measuring cylinder. The urea-acrylamide solution was then filtered 
through an 0.45 pm Ministart NML filter (Sartorius) into a conical flask
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before cooling on ice for 2 minutes. 120 pi of 25% ammonium persulphate 
and 100 jil of TEMED were added just prior to pouring the gel. A 32 well 
comb was inserted and the gel was sealed from the atm osphere with 
Gladwrap and left overnight to polymerise.
2.2.10.3 Template preparation for sequencing of double-stranded 
supercoiled plasmid DNA
D ouble-stranded supercoiled plasm id DNA was denatured  for 
sequencing by the following procedure. DNA was aliquoted (4 jig) into an 
Eppendorf tube and made up to a volume of 16 pi with sddH 20 , 4 pi of 1 M 
NaOH was added and the tube left at RT for 5 minutes. The solution was 
then neutralised  and the DNA precipitated  by adding  2 pi of 2 M 
ammonium acetate, pH  4.6, and 75 pi of absolute ethanol before placing the 
tube in a dry-ice/ethanol bath for 15 minutes. After a 20 minute spin in an 
Eppendorf centrifuge at 4°C the pellet was washed with 70% ethanol and 
dessicated for 5 minutes in the Speedvac. The pellet was then resuspended 
in the appropriate annealing buffer (see sequencing procedures below).
2.2.10.4 Sequencing with Klenow fragment of E. coli DNA polymerase I
The first 120 M13 5’mIL-5 clones were sequenced with the Klenow 
fragment of E.coli DNA polymerase I. Four pmol (4 pi) of primer (M13 '-40' 
primer, i.e., the 3' end of the primer is 40 bp from the H indlll cloning site), 
lp l of lOx TM (100 mM Tris-HCl pH 8.0, 100 mM MgCl2) and 5 pi (~ 1 pg) of 
single strand M13 DNA was added to an Eppendorf tube and heated at 80°C 
for 3 minutes then cooled to RT on the bench. A 96 well round bottom 
microtitre plate (Linbro, Flow Laboratories) was labelled such that vertical 
columns represented each ddNTP termination reaction and horizontal rows 
were labelled for each prim er-tem plate. Two microlitres of term ination 
reaction nucleotide mix (see table 2.1) were added to each well in the 
appropriate column. Next, 2 pi of tem plate w ith annealed prim er was 
added to the appropriate row. A polym erase/label mix was made up (to a 
total volume of 2x the num ber of reactions + 2 pi) consisting of 12% v /v  
[a35S]dATP, 1000 C i/m m ol (Amersham International) and 4% v /v  Klenow
polymerase solution (5 units/ml, from Promega) in lx TM. Two microlitres 
of this polymerase/label mix was distributed to all wells and the reactions 
were started with a 20 second spin in a microtitre plate centrifuge (Clements 
2000). After incubating at 37°C for 15 minutes, 2 jil of 0.25 mM dNTP mix 
was added to each well and the plate was incubated for a further 25 minutes 
at 37°C. The reactions were stopped by adding 3 |il of formamide dye mix 
(96% formamide, 20 mM EDTA, pH 8.0, 0.1% bromophenol blue, 0.1% 
xylene cyanol). The microtitre plate was left at 80°C for 10 minutes with the 
lid off to denature and concentrate the samples prior to loading.
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Table 2.1 Nucleotide mixes (mM) for Klenow DNA polymerase sequencing 
reactions.
Nucleotide 'A' mix ’G' mix 'C' mix T  mix
dGTP 75.0 8.0 107.5 107.5
dCTP 75.0 107.5 8.0 107.5
dTTP 75.0 107.5 107.5 8.0
ddATP 50.0
ddGTP 300.0
ddCTP 150.0
ddTTP 500.0
2.2.10.5 Sequencing with T7 DNA polymerase.
The remaining 66 clones were sequenced with T7 DNA polymerase 
(Promega). One microgram of M13 DNA was used for single-stranded 
template sequencing with T7 DNA polymerase (Promega Sequencing 
System) while for double-stranded sequencing 4 gg gave the best results. In 
both cases, 4 pmol of primer was annealed with the template in T7 
sequencing buffer (40 mM Tris-HCl, pH 7.5, lOmM MgCl2, 50 mM NaCl, 0.1 
M DTT) at 37°C for 15 minutes. The sequencing reactions were carried out 
in a 96 well round bottom microtitre plate as in the Klenow procedure (see 
previous section); otherwise the procedure was as described in the Promega 
technical manual.
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2.2.10.6 Electrophoresis of samples
An alum inium  sheet (280 mm x 170 mm x 1 mm) was taped to the 
notched glass plate to maintain an even tem perature during electrophoresis 
and the gel assembly was set up in the electrophoresis apparatus. The upper 
and lower buffer reservoirs were filled with lx  TBE, with the buffer for the 
lower chamber also containing sodium acetate (375 mM). The comb was 
removed and excess urea flushed from the wells with a needle and syringe 
just prior to loading samples. The 2.5 fil reaction samples were loaded with 
a m icropipette tip. Initially, the samples were run into the gel at 2000 V 
(supplied by ISCO Electrophoresis Power Supply unit, model 494) for two 
m inutes before low ering the pow er o u tp u t to 35 w atts until the 
brom ophenol blue dye front had just run off the gel (~2 hrs). After 
electrophoresis, the two plates were separated using a spatula, the urea was 
removed by soaking in 10% acetic acid for 20 minutes, and the gel was dried 
to the backing plate at 80°C for 90-120 m inutes prior to setting up 
autoradiography.
2.2.11 Analysis of sequence data
Sequencing gel autoradiographs were read using a G raf/bar sonic 
digitizer and the sequence database was assembled and edited using the 
programs of Staden [1980,1982b and 1984].
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2.3 Results
The upstream  region of the mIL-5 gene was sequenced by the random 
m ethod [Sanger et al. 1982]. This procedure involved isolation of the 
fragment to be sequenced, ligation to itself, random shearing by sonication, 
subcloning into an M13 phage vector, and sequencing by the chain 
termination m ethod [Sanger et al. 1977]. The sequencing of 186 M13 clones 
was carried out using two different types of DNA polymerase; the first 120 
were sequenced with the Klenow fragment of E. coli DNA polymerase I and 
the rem aining 66 were sequenced with T7 DNA polymerase. T7 DNA 
polym erase yielded far superior sequence data giving more even band 
intensity and was also used to resequence some of the clones first sequenced 
with the Klenow fragm ent of E. coli DNA polymerase I. The sequencing 
data were assembled using the program s of Staden [1984] yielding the 
complete 3884 bp sequence. In this 3884 bp contig, both strands were 
sequenced entirely and each base was determ ined w ith an average 
redundancy of 6.94. The known 5' flanking sequence of the mIL-5 gene was 
extended by 3312 bp to 3859 bp (Figure 2.1)
C om parison of the mIL-5 gene 5’ flanking sequence w ith the 
GenBank nucleotide sequence database using the program  FASTA revealed 
significant similarity with a num ber of mouse and rat gene sequences. The 
similarities were common to two regions in the mIL-5 5' flanking gene 
sequence and were identified as m urine Alu-\ike repetitive elements. One, 
on the positive strand in the region -2538 to -2403 of mIL-5, showed -93% 
hom ology w ith the m urine B1 A lu -like repetitive elem ent consensus 
sequence [Rogers 1985]. The other, on the negative strand in the region 
-1530 to -1374 show ed 92% hom ology w ith the m urine B2 A lu - lik e  
repetitive element consensus sequence [Rogers 1985]. The positions and 
orientation of each of these elements are shown in Figure 2.1 along with 
their polyA tails and flanking direct repeats. The sites for restriction 
endonucleases which were used in later w ork in this Thesis for the 
construction of various reporter gene plasmids are shown in bold in Figure 
2.1.
The high degree of homology between the hum an and m urine IL-5
Figure 2.1 Nucleotide sequence of the upstream region of the mouse IL-5 
gene from +29 to -3859. The sequence was determined from 186 random  
clones generated by sonication. Both strands were sequenced entirely and 
each position was determ ined with an average redundancy of 6.94. A 
murine B1 Alu-like sequence was identified in the region -2538 to -2403 and 
is underlined with polyA tail and flanking direct repeats indicated (arrow 
shows orientation of insert). A m urine B2 Alu -like sequence (in reverse 
orientation, see arrow) was also located and is underlined in the region 
-1374 to -1530 along with the polyA tail and flanking direct repeats. Also 
shown (in bold) are a number of restriction endonuclease sites found in this 
sequence but not in pSVOCAT (used for later work, see Chapter 3). Seven of 
these sites occur only once (Hindll l ,  Sacl, Age  I, Nhe  I, Sphl, Nsi l ,  and 
Eco47III); four of these sites occur two times (NdeI, Xbal, T t h l l l l ,  and 
EcoNI); two of these sites occur three times (Bell and BspMl); and one of 
these sites (Accl) occurs five times.
CCAGTTTGTC TCCCACAATA CTTGAGAGTG TTCAACTCAG TTATGTCTAG CCAAGACCTC AAACCTCAGT ACATACCTGA -3700
S a c l
AGATGCACAA CACACATACA CATGTGCACT CGCACACACT TTGCACCCGT AGCTAAATGC TAACGGCCTC TGCATCTCAT -3620
A gel
GTAGAACCAT ACACAGCCTT GGAAAAAGAT TCAGGGAAAC AATCTGTGGA TGCTTCTGGG ATTATTGATT TAAGCCTAAA -3540
AAACAAAAGA CTGGTTCTCC TCGTGACACA TACTCATGGA CAGGCAACAC TCCATATGAA AGGACCTCAG CCTGAGGGAC
N d e l
ATATGGGAGA GGCTAAGCCC ACATGCTCCC TGTCTGTGAT ACGTTTGTTT CTTTCCCAAC ATCTACATCC CTCTTACAAG 
N d e l
TACCGTGAAC CCTGGATGCC CCAGCTGTGT GCTTTGGACG GGATGATGCC CACTTCCAGC TCAGGATGAG CAAGCGGTGT 
ATCCCATAGG CTTAGCCACA GGTCCATGGT GAACACATAA ACCCCCTTAC TGAGCTGGGT TTTCCTTTAT TTCATTGGTG 
TATGGTAATT TTATAAGATA AGGAGTTCCA CTATGACATT TCATACATGT TTATATTGTC TTTTGTCACA TTCACTCCTT 
CCTGTCTCAT CTCTTTCCTT CTTCCCATTA GTCCCCCTCC TCTTTCCAAA CAGAGACCTG ATTCATTGAA TGTTGTTGTT 
TGTGTTTGGG GCATTTGGTT TTTTAGAGAC TCTTGTAGCC TACACTTGGC CTCAAATTCA CTGTGTAGCT GAGATTGGAC 
TCAAATTCCT GATTCTTCTG CTTTAAACTC TTAAATGCCA GGAATATAGG CGTTAGGCAC CATGTTTTGC TAGAGACTGA 
ACTGGTTTTG TTTGTTTGTC TTAACTTTTT ATTTATTCTT TGTGAGTTTC ACATCATGCA CCCCAGTCCT GCTCATCACC 
CTATCTCCCC AAATCTGCCG TTCACCCTTG CAGCCTCCCC ACAAGCTAAA AAAAAAAAAC AAGCCAAAAA CCAAAAAACA 
CATACACACA TAAACAACAA CAAAATAACA ACGCATAGAA AACATCTCAT TATGGAAGCT GTACTATGTC ACAGTGTGTCAccI
TACAGTGTAT CCCTCTGTCT TTGAACTGTT TTTTTAAAAT CTAGTTTTCT AATTAGCATT AATCAGTATA CACAGCAATG
AccI AccI
GATTCCATTA TGATATTTTG ATGATATTAA TGATGATTTA TGCTGGGCGG TGGTGGCACA TGCCTTTAAT CCCAGCACTT
direct repeat
GGGAGGCAGA GGCAGGAGGA TTTCTGAGTT CGAGGCCAGC CTG
:c t^ ta
M u
ACA AAGTGAGTTC CAGGACAGCC AGGGCTATAC
-3460
-3380
-3300
-3220
-3140
-3060
-2980
-2900
-2820
-2740
-2660
-2580
-2500
-2420
-2340
-2260
-2180
-2100
-2020
-1940
-1860
-1780
-1700
-1620
-1540
-1460
AGAGAAACTC TGTCTCGAAA AAATAAAAAA ATAAAAAAAA TTTTTAAATG GTGATTTATT GTAGCAATAT TAACCCCATT
polyA tail direct repeat
TCCCTCTCAA GTCCCCTTTC CACTCCTGTT AATCCTCTCC CTATTCTAAA CTAATATTCT TCTGTGTTTT TCTCTAGAGA
Xbal
TCCAGTGTTT ATAGGACCGC AGGCATCTTG ATCACTGAAA AAAAAGTCTC TTCCTCACCT ATCAACTATT AACTGCAACT
B e l l
GCATATAAAT GCTTGGGAAG GGTGGGGGCC CCTGAGCCTC TCACTCCTCC ATGACTGATG TTGATGGCTG ACCCAGTCTTrtAllll
GCATAGGTGA TCACAACAGC CACATCATGC CCAGAAACCA GCATTCCACA GTGTCTACCA GTTCCCAAGG CACTTTAGTT 
B e l I A c c I
CTGTCTGCTC CTTCTTCCTG CTGTGTTTCC TGAGCATTGG AGGGGGTGAT ATAGATAAAT CCTTTGGGGA CTGAGCATTC 
AATAGTCACT CATCCTCAGT ACCTTGGCCA GTTACGGGTC TCCACAATTA CCATTGGCAA CTTTAAAACA AGTGTTCCTG 
ACCAAAGCTG GCAGCTGTGC TGATGTGTGG ACACACACAG TTACTTAGAA GACAATTTGG CAGACATATC ATATCCATTC 
AGCGCAACAA CCTTACCACT TTCCCTGCTA GGGCCAATGA CCCAGTTGTG AGCCTTTCCC AGGCTCCCTG TGAATTCCTT 
CCTATGGAGT ATGCCTCAAA TTCACCTCTA AAGCCGTTGG TTGCTTCCAT AACTGTCTTA CCACTAGGGC ACCAGATGGC 
ACATCTTGCT TGGCCAGTTG ACCTGTGTAA ACAGGGTGCA GAGCTAAGTA AGACTGTTTT TTTTTTAAAA AAAGATTTAT
direct repeat polyA tail
TT ATT ATT AT AGATAAGTAG AGTGTAGCTG TCTTCAGAGA GACCAGAAGA GGACATGAGA TCTCCTTATG GGTGGTTGTG
AGAGACCATG TGGTTGGTGG GATTTGAACT ACGGACCTTG AGAAGAGCAG TCAGTGCTCT TATCCACTGA GCCATCTCGC -1380A1
CAGCCCATAA GACTGTTTCT ACAGCTCTCC CTCAGCAGTC CATATACTAC CTGCCAGCAC TGTGAGTGCT AGCCAGCCAG -1300
.. BapM I N h ddirect r«p«at
CAGGGAGAAA CATTCAGGCT CCTTCCAGCT TGATTCCTCT GCATCTTGAA ACTAGAGAGT GCTGAGGGAC TGAATTGTTC -1220 
TGATTGAACA ATGAGAAGAG CACGACTGGA ACCCGGTGCA GGGGAGCATG CCTGACACAG TGCTTGAGAG GCTGAGGCTG -1140
S p h l
AGGCAGGAGC ATCAGAAGTT CATAGACAGT TTGGGCCACA TAGTCAAGAC TGTGTCCTAA TAAACCCACC ACAAATGAAA -10 60rtAini
GACAGAAGGA AAAGGAGAAG AAATGCGAAC CTGCTGTGTG TGACAAGATA CAGAGAGAGC CAGGAGTCCT GTTGTCACCC -980
B sp ti l
TGGAGCACCC CTCATACACA CAGTAAGCTG CTTGAAAAGT GGGTCAAGGC CAAGCCACCA AAGCAGTACA GGAAGGAGCC -900 
TCTGCCCTGC ACTTTTTGTC ATAGGAACCA AGAAGCATCC TCTTATCTCC ACTCAGTCTG GGTTGGCCTT TTAGTAACAG -820 
ACAGGATGCT GATCAAAAAC CTACATCATG CAACTCAACT CTGTCAGACC AGCTGCTTTA ATAAATGTCT TTCCCAGAGA -7 4 0Bell
GTTTTCAATT CTTTTTTTCT TTTCTTTTTT TAAGCACAGA TAAGTCTAGC TACCGCCAAT ATAGAAAAAA AAACACCCCC -660 
TTTCCCTTTT CTCTTTGGCA GTTTGGAGCA GGGTCTTGTG TGTTCCAGAT TGAACTCACC TTTGCTGTAC ACACAAAAAA -580 
GCCAAAGATG CTGTCACCTC TTGATCCTCC TGACTGTACC TCCCACATCT GCTGGTGTGT ACCACCACAC CTAGTAAGAT -500 
ATTCTCAACA TTTATGTATT TTAGCCTAAC CCTGTTCGAC CTATACATTT GAATACATTT TTTCTCACTT TATCAGGAAT -4 2 0£coNI AccI
TGAGTTTAAC ACATATTAAA GCAGGTGTGG GGCAGGGAGG GGGGGATAAA AAAGAAGGTG CTCAAGAAAA GCCGATCACG -340
B a p tM
CTCCCAAGAG TGTGAGCATG GGCGTCTCTA GAGAGATCCG CCATATATGC ACAACTTTTA AAGAGAAATT CAATAACCAG -2 60
X b a l
AATGGAGTGT AAATGTGGAT CAAAGTTGTA GAAACATTCT TTTATGTTAT AGAAAATGCT TTTTAAGCAG GGGTGGGGGT -180 
CAAGATGTTA ACTATTATTA AAGAGCAAAA AAAAAAAAAT GCATTTTGTT TGAAGACCCA GGGCACTGGA AACCCTGAGT -100
N a l l
TTCAGGACTC GCCTTTATTA GGTGTCCTCT ATCTGATTGT TAGCAATTAT TCATTTCCTC AGAGAGAGAA TAAATTGCTT -20 £coNi +1
GGGGATTCGG CCCTGCTCTG CGCTCTTCCT TTGCTGAAGG CCAGCGCT +29
£co47III
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genes [Campbell et al. 1988; Mizuta et dl. 1988] extends only a short way into 
the 5' flanking region. Figure 2.2 shows an alignment of -953 bp of the 
mouse 5' flanking sequence using the GCG program  Gap [Devereux et al. 
1984] with all of the known hum an 5' flanking region (up to -506). It is 
evident that the homology decreases dramatically after the first -300 bp of 5' 
flanking sequence w ith only short stretches of possible homology further 
upstream. Five sites of potential regulatory elements are also shown on this 
alignm ent to indicate their relative positions between the two genes (see 
Figure 2.4 and Table 2.2 for more details of putative regulatory sites).
A further comparison between the two sequences was made using the 
program  DIAGON [Staden 1982a] in order to obtain a more global view of 
possible alignm ents. The result is shown in Figure 2.3; once again 
hom ology was high for the first -300 bp w ith only short stretches of 
homology further upstream.
The upstream  sequences of both mIL-5 and hIL-5 were searched for 
conserved sequences and consensus binding sites of known mammalian 
transcription factors using the program Sigscan [Prestridge 1991]. Figure 2.4 
shows the positions of the consensus sites in both the mIL-5 and hIL-5 genes 
and Table 2.2 summarises the sites annotated in Figure 2.4.
Figure 2.2 Alignment between the upstream  regions of the mIL-5 (upper 
sequence) and hIL-5 (lower sequence) genes. The alignment was made using 
the GCG program  Gap [Devereux et al. 1984] with a gap penalty of 5.0 and a 
gap length penalty of 0.3. This alignment yields a percentage similarity of 
66.3. Sites of interest (underlined) which are common to both genes 
include, NFI from -940 in mouse and -476 in human, HiNF-A from -490 in 
mouse and -441 in human, octamer from -453 in mouse and -243 in human, 
lymphokine consensus site CK-1 from -103 in mouse and -105 in human, 
and the IL-5/GM-CSF conserved region from -54 in m ouse and -56 in 
human (see Figure 2.4 and Table 2.2 for further details).
-953 GCTGCTTGAAAAGTGGGTCAAGGCCAAGCCACCAAAGCAGTACAGGAAGGAGCCTCTGCCCTGCACTTTTTGTCATAGGA -874
I I I I I I I I  I 111 11 11 III II 111 111
-50 6 GGATCCTAATCAAGACCCCAGTG........... AACAGAACTCGACCCTGCCAAGGCTTGGCAGTTT........... -450
-873 ACCAAGAAGCATCCTCTTATCTCCACTCAGTCTGGGTTGGCCTTTTAGTAACAGACAGGATGCTGATCAAAAACCTACAT -794
-44 9 .................................................................................  -449
-793 CATGCAACTCAACTCTGTCAGACCAGCTGCTTTAATAAATGTCTTTCCCAGAGAGTTTTCAATTCTTTTTTTCTTTTCTT -714
I I I I I I I I I I II I II II I I I I I I I I I I I I I
-4 4 9 ......................... CCATTTCAATCACTGTCTTCCCACCAGTATTTTCAATTTCTTTT.......... -4 0 6
-713 TTTTTAAGCACAGATAAGTCTAGCTACCGCCAATATAGAAAAAAAAACACCCCCTTTCCCTTTTCTCTTTGGCAGTTTGG -634
I I I I I I I I I I I I I I II I II I I I I I I I
-4 0 5 .....AAGACAGATTAATCTAGCCACAGTCATAGTAGAACATA..................................... -3 68
-633 AGCAGGGTCTTGTGTGTTCCAGATTGAACTCACCTTTGCTGTACACACAAAAAAGCCAAAGATGCTGTCACCTCTTGATC -554
-367 .................................................................................  -367
-553 CTCCTGACTGTACCTCCCACATCTGCTGGTGTGTACCACCACACCTAGTAAGATATTCTCAACATTTATGTATTTTAGCC -474
II I I I I I I I I I I I I I I I I I II I I I I I I I I I
-367 ..................................... GCCGATCTGAAAAAAACATTCCCAATATTTATGTATTTTAGCA -325
-473 TAACCCTGTTGGAGGTATACATTTGAATACATTTTTTCTCACTTTATCAGGAATTGAGTTTAACACATATTAAAGCAGGT -394
-324 TAAAATTCTGTTTAGTGGTCTACCTTATACTTTGTTTTGCA.......................................  -284
-3 9 3 GTGGGGCAGGGAGGGGGGGATAAAAAAGAAGGTGCTCAAGAAAAGCCGATCACGCTCCCAAGAGTGTGAGCATGGGCGTC -314 
-283 .................................................................................  -283
-313 TCTAGAGAGATCCGCCATATATGCACAACTTTTAAAGAGAAATTCAATAAC...CAGAATGGAGTGTAAATGTGGATCAA -237
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I III
-28 3 ....................... CACATCTTTTAAGAGGAAGTTAATTTTCTGATTTTAAGAAATGCAAATGTGGGGCAA -227
-236 AGTTGTAGAAAC...ATTCTTTTATGTTATAGAAAATGCTTTTTAAGCAGGGGTGGGGGTCAAGATGTTAACTATTATTA -160
I I I  I I I I I  I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I  I I I
-226 TGATGTATTAACCCAAAGATTCTTCGTAATAGAAAATGTTTTTAAAG...... GGGGGAAACAGGGATTTTTATTATTA -154
-15 9 AAGAGCAAAAAAAAAAAAATGCATTTTGTTTGAAGACGCAGGGCACTGGAAACCCTGAGTTTCAGGACTCGCCTTTATTA -8 0
II I I I I III II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
-153 AAAGATAAAAGTAAA...... TTTATTTTTTAAGATATAAGGCATTGGAAACATTTAGTTTCACGATATGCCATTATTA -8 2
-79 GGTGTCCTCTATCTGATTGTTAGCAATTATTGATTTCGTC..AGAGAGAGAATAAATTGCTTGGGGATTCGGCCCTGCTC -2
II I I I I I I I I I I I I I I I I I I I I II I I I I I I II I I I I III III I I I I I I I I I I I I I I I I I I II I
-81 GGCATTCTCTATCTGATTGTTAGAAATTATTCATTTCCTCAAAGACAGACAATAAATTGACTGGGGACGCAGTCTTGTAC -2
-1 TGCGCTCTTCCTTTGCTGAAGGCCAGCGCTGAAGACTTCAGAGTCATG +47 mouse IL-5 sequence.
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-1 TATGCACTTTCTTTGCCAAAGGCAAACGCAGAACGTTTCAGAGCCATG +47 human IL-5 sequence.
Figure 2.3 Dot matrix comparison of the hIL-5 and mIL-5 upstream flanking 
regions. The alignment was performed using the program DIAGON with a 
span length of 21 and a score of 14.
hu
ma
n 
IL
-5
 
5'
 
fl
an
ki
ng
 s
eq
ue
nc
e
-32-
-109-
-186 -
-263 -
-340
-417 -
-175-835 -615 -395
flanking sequencemouse IL-5 5
Figure 2.4 U pstream  regions of A, the mIL-5 and B, the hIL-5 genes, 
show ing consensus binding sites for know n transcription factors and 
conserved sequences. More information about these potential regulatory 
sites is given in Table 2.2. Arrows indicate the orientation of each site with 
respect to the transcription initiation site (+1). The restriction endonuclease 
sites (in bold) are for later reference (Chapter 4).
CAGGGAGAAACATTCAGGCT CCTTCCAGCT TGATTCCTCT GCATCTTGAAACTAGAGAGT GCTGACGGA(TTciAAlF?rGtT£l-12 20 
EtATTGAACAATGAGAAGAG CACGACTGGAACCCGGTGCA GGGGAGCATG CCTGACACAG TGCTTGAGAG GCTGAGGCTG -1140 
AGGCAGGAGCATCAGAAGTTCATAGACAGTTTGGGCCACATAGTCAAGACTGTGTCCTAATAAACCCACC ACAAATGAAA -10 60 
GACAGAAGGAAAAGGAGAAG AAATGCGAACCTGCTGTGTG TGACAAGATA CAGAGAGAGC CAGGAGTCCTGTTGTCACCC-980
NFI
TGGAGCACCCCTCATACACACAGTAAGCTGCTTGAAAAQTGGGTCAAGGCCAtAGCCACCA AAGCAGTACAGGAAGGAGCC-90 0
“!► ^
TCTGCCCTGC ACTTTTTGTC ATAGGAACCA AGAAGCATCC TCTTATCTCC ACTCAGTCTG GGTTGGCCTT TTAGTAACAG -8 2 0 
ACAGGATGCTGATCAAAAACCTACATCATGCAACTCAACTCTGTCAGACCAGCTGCTTTAATAAATGTCTTTCCCAGAGA -74 0 
GTTTTCAATT CTTTTTTTCTTTTCTTTTTT TAAGCACAGATAAGTCTAGCTACCGCCAAT ATAGAAAAAA AAACACCCCC -660 
TTTCCCTTTTCTCTTTGGCAGTTTGGAGCAGGGTCTTGTGTGTTCCAGATTGAACTCACCTTTGCTGTACACACAAAAAA -580 
GCCAAAGATGCTGTCACCTC TTGATCCTCCTGACTGTACCTCCCACATCT GCTGGTGTGTACCACCACAC CTAGTAAGAT -500
PRL conserved motif
ATTCTCAACATTT^TGTATT TtTAGCCTAAC CCTGTTCGAG GTATAQ A ^ ^ A  A~F\CATTT TTTCTCAc Jt - 4 2 0
TGAGTTTAAC ACATATTAAA GCAGGTGTGG GGCAGGGAGG GGGGGATAAA AAAGAAGGTG CTCAAGAAAA GCCGATCACG -34 0flspMI
Spl Spl
CTCCCAAGAG TGTGAGCATfc GGCGTCTCTAGAGAGATtf 6 tOATATATGC ACAACTTTTA AAGAGAAATT CAATAACCAG -2 60----  Xbal
MAT-a2
AATGGAETg T AAATCTGGATCAAAGTTGTA GAAACATTCT TTTATGTTAT AGAAAATGCT TTTTAAGCAG GGGTGGGGGT-180
CAAGATGTTA ACTATTATTA AAGAGCAAAA AAAAAAAAAT GCATTTTGTT TGAAGACCCA GGGCACTGGA AACCCTCa g t T-1 PC 
GR/PR IL-5/GM-CSF conserved region
tTTCAGbACTC GCCTTTATTAC(3TGTCCTCTKTCTGATTGT TAGCfl ATTfl'nT^ÄTTTfWflAGAGAGAGAA T AAATTGCTT -20EcoNI ^  TATA box
GGGGATTCGG CCCTGCTCTG CGCTCTTCCT TTGCTGAAGG CCAGCGCT +29
CAP site
B.
ICS bf
GGATCCTAAT CAAGACCC3A GTGAACAtOAACfTCGACCCTG CCAACGCTTG GcIaGTTTCCATTTC&ATCAC TGTCTTCCCA - 4 28 
CCAGTATTTTCAATTTCTTTTAAGACAGATTAATCTAGCCACAGTCATAGTAGAACATAG CCGATCTGAAAAAAACATTC - 34 8 
CCAAT^WTAT'GTATfTt’AG CATAAAATTC TGTTTAGTGGTCTACCTTAT ACTTTGTTTf f f ^ @ l TCT TTTAAGAGGA -2 68
AGTTAfoTTTTCTGATTTlTAAGAAATGt^A A TbTGGGGCAATGATGTATTA ACCCAAAGAT TCTTCGTAAT AGAAAATGTT -18 8
si lener r binding site
TTTAAAGGGGGGAAACAGGGATTTTTA11TATTAAAAGATAAAAGTAAATTTATTTTTTAAGATATAAGGCATTGGAAACA -108
CK-1 IL-5/GM-CSF conserved region
TTtTAGTTTCACfcATATGCCATTATTAGGCATTCTCTATCT GATTGTTAGA AlAfrTAlTirCAT TTCCTCftAAG ACAGACAATA - 28
&&TTGACTGG GGACGCAGTC TTGTACTATG CACTTTCTTT GCCAAAGGCA AACGCAGAAC GTTTCAGAGC CATG +47
TATA box CAP site
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Table 2.2 Consensus sites found in the 5' flanking sequences of the murine 
and human IL-5 genes3.
consensus site gene & 5' end of site reference
1. IL-5/GM-CSF 
conserved region
hIL-5,-56 
mIL-5, -54
Campbell et al. 1988
2. glucocorticoid 
receptor
hIL-5, -488 
mIL-5, -77, -1234
Jantzen et al. 1987 
von der Ahe et a l  1985
3. cytokine consensus, 
CK-1 and CK-2
hIL-5, -105 
mIL-5, -103, -427
Stanley et al. 1985 
Shannon et al. 1988
4. MAT-a2b mIL-5, -253 Ko et al. 1988
5. octamer hIL-5, -234 
mIL-5, -453
Singh et al. 1986 
Staudt et al. 1986
6. Spl mIL-5, -302, -320 Kadonaga et al. 1986
7. HiNF-Ac hIL-5, -262, -342 
mIL-5, -490
van Wijnen et al. 1988
8. MRE CS2d hIL-5, -288 Culotta & Hamer 1989
9. ICS bf CSe hIL-5, -455 Shirayoshi et al. 1988
10. PRL conserved 
motiff
mIL-5, -430 Gutierrez-Hartm ann et al. 
1987
11. silencer binding 
siteg
hIL-5,-159 Weissman & Singer 1991
12. NFI hIL-5, -476 
mIL-5, -940
Hatamochi et al. 1986 
Leegwater et al. 1986
3 for further information on the sites numbered 1,2, 5,6 and 12 see Discussion, 
b MAT-a2 is a yeast mating type protein. The recognition site is of interest here because a 
lymphoid-restricted human homeobox protein has been shown to bind the same recognition 
site as the MAT-a2 protein and Drosophila homeotic proteins.
c HiNF-A is a protein which binds to A/T rich motifs in the promoter region of the human 
Hl, H3 and H4 histone genes.
d MRE CS2 is a metal-responsive-element core-sequence which is highly conserved in the 
metallothionein genes of higher eukaryotes.
e ICS bf CS is the conserved sequence for the interferon-consensus-sequence binding factor 
which is found in the promoter regions of interferon-inducible genes such as major 
histocompatibility (MHC) class I genes.
f PRL is the prolactin-conserved-motif bound by a factor from rat pituitary tumor cells which 
was characterised by an in vitro transcription assay and DNasel "footprinting".
8 Silencer binding site from a MHC class I gene which was originally identified as a negative 
regulatory element in yeast a2 mating-type repression.
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2.4 Discussion
The sequence of the upstream  region of mIL-5 was determined and 
analysis of the sequence revealed similarity with two repetitive elements 
approximately 1.3 kb and 2.4 kb upstream of the transcription initiation site. 
The sequences corresponded to B2 and B1 A lu -like repetitive elements, 
respectively. These repetitive elem ents are common in the m urine 
genome.
Two types of comparison, an alignment and a dot matrix comparison, 
were made between the first kilobase of the mIL-5 gene and all the known 5' 
sequence of the hIL-5 gene (-500 bp). Homology between the two genes 
extended up to approxim ately 300 bp upstream  of the transcrip tion 
initiation site with some stretches of similarity further upstream.
Searches were also carried out on both the mIL-5 and hIL-5 5’ flanking 
regions for consensus sequences associated w ith prom oter regions and 
consensus binding sites of known m am m alian transcription factors. A 
variety of sites were identified including some, NFI, octamer and Spl, for 
which the respective binding proteins have been well characterised in the 
literature. The five sites which were common to both genes are also shown 
on the mIL-5/hIL-5 alignm ent (Figure 2.2). Three of these sequences, 
IL-5/GM-CSF conserved region, CK-1 and HiNF-A, were in conserved 
regions of the two genes, although none of the three have been particularly 
well characterised. The two other sites, NFI and octamer, were not in 
conserved regions, nor were their respective sequences identical between 
the two genes. The NFI and octamer sites also differed in their positions 
relative to the transcription initiation site of each gene. Nonetheless, of all 
the sites identified (Figure 2.4), NFI and octamer were closest to their 
respective consensus sequences and so the NFI a n d /o r  octamer proteins 
may be able to bind to these sites and function in regulating IL-5 gene 
transcription.
NFI is a m em ber of the CTF/N FI gene family which is highly 
conserved among higher eukaryotes [Gil et al. 1988; Rupp et al. 1990]. NFI 
has been associated with tissue-specific induction of transcription of the
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myelin basic protein in the mouse cerebellum [Inoue et al. 1990b] and its 
many forms may have different functions in different cell types [Rupp et al. 
1990]. The NFI site in the mIL-5 gene (TGGGTCAAGGCCA) was more 
canonical (NFI consensus site being, TGGCANNNTGCCA [Borgmeyer et al. 
1984]) than the one in the hIL-5 gene (TCGACCCTGCCAA).
The octamer family of transcription factors are also associated with 
the transcription of many genes [Schaffner 1989]. The octamer family is 
known to have cell type-specific members, an example being OCT-2 which is 
lymphoid-specific [Staudt et al. 1986]. In the case of the octamer sites, the 
hIL-5 gene contained the canonical octamer site (ATGCAAAT) matching 
the consensus sequence exactly (ATGCAAAT). Nonetheless, an octamer 
site identical to that in the mIL-5 gene, which is in the reverse orientation 
(ATTTGAAT), has been shown to compete with the consensus sequence for 
binding of a lymphoid-specific octamer binding factor [Staudt et al 1986].
Figure 2.4 shows additional consensus sites on both the mIL-5 and 
hIL-5 upstream regions. In view of the demonstrated repressive effect of 
dexamethasone on murine [Wang et al. 1993] and human [Rolfe et al. 1992] 
IL-5 transcription, the potential sites for the glucocorticoid receptor at -77 
and -1225 in the mIL-5 gene and at -488 in the hIL-5 gene are of particular 
interest, although involvment of these sites in the action of 
dexamethasone could only be assessed in appropriate functional assays.
Although all sites in Table 2.2 are of potential interest it remains to be 
seen if they are in functional regulatory regions of the murine and human 
IL-5 genes. Chapter 3 describes the initial approach used in the search for an 
assay system suitable for locating functional cis-acting sequences of the 
mIL-5 gene.
CHAPTER 3
ANALYSIS OF mIL-5-REPORTER GENE CONSTRUCTS 
USING TRANSIENT TRANSFECTION ASSAYS
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3.1 Introduction
The aim of the present work was to define the sequences in the mIL-5 
gene which were important in transcriptional regulation using transient 
transfection assays. The immediate objective was to identify a mIL-5-reporter 
gene construct that showed the inducible and tissue-specific expression 
characteristic of the mIL-5 gene, including repression by the anti-inflammatory 
drug dexamethasone. This would represent the first step in a detailed analysis 
of the mechanisms controlling IL-5 transcription.
3.1.1 Reporter genes
Reporter genes are now widely used as an indirect measure of 
transcription initiated from enhancer/promoter sequences [for review see Alam 
and Cook 1990]. Reporter genes code for proteins that possess enzymatic 
activities which are not present in the cells used for transfection experiments. 
Thus, expression of such enzymatic activity can be directly attributed to the 
regulatory activity of the sequences present on the plasmid DNA transfected 
into the cells.
Two reporter genes, coding for chloramphenicol acetyltransferase (CAT) 
[Gorman et al. 1982a] and luciferase [deWet et al. 1987] were utilised during this 
investigation. Both reporter gene vectors are derived from pSV2 [Subramani 
and Southern 1983] and contain a segment of pBR322 DNA carrying the 
plasmid origin of replication and the ß-lactamase gene, which confers 
ampicillin resistance. Both vectors also contain the small t intron and a 
polyadenylation site from SV40 which are necessary for mature mRNA 
production in mammalian cells [Subramani and Southern 1983]. The cloning 
site for insertion of potential regulatory elements is located 5' of the CAT or 
luciferase coding sequences. The chimeric genes generated with these 
constructs were assayed quantitatively for expression in mouse T-cell derived 
tissue culture cell lines after transient transfection. The initial approach used to 
delineate regulatory elements was to compare expression of reporter constructs 
carrying 5' regions of the IL-5 gene progressively truncated from the 5’ end. It 
was expected that this would broadly locate the regulatory elements of interest 
which could be further studied using site-directed mutagenesis or internal
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deletions.
3.1.2 Transient transfection
In the work described in this chapter expression of reporter constructs 
was measured in transient transfection assays where the DNA was introduced 
as a covalently closed supercoiled plasmid. In this type of experiment a portion 
of the exogenous DNA becomes localised in the nucleus where it may be 
transcribed after interacting with appropriate nuclear proteins. Transient 
transfection is a popular method for assessing expression of cytokine genes in 
tissue culture cell lines [Rosenthal 1987; Taniguchi 1988]. The main advantage 
of the transient assay is the short time between transfection and harvest, 
allowing for rapid screening of large numbers of constructs, which is a 
necessary part of the process of identifying sequences involved in transcription. 
Another possible advantage of the transient assay is the extrachromosomal 
nature of the free plasmid which tends to reduce interference from host 
enhancers since such interactions are generally less effective in trans.
However, the artificial state of the DNA, including, for example the 
presence of bacterial methylation patterns and erroneous chromatin assembly 
on the soluble supercoiled plasmid, may be the biggest drawback of the 
transient transfection approach. The appropriate genomic enhancers and/or 
repressors may not function normally outside their usual chromatin 
environment. In addition, the large amounts of plasmid DNA entering the cell 
may interfere with coordinated assembly of the transcription apparatus on a 
particular template by competitively displacing critical factors which may be in 
low abundance. Nonetheless, there are many examples in the literature (Table 
3.1) where transient transfection assays have been used to identify DNA 
sequences of importance in transcriptional regulation. Consequently transient 
transfection was considered to be the most reasonable initial approach to use 
for mIL-5 regulation studies.
Two different methods of transfection were tested to introduce plasmid 
DNA into tissue culture cell lines. The first was a cationic liposome-mediated 
transfection utilising Lipofectin™ (BRL). It has been claimed that Lipofectin is 
up to 100-fold more effective than either the calcium phosphate or DEAE-
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dextran transfection procedures depending on the cell line [Feigner et al 1987]. 
The postulated mechanism of action for Lipofectin is that this cationic lipid 
complex acts as a carrier molecule for the negatively charged DNA [Feigner 
and Ringold 1989]. The DNA is trapped in the interior of the liposome/nucleic 
acid complex effectively neutralising the negative charges of the plasmid DNA. 
This complex is assumed to have a slightly positive net charge thus facilitating 
interaction and perhaps fusion with the negatively charged cell surface. The 
second transfection method was a physical method known as electroporation 
[for review see Potter 1988]. In this method an electrical pulse delivered by a 
capacitor is believed to transiently disturb membrane integrity creating pores 
through which the plasmid DNA enters the cell. Plasmid uptake has been 
assumed to occur by passive diffusion although recently evidence has been 
obtained suggesting that DNA entry is a rapid electrophoretic event [Klenchin 
et al 1991].
3.1.3 Murine T-cell lines for transient transfection
Three different mIL-5-producing mouse T-cell derived tissue culture cell 
lines were available at the commencement of this study, i) The T-cell 
hybridoma NIMP-TH1 [Warren and Sanderson 1985] (kindly supplied by Dr 
Colin Sanderson, National Institute for Medical Research, Mill Hill, UK) was 
originally cloned from a fusion between spleen cells from mice suffering a 
parasite-induced eosinophilia and an azaguanine-resistant subline of the 
thymoma BW5147. ii) The anti-conalbumin Th2 helper T-cell clone D10.G4.1 
[Kaye et al 1983]. D10.G4.1, which was derived from an AKR/J mouse, was 
obtained from DNAX Research Institute of Molecular and Cellular Biology, 
Inc., California, iii) The murine lymphosarcoma EL4, which was originally 
induced in C57B1 mice by 9,10-dimethyl-1,2-benzanthracene [Gorer 1950]. EL4 
clone 23 was obtained from Dr Colin Sanderson (National Institute for Medical 
Research, Mill Hill, UK). EL4 clone 23 is a subline which expresses relatively 
high levels of mIL5 mRNA after PMA stimulation [Sanderson et al 1986]. 
Previous work in this laboratory had shown that in NIMP-TH1 the regulation 
of IL-5 gene expression was largely transcriptional [Wang et al 1993].
3.1.4 Mouse IL-5 reporter gene expression
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Initial functional data were sought using a CAT reporter gene construct 
containing 547 bp of 5’ mIL-5 flanking sequence. At the commencement of 
these experiments this construct covered all of the 5' region where the sequence 
was established [Campbell et al. 1988]. Since the functional data available for 
other related cytokine genes (Table 3.1) suggested czs-acting DNA regulatory 
elements responsible for induction of transcription were often present within 
400 bp upstream of the site of transcriptional initiation, the 547 bp construct 
was a reasonable starting point. Subsequently, additional sequence upstream 
of the IL-5 gene was determined as described in chapter 2 and constructs 
carrying up to 3859 bp of upstream sequence were prepared and tested.
Table 3.1 Regions of 5' flanking sequence of cytokine genes necessary for 
_________ tissue-specific induction of transiently transfected reporter genes.
Cytokine
Minimum 5' 
flanking sequence 
for tissue-specific 
induction
Reporter
gene
Reference
hGM-CSF -53 to +37 CAT Nimer et al. 1988
hIL2 -319 to +51 CAT Fujita et al. 1986
hIL2 -326 to -52a CAT Durand et al. 1987
hIL3 -313 to +42 CAT Shoemaker et al. 1990
mIL3 -358 to +12 CAT Dr B vanLeeuwenb
a Heterologous promoter construct, 
b Personal communication.
In addition, luciferase reporter gene constructs were utilised and assay 
for expression of whole gene reporter constructs was carried out using PCR.
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3.2 Materials and Methods 
3.2.1 Tissue Culture
All cells were maintained at 37°C, 5% CO2 and 95% humidity in a 
Hotpack CO2 incubator model 351920. NIMP TH1, EL4 and D10.G4.1 cells 
were maintained in RPMI 1640 (Gibco) medium with the following additives: 
10 mM NaCl; 1 mM sodium pyruvate; 62 pl/1 monothioglycerol; 100 units/1 
benzylpenicillin (CSL); 100 mg/1 streptomycin (Sigma); 2 mM L-glutamine 
(CSL).
The RPMI 1640 medium for the T cell clone D10.G4.1 had two additional 
additives:- 0.05 mM ß-mercaptoethanol (Kodak) and 10 units/ml of human 
IL-2 (Amersham) or later, the IL-2 source was conditioned medium from a cell 
line transfected with a mouse IL-2 construct [Karasuyama and Melchers 1988]. 
This conditioned medium was titrated to determine the minimum dilution 
necessary for D10.G4.1 survival. D10.G4.1 cell growth was induced by 
allogeneic stimulation every 10-14 days with irradiated spleen cells from 6-8 
week old C57B1/6 female mice (supplied by The John Curtin School of Medical 
Research Animal Breeding Facility). Briefly, mice were killed by either cervical 
dislocation or CO2 gas before dissecting out the spleen in a biohazard hood 
under sterile conditions. The material was kept on ice between the following 
processing steps. Spleens were sieved through a 0.5 to 1.0 mm sieve and 
suspended in serum-free RPMI 1640 medium at lxlO7 cells/ml. Spleen cells 
were then y-irradiated with 2000-3000 rads using a 60Co source (CSIRO Plant 
Industry, Black Mountain, Canberra). D10.G4.1 cells were resuspended at 
5xl05/m l and stimulated with irradiated spleen cells at 5xl06/ml.
3.2.2 Northern Blot Analysis of mRNA
RNA was prepared according to the method described (section 3.2.7.1). 
All glassware utilised in RNA work was pre-baked at ~220°C for a minimum of 
2 hrs. In addition all water used in RNA work was pre-treated with diethyl 
pyrocarbonate (DEPC) as described in Maniatis et al. [1982]. Two solutions not 
described in the text are 20xSSC (3 M NaCl, 0.3 M trisodium citrate, pH 7.0) and 
50x Denhardt's solution (10 g/1 Ficoll; 10 g/1 polyvinylpyrrolidone; 10 g/1 BSA
52
(Pentax Fraction V)) [Maniatis et al. 1982].
3.2.2.1 Preparation of formaldehyde-agarose denaturing gels
Electrophoresis of RNA on formaldehyde-agarose gels was carried out in 
either a Pharmacia GNA-100 electrophoresis apparatus (8 cm x 10 cm tray with 
50 ml gel volume) or a Bio-Rad DNA Sub-Cell™ (15 cm x 15 cm tray with a 100 
ml gel volume). The following protocol is for the 50 ml gel in the Pharmacia 
apparatus. A 1.1% agarose gel was made by dissolving 0.55 g of agarose in 36 
ml of DEPC treated H2 O in a microwave oven, then cooling this solution to 
60°C before adding 5 ml of lOx RNA gel buffer (200 mM triethanolamine, 50 
mM EDTA, pH 7.4) and 9 ml of 37% formaldehyde (giving 2 M formaldehyde 
in the gel). The gel solution was then poured into the gel mould and allowed to 
set at room temperature (covered in Gladwrap in a fume hood) for 1 hr.
3.2.2.2 Preparation of RNA samples for electrophoresis
Twenty micrograms of total RNA was dissolved in 6 pi of DEPC treated 
H 2 O and 14.4 pi of RNA sample buffer (made by adding 1 ml of deionized 
formamide, 200 pi of lOx RNA gel buffer and 300 pi of 37% formaldehyde) was 
added before denaturing at 60°C for 15 minutes. Samples were then transferred 
to ice and 1 pi of RNA loading solution (50% glycerol, 1 mM EDTA, 0.4% 
bromophenol blue, 0.4% xylene cyanol) was added just prior to loading on the 
formaldehyde-agarose denaturing gel.
3.2.2.3 Electrophoresis of RNA
The Pharmacia GNA-100 electrophoresis apparatus required 400 ml of 
electrophoresis buffer consisting of 40 ml of lOx RNA gel buffer, 72 ml of 37% 
formaldehyde and 288 ml of DEPC treated H2 O. The Bio-Rad DNA Sub-Cell™ 
required 1500 ml of electrophoresis buffer consisting of 150 ml of lOx RNA gel 
buffer, 270 ml of 37% formaldehyde and 1080 ml of DEPC treated H2O.
The formaldehyde-agarose denaturing gel was set up in the appropriate 
electrophoresis apparatus and electrophoresis buffer was added to a level that 
did not permit buffer to enter the wells. RNA samples were loaded and
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electrophoresed into the gel at 60 mA for 15-20 minutes before topping up the 
buffer level to cover the gel (buffer was circulated with an Eheim 1018 pump 
when using the Pharmacia GNA-100 electrophoresis apparatus). RNA samples 
were electrophoresed until the bromophenol blue dye front had migrated two- 
thirds the length of the gel.
3.2.2.4 Blotting of RNA to nylon-reinforced-nitrocellulose
After electrophoresis the gel was submerged in distilled water for 5 
minutes and then lOx SSC for 10 minutes. During this time a tray was filled 
with 20x SSC and the following were soaked in it (all handled with gloved 
hands or forceps); i) three sheets of Whatman 3MM paper cut to the same 
width as the gel and -30-40 cm in length, ii) one piece of (pre-wet) nylon- 
reinforced-nitrocellulose (Schleicher and Schuell BA-S 85) cut with -5 mm 
overhang around the perimeter of the gel. iii) three sheets of Whatman 3MM 
cut to the same size as the gel.
The transfer apparatus was set up by placing a glass plate over a tray 
containing 20x SSC solution. The three 30-40 cm sheets of pre-soaked 3MM 
paper were placed on the glass plate with their ends submerged in the 20x SSC 
solution. The gel was placed on top of the 3MM sheets with well openings 
facing down and care was taken to avoid trapping air bubbles between the gel 
and the 3MM paper. The pre-soaked nylon-reinforced-nitrocellulose was 
placed on top of the gel, again excluding air bubbles. The three sheets of gel­
sized 3MM paper were placed on top of the nylon-reinforced-nitrocellulose 
again excluding air bubbles. The transfer apparatus was then covered with 
gladwrap to minimize evaporation. The section of gladwrap covering the top 
piece of 3MM was cut out with a razor blade. A stack of paper towels was 
positioned over the top piece of 3MM paper in order to transfer the RNA from 
the gel to the nylon-reinforced-nitrocellulose filter via capillary action. The 
transfer was left for -20 hrs at room temperature with a -500 g weight placed 
on top to ensure even transfer.
The nylon-reinforced-nitrocellulose filter was then removed and air 
dried on Whatman 3MM paper for -30 minutes. The filter was then 
sandwiched between two sheets of Whatman paper and baked in a vacuum
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oven at 80°C for 1.5-2 hrs.
3.2.2.5 Preparation of radioactive probe by random primer method
Approximately 100 ng of probe fragment and 1 pg of random primer (10- 
mer) were mixed in an Eppendorf tube in annealing buffer (15 mM Tris, pH 7.4, 
15 mM MgCl2, 75 mM NaCl) to a volume of 10 pi. This mixture was then boiled 
for 4 minutes before snap chilling in an ice/water bath. The probe synthesis 
reaction was set up by adding the following reagents to the annealed 
template/primer: 8 pi of 5x probe mix (5 mM each of dA, G, C and TTP, 50 mM 
MgCl2, 250 mM sodium phosphate, pH 6 .8); 1 pi of DTT; 10 pi sddH2Ü; 10 pi of 
a_32p_dATP (3000 Ci/mmol, Amersham); 1 pi (5 units) of Klenow fragment of 
E. coli DNA polymerase I (Promega). The 40 pi reaction was incubated at 37°C 
for 2-3 hrs and incorporation was estimated by running 1 pi of probe synthesis 
product on a TLC plate (Merck) in 0.75 M KH2PO4. Finally, unincorporated cc- 
32P-dATP was removed by passing the probe synthesis reaction through a 
NICK Column (Pharmacia) in accordance with the manufacturer's instructions. 
The eluted probe (in 400 pi of T10E0.1) was then boiled for 5 minutes before 
adding directly to the hybridisation solution.
3.2.2.6 Hybridisation and autoradiography
The baked nylon-reinforced-nitrocellulose filter from section 3.2.2.4 was 
pre-hybridised at 42°C for at least 4 hours (up to overnight) in 30 ml of 
hybridisation buffer for 10 cm x 8 cm filter. The hybridisation buffer (lOx SSC, 
100 mM sodium phophate pH 6.5; lOx Denhardts solution; 50% deionised 
formamide) contained 40 pg/m l of sonicated salmon sperm DNA (Sigma) 
[prepared as in Maniatis et al. 1982] which had been boiled for 5 minutes. The 
radioactive probe was added and the hybridisation continued for a further lb- 
20 hrs at 42°C. The nylon-reinforced-nitrocellulose filter was first washed in 
500 ml of 2x SSC; 0.1% SDS at room temperature then in 250 ml of lx SSC; 0.1% 
SDS at 42°C for 30 minutes. The last wash was repeated with fresh solution 
before washing twice in 0.5x SSC; 0.1% SDS at 42°C for 30 minutes. Finally, the 
filter was placed between two sheets of plastic microwave oven wrap and 
exposed to Kodak XAR film at -70°C in a cassette containing intensifying
screens.
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3.2.3 Reporter Gene Constructs
This section describes three different types of reporter gene plasmids. 
All constructs were sequenced (see section 4.2.2) across ligation junctions to 
confirm exact boundaries. The method for large scale CsCl preparative 
gradients is described in section 2.2.3.
3.2.3.1 CAT vectors
pSVOCAT and pRSVCAT are described in Gorman et al. [1982a and b]. 
pSVOCAT is shown in Figure 3.1.
SV40 polyadenylation site
pSVOCAT 
4504 bp
SV40 small t intron
5-GCG GTATTTTCTCCTT-3' 
\  sequencing primer 
V \  RC44 ,
CAT Gene
Hin dill 3'-GGG TTA CCG TAG CAT-5’
cloning sequencing primer
site RC37
Figure 3.1 pSVOCAT. The diagram shows the Hindlll cloning site and position 
of sequencing primers RC44, which extends down toward the CAT gene, and 
RC37 which extends back from the CAT gene.
The first mIL-5CAT construct was generated by subcloning a PCR 
product. This was obtained using the 5' primer PB1 (which binds to the region 
-547 to -516, and has a Hindlll site on its 5' end) and the 3' primer PB2 (which 
binds to the region +45 to +74, and has an EcoRI site on its 5' end) on D10.G4.1
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genomic DNA. This fragment was subcloned into M13mpl9 and its sequence 
determined. The M13mpl9 vector containing the 627 bp PCR product was 
digested with Hindlll (Promega) and Eco47III (Amersham). The Hindlll end 
was filled in using the Klenow fragment of DNA polymerase I (Promega). 
pSVOCAT was linearised at the Hindlll cloning site (located 37 bp 5' of the CAT 
gene coding sequence), the ends were filled in with Klenow fragment of DNA 
polymerase I and phosphatased using alkaline phosphatase (Boehringer- 
Mannheim). The 579 bp blunt-ended PCR fragment was ligated into the blunt- 
ended and phosphatased pSVOCAT vector. Constructs with the insert in both 
the forward and reverse orientation were prepared. The forward construct has 
547 bp of mIL-5 5' of the CAP site and 25 bp of mIL-5 3’ of the CAP site.
The largest mIL5-CAT construct contained -3859 to +25 of the 5' mIL-5 
genomic sequence relative to the CAP site. This construct (known as 
-3859mIL-5CAT) was created using a 3884 bp Hindlll to Eco47III fragment from 
pSV2neo-10kbmIL-5G (kindly provided by Dr H. D. Campbell) which had been 
prepared on a LMP agarose gel (section 2.2.7). The Hindlll site was filled in 
using the Klenow fragment of DNA polymerase I (Promega) and the fragment 
was cloned into the phosphatased and blunt-ended Hindlll cloning site of 
pSVOCAT.
Initial 5' truncation mutants were obtained by restriction digests of 
-547mIL-5CAT. The 5' end of this construct has an NheI site which was 
generated upon ligation of the two blunt Hindlll ends. Double digests were 
performed with Nhel and four other restriction enzymes unique to the -547 bp 
of mIL-5 sequence. The enzymes employed were Accl to create -458mIL-5CAT, 
Xbal to create -312mIL-5CAT, Nsil to create -140mIL-5CAT and EcoNI to create 
-88mIL-5CAT. Noncompatible sticky ends were made blunt using T4 DNA 
polymerase before the vector was purified on an LMP agarose gel (section 2.2.7) 
and religated before transformation into DH5a (section 2.2.1.1) for plasmid 
preparation (section 2.2.3).
3.2.3.2 Luciferase vectors
Luciferase vectors pSVOAL and pRSVL are described in detail in deWet 
etal [1987].
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3.2.3.3 Whole gene reporter constructs
The HmdIII-Hiwdlll 10,040 bp mIL-5 genomic fragment was transferred 
from pSV2neo (kindly provided by Dr. H.D. Campbell) to pSP73 (Promega), a 
bacterial vector containing no eukaryotic promoter sequences. This construct 
was designated pSP73-10kbmIL-5G. A 10 bp linker containing a unique Mlul 
restriction site was cloned into the unique BsfEII site in the 3’ untranslated 
region of the mIL-5 gene, creating pSP73-10kbmIL-5G(M/wI). This minor 
insertion provided the basis for distinguishing between expression from the 
transfected mIL-5 construct and expression from the endogenous mIL-5 gene 
(Figure 3.2). An analogous construct, pSP73-10kbmIL-5G(EcoRV), contained an 
EcoRV linker at the same site.
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Polyadenylation site
10 bp M/uI 
BstEII linker
Exon IV was inserted 
into
Exon III u n iq u e  B s tE ll  
site
(see below).
Exon II
Exon II
Position of 10 bp M lu l  linker in gene 
5'-GTG ACA GTA CGC GTC-3'
3'-T CAT GCG CAG CAC TG-5'
Unspliced mIL-5 RNA transcript
Intron I Intron II Intron III' '  *
I I 
I I 
I I 
I  f  
I I
t
7
Processed mIL5, v *
mRNA
-AAAAA-3'
-LI— 1 J-TTTTTTT-5'
PCR primer PB19 ;
5'-ATT GAC CGC CAA AAA GAG AAG TG-3’
PCR primer PB20 
3'-TCA TGC GCA GCA CTG GGA CTT-5'
Figure 3.2 mIL-5 whole gene-PCR reporter construct, showing how expression 
is detected by PCR primers PB19 and PB20.
A positive control for PCR analysis was constructed from a mammalian 
expression vector, pcEXV3 [Miller et al. 1985] carrying a 6457 bp mIL-5 genomic 
fragment (kindly provided by Dr H. D. Campbell). This fragment spans Xbal  to 
H i n  d ill and includes 312 bp of 5' mIL-5. pcEXV3 contains SV40 
enhancer/promoter sequences which generate high expression levels in
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mammalian cells. This vector was modified to create a construct analogous to 
pSP73-10kbmIL-5G(EcoRV) by inserting an EcoRV linker into the unique BsfEII 
site of the mIL-5 gene. This positive control construct was designated pcEXV3- 
6.5kbmIL-5G(£coRV). A second positive control pcEXV3-6.5kbmIL-5G(M/uI) 
was created by inserting an Mlul linker at the same site.
3.2.3.4 Polymerase chain reaction primers
The PCR approach to investigating mIL-5 gene expression required the 
construction of 6 different PCR primers (Figure 3.3).
PCR primers MF74 and MF75 were designed by Dr M. C. Fung to detect 
wild type mIL-5 expression. PCR primers PB19 and PB20 were designed to 
detect expression from the modified mIL-5 genomic construct carrying the Mlul 
linker. PCR primer PB26 was designed to amplify with PB19 in detecting 
expression from the modified mIL-5 genomic construct carrying the EcoRV 
linker. PCR primer PB21 was designed to test primers PB20 and PB26 in PCR 
reactions and also as a primer to verify the sequence across the Mlul and EcoRV 
linker inserts.
In experiments with the positive controls it was established that 
PB19/PB20 were far less effective PCR primers than PB19/PB26 (see Figure 3.10 
B and C in Results).
3.2.4 Transient Transfection Assays
Supercoiled plasmid DNAs carrying mIL-5-CAT reporter gene 
sequences were prepared using the CsCl-ethidium bromide density gradient 
method as described in section 2.2.3.
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10 bp EcoRV linker 
5-GTG ACC ACG ATA TCT-3'
3'-G TGC TAT AGA CAC TG-5'
mIL-5 Gene
intron I intron II intron III '  * „
>-----------------  PCR primer MF75
T-GCG TCC GAC CGG AGT TTG AC-5'
cDNA
V lT l l l“I -5’
PCR primer PB26
3'-G TGC TAT AGA CAC TGC GAC TTG-5’
PCR primer MF74
5’-TTG AC A AGC A AT GAG ACG ATG AG-3'
PCR primer PB20
3'-TCA TGC GCA GCA CTG GGA CTT-5'
PCR primer PB21
5-CGC AGG CTG GCCTCA AACTG-3'
PCR primer PB19
5'-ATT GAC CGC CAA AAA GAG AAG TG-3'
Figure 3.3 Summary of mIL-5 PCR primers used on whole gene reporter 
constructs.
3.2.4.1 Liposome-mediated transfection
Lipofectin™ (BRL) is a 1:1 (w/w) mixture of DOTMA, a synthetic 
cationic lipid, N-[l-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
chloride, and dioleoyl phosphatidylethanolamine and was used as a DNA
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delivery agent.
Transfection conditions were optimised by varying the amount of 
plasmid DNA and Lipofectin™ reagent within the range recommended by the 
manufacturer. The transfection procedure was carried out in a 12 well plate 
(Cat. No. 76-053-05, Linbro, Flow Laboratories), each well having ~7.5 ml 
capacity. Cells were first washed twice in serum-free RPMI1640 medium and 
then resuspended at a concentration of 2x106/ml. Plasmid DNA (optimally 10 
jig) was diluted to 750 jil in serum-free RPMI 1640 medium in a sterile 
Eppendorf tube. Optimally 50 |ig (=50 |il) of Lipofectin™ was dispensed into a 
sterile 5 ml polystyrene Falcon tube containing 700 jil of serum-free RPMI 1640 
medium. The diluted plasmid DNA was mixed with the Lipofectin™ in the 
polystyrene tube and allowed to stand at RT for approximately 10 minutes 
before resuspending 2xl06 cells in the 1.5 ml of Lipofectin™/plasmid DNA 
mixture with gentle swirling. After 5 hours incubation at 37°C the medium was 
drawn from the wells (cells were settled on the bottom) and replaced with 5ml 
of fresh RPMI 1640 medium supplemented with 10% FCS. After overnight 
incubation the medium was replaced again. The transfected cells were divided 
into two halves and PM A (to 10 ng/ml final concentration) was added to one 
half. The cells were harvested after another 24 hours of incubation.
3.2.4.2 Electroporation
Optimal electroporation conditions were established as described in 
Results. The conditions described below are those which ultimately gave the 
most consistent and reproducible transfections. Incubating cells on ice before 
or after electroporation did not increase transfection efficiency. RPMI 1640 
medium with 10% FCS gave more consistent data as an electroporation 
medium than PBS (either at 0°C, 4°C or RT) or serum-free RPMI 1640 (either at 
0°C, 4°C or RT).
Cells were resuspended (at lxlO6 - 2xl06 /ml) in fresh medium the day 
before electroporation. Cells were centrifuged and resuspended in RPMI 1640 
complete with 10% FCS at a concentration of 1x10s /ml. Two hundred 
microlitres (2xl07 cells) were mixed with vector DNA (30 jig for reporter gene 
analysis or 10 jig for PCR analysis) in an 0.4 cm Gene PulserR cuvette (Bio-Rad).
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Electroporation was performed with a Bio-Rad Gene Pulser™ and Bio-Rad 
Capacitance Extender. Empirically determined optimum parameters were 270 
V at 960 pF for NIMP-TH1 (z ~27±2 ms); 250 V at 500 pF for EL4 (z ~14±2 ms) 
and 300 V at 500 pF for D10.G4.1 (x -15+2 ms). The 400 pi of electroporated 
cells was immediately transferred to 20 ml of fresh medium in an 80 cm2 tissue 
culture flask (Nunc). The cells were allowed to recover for -16 hrs (overnight). 
The transfected cells were divided in half and PMA was added to one half to a 
final concentration of 10 ng/ml for NIMP-TH1 and EL4, or Con A (5pg/ml) for 
D10.G4.1. Cells were harvested after 6 hours stimulation for PCR analysis and 
12 to 16 hours for reporter gene analysis.
3.2.5 Chloramphenicol Acetyltransferase (CAT) assay
3.2.5.1 Acetyl CoA/TLC method
Early experiments with the CAT reporter gene utilised acetyl CoA as the 
substrate for the CAT enzyme assay [Gorman et al. 1982a]. Di- or mono- 
acetylated 14C-labelled chloramphenicol product was separated from 
unacetylated substrate using thin layer chromatography (TLC).
Transiently transfected cells were harvested 36-48 hours after 
electroporation, including stimulation time. Cells were transferred to a 50 ml 
polypropylene centrifuge tube (NUNC), the tissue culture flask was rinsed once 
with 10 ml of PBS containing 5 mM EDTA, and this wash was pooled with the 
culture sample. Cells were centrifuged at 20°C, 1500 rpm for 5 minutes in a 
Technospin R (SorvallR Instruments, Du Pont). The cells were then washed 
once in 30 ml of PBS. After the second centrifugation the supernatant was 
discarded and the tubes were inverted on tissue paper to drain. Cell pellets 
were resuspended in 150 pi of 0.25 M Tris-HCl, pH 8.0, and transferred to 1.5 
ml Eppendorf tubes. At this point samples were either stored at -20°C or 
processing continued. Further processing involved two 10 second bursts of 
sonication (Ystrom Sonic Pen) with the sonicator on power setting 7. Samples 
were maintained on ice between sonication bursts. Samples were then 
incubated at 65°C for 10 minutes and immediately centrifuged in an Eppendorf 
centrifuge at 4°C for 10 minutes. Each supernatant (140 pi) was transferred to a 
fresh Eppendorf tube. Forty microlitres of this supernatant was transferred to
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another tube for enzyme assay. A master mix for CAT assay was made so that 
each assay contained 70 pi of 0.25 M Tris-HCl, pH 8.0; 10 pi of 14C- 
chloramphenicol, 55 mCi/mmol (Amersham International) and 10 pi of 30 mM 
acetyl CoA (dissolved in 2 mM MES, pH 6.0). The 130 pi samples were 
incubated at 37°C for 4 hours. Positive and negative enzyme controls were 
included in the assay. The positive control contained 1 pi (~1 unit/pi) of CAT 
enzyme (Boehringer-Mannheim) diluted in 0.25 M Tris-HCl pH 8.0 and the 
negative control 0.25 M Tris-HCl pH 8.0 alone.
Following incubation, 500 pi of ethyl acetate was added and each sample 
was vortexed for 15 seconds before centrifuging for 2 minutes and the upper 
phase was then transferred to a new Eppendorf tube. Another 500 pi of ethyl 
acetate was added to the aqueous phase from the CAT enzyme assay and each 
sample was vortexed again, centrifuged and the upper ethyl acetate phase 
pooled with the first extraction. The 1 ml of ethyl acetate was dried in a 
Speedvac (Savant). When dry, the pellet was resuspended in 4 pi of ethyl 
acetate and spotted onto a TLC sheet (Merck). TLC was run in 
chloroformimethanol (95:5 v/v). The resultant chromatograph was exposed to 
X-ray film. Quantitation involved cutting out the bands containing substrate or 
product (located with the aid of the autoradiogram) and counting in a 
scintillation counter using a toluene-based scintillant.
3.2.5.2 Butyryl CoA/LSC method
Later CAT assays were assessed by a faster and immediately quantifiable 
method developed by Seed and Sheen [1988]. This method involved extraction 
of butyrylated 14C-chloramphenicol product with an organic solvent (mixed 
xylenes) followed directly by liquid scintillation counting (LSC).
The transfected cell extract preparation and CAT enzyme assay was 
identical to that described for the acetyl CoA method in the previous section 
except the 10 pi of 30 mM acetyl CoA was replaced with 5 pi of n-butyryl CoA, 
5 mg/ml (Sigma)
Following incubation, 300 pi of mixed xylenes (Aldrich-Chemie) was 
added to each sample and the mixture vortexed for 30 seconds before
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centrifuging (at RT) for 3 minutes to separate the phases. The upper phase 
(xylenes) was transferred to a new tube containing 100 pi of 0.25 M Tris-HCl, 
pH 8.0 for back-extraction. After vortexing for another 30 seconds and 
centrifuging, the upper xylene phase was transferred to another tube for a 
second back extraction. Finally 200 pi of the xylene phase was removed and 
placed in a scintillation pony vial (Packard). Five hundred microlitres of 
Optiscint (LKB) was added and the butyrylated 14C-chloramphenicol was 
measured in a scintillation counter.
3.2.6 Luciferase assay
Tissue culture cells were harvested and assayed for luciferase activity 
[Brasier et al. 1989] 24 hours after electroporation with luciferase reporter gene 
constructs. The harvesting procedure was identical to that described for the 
CAT assay in section 3.2.5.1 except the drained cell pellet was resuspended in 1 
ml of lysis buffer (1% Triton X-100, 25 mM glycylglycine, pH 7.8, 15 mM 
MgSC>4,4mM EDTA, with DTT added to 1 mM just prior to use). The cell lysate 
was transferred to an Eppendorf tube and centrifuged for 5 minutes at 4°C.
The supernatant was transferred to a new Eppendorf tube and 100 pi of 
this cell lysis extract was mixed with 460 pi of assay buffer (25 mM 
glycylglycine, pH 7.8,15 mM MgSC>4, 4 mM EDTA, 15 mM K3PO4 ,pH 7.8, with 
ATP and DTT added to 2 mM and 1 mM, respectively, just prior to use) in a 5 
ml Roehren tube (No 55.476, Sarstedt). Luciferin (Sigma) was freshly diluted 
from a 33 mM stock (stored at -20°C in foil to protect from light) to 200 pM in 
luciferin dilution buffer (25 mM glycylglycine, pH 7.8, 15 mM MgSC>4, 4 mM 
EDTA, with DTT added to ImM just prior to use). The luciferin solution was 
added to a polystyrene 5 ml tube (Falcon) and set up in a Lumat LB9501 
luminometer (Berthold) for automatic 100 pi injections into each assay sample. 
A luciferase (Sigma) standard curve was also prepared by diluting stock 
luciferase in 0.75 M glycylglycine pH 7.8. Relative light units for each sample 
were read in the raw data mode on the luminometer and were integrated 
values over 4 seconds.
3.2.7 Polymerase Chain Reaction Assay for mRNA Expression
3.2.7.1 Small scale total RNA preparation
The procedure used was adapted from the method of Chomczynski & 
Sacchi [1987]. Approximately 2xl07 cells were transferred to a 50 ml 
polypropylene centrifuge tube (Nunc), the tissue culture flask was rinsed once 
with 20 ml PBS (containing 5 mM EDTA) and this was pooled with the culture 
sample. Cells were centrifuged at 20°C, 1500 rpm for 5 minutes in a Technospin 
R centrifuge. The supernatant was poured off and the tube inverted on tissue 
paper to drain. The cell pellet was resuspended in 500 pi of solution D (4 M 
guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, 100 mM 
ß-mercaptoethanol) and transferred to a sterile Eppendorf tube. The following 
solutions were added: 50 pi of 2 M sodium acetate (pH 4.0); 500 pi of 
equilibrated phenol [Maniatis et al. 1982] and 100 pi of chloroform-isoamyl 
alcohol (49:1). Each sample was vortexed for 10 seconds before being stored on 
ice for 10 minutes or at -20°C for long term storage.
Phases were separated by a 5 minute spin in an Eppendorf centrifuge at 
4°C. Carefully avoiding debris at the interface, the aqueous phase (500 pi) was 
transferred to a new Eppendorf tube and 500 pi of isopropanol was added to 
precipitate the RNA. Samples were immediately centrifuged at 4°C for 15 
minutes. The supernatant was aspirated off using a fresh micropipette tip on 
the end of a Pasteur pipette for each sample to avoid cross-contamination. 
RNA pellets were washed with 1 ml of 70% ethanol (at RT) then samples were 
centrifuged for a further 5 minutes before aspiration. RNA pellets were then 
dissolved in 300 pi of DEPC-treated H20 , ethanol precipitated, washed with 
70% ethanol, dried under vacuum and resuspended in 100 pi of DEPC-treated 
H20. OD readings were taken at 260 nm and 280 nm on 10 pi of sample diluted 
to 1 ml. Calculations of concentration were based on the relationship where an 
OD at 260 nm of 1 corresponds to an RNA concentration of 40 pg/ pi [Maniatis 
e t a l  1982].
3.2.7.2 cDNA synthesis
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One microgram of total RNA was diluted to 10 pi in DEPC-treated H20.
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This sample was then denatured at 65°C for 5 minutes and placed on ice. A 
master mix for the Moloney Murine Leukemia Virus Reverse Transcriptase 
(MMLV-RT) reaction was prepared to ensure all samples were subjected to the 
same conditions. The final reaction conditions were: 50 mM Tris-HCl (pH 8.3), 
75 mM KC1, 3 mM MgCl2 [i.e., lx  MMLV-RT buffer (BRL)]; 0.5 mM each of 
dGTP, dATP, dTTP, dCTP; 5 p g /m l oligo (dT)12.i8; 40 units of RNasin 
(Promega); 1 mM DTT; 200 units MMLV-RT (BRL). The reaction mixture (20 pi) 
was incubated at 37°C for 1 hr before being heat-inactivated at ~95°C for 5 
minutes and stored on ice ready for use in the PCR reaction.
3.2.7.3 Polymerase chain reaction
The polymerase chain reaction (PCR) was carried out on between 2 pi 
and 20 pi (depending on the PCR primer pair) of heat-inactivated product from 
the cDNA synthesis. A PCR master mix was prepared for each pair of primers. 
The PCR reaction conditions were: 50 mM KC1, 10 mM Tris, pH  8.8, 1.5 mM 
MgCl2, 0.1% Triton X-100 [i.e., lx  Taq buffer (Promega)]; 1 mM for each primer, 
0.2 mM each of dATP, dGTP, dTTP, dCTP. The reaction volume depended on 
the PCR machine employed. Early PCR work was performed in an Innovonics 
Gene Machine with a 50 pi reaction volume overlayed with approximately 100 
pi of mineral oil. PCR generally consisted of 30 cycles: 94°C for 1 minute to 
denature the DNA template; 56°C for 1 minute for annealing of primers and 
72°C for 1 minute for Taq polymerase extension. Similar conditions were used 
for the Corbett Research FTS-lc machine except denaturation times were 
reduced to 45 seconds and annealing times were reduced to 30 seconds. 
Toward the end of this work a Corbett Research FTS-ls was employed. The 
PCR in this machine was carried out in a capillary in a volume of 20 pi. 
Reaction times were altered to 15 seconds at 94°C, 15 seconds at 62°C and 60 
seconds at 72°C. The products of PCR reactions were loaded directly onto a 
1.5% agarose gel along with a 1 kb ladder size standard (BRL).
67
3.3 Results
3.3.1 Murine Cell Lines Expressing IL-5 mRNA
Two mouse T cell lines, NIMP-TH1 [Warren and Sanderson 1985] and 
EL4 clone 23 [Sanderson et al. 1986; Tominaga et al. 1988], which were known to 
express IL-5 mRNA when stimulated with PMA, were available at the 
commencement of this study. These cell lines represented potential models for 
studying the inducible expression of IL-5 in T lymphocytes. Of these, the T cell 
hybrid NIMP-TH1 had been studied previously in this laboratory and it had 
been established that the regulation of IL-5 expression was largely 
transcriptional using nuclear run-on assays [Wang et al. 1993]. The T cell clone 
D10.G4.1 [Kaye et al. 1983] was also available. D10.G4.1 is much more closely 
related to normal T lymphocytes requiring stimulation via the antigen receptor 
for growth.
Since T cell hybrids can be unstable, a number of independent clones of 
NIMP-TH1 were obtained by dilution cloning and analysed for IL-5 production 
using a BCLi bioassay [O'Garra et al 1989] which was carried out by Mrs Sally 
Ford. Positive clones showing inducible expression were further analysed by 
Northern analysis (Figure 3.4.A). The levels of IL-5 mRNA produced by 
NIMP-TH1 even after purification were much lower than those produced by 
D10.G4.1. EL4 also produced lower levels than D10.G4.1 (Figure 3.4.B). 
However, the known difficulties of growing and transfecting T cell clones like 
D10.G4.1 led to the decision to use the T cell lines and particularly NIMP-TH1 
for most of the experiments. It was proposed to extend the analysis to D10.G4.1 
whenever possible to confirm that the findings obtained with the T cell lines 
were also true for the T cell clone D10.G4.1 as this is more representative of 
normal T lymphocytes.
B
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1  -<-23 130 bp
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A. Lane 1- NIMP-TH1 clone 33 unstimulated.
Lane 2- NIMP-TH1 clone 33 PMA (10 ng/ml) stimulated. 
Lane 3- NIMP-TH1 clone 40 unstimulated.
Lane 4- NIMP-TH1 clone 40 PMA (10 ng/ml) stimulated. 
Lane 5- D10.G4.1 unstimulated.
Lane 6- D10.G4.1 Con A (5 pg/ml) stimulated.
B. Lane 1- EL4 unstimulated.
Lane 2- EL4 PMA (10 ng/ml) stimulated.
Lane 3- D10.G4.1 unstimulated.
Lane 4- D10.G4.1 Con A (5 pg/ml) stimulated.
Lane 5- Hindlll cut Lambda DNA size standard.
A
1 2 3 4 5 6
Figure 3.4 Northern blot analysis of endogenous mIL-5 mRNA expression 
levels for the three T cell lines used in this work. Cells were stimulated with 
either PMA or Con A for 6 hrs before harvesting total RNA and loading 20 |ig 
per lane on formaldehyde-agarose denaturing gels (section 3.2.2). Blots were 
taken and probed with a 600 bp {HaeII to AccY) mIL-5 cDNA fragment which 
was 32P labelled by the random-primer procedure (section 3.2.2.5). Following 
hybridisation the blots were washed before autoradiography (section 3.2.2.6) 
and the results are shown. mIL-5 mRNA is -1700 bp in length.
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3.3.2 Comparison and Optimisation of Transfection Methods
Two different reporter gene plasmids, pRSVCAT and pRSVL, were used 
as positive controls to compare different transfection methods and to optimise 
the conditions of transfection for the cell lines used. pRSVCAT and pRSVL 
carry the CAT and luciferase reporter genes, respectively, with expression 
being controlled by the Rous Sarcoma Virus (RSV) Long Terminal Repeat (LTR) 
[Gorman et al. 1982b]. pSVOCAT and pSVOAL are enhancerless versions of the 
above plasmids and were used as the corresponding negative controls for their 
respective reporter genes.
3.3.2.1 Transfection using cationic liposomes
Transfection conditions were optimised for Lipofectin (BRL) by varying 
the amount of pRSVCAT plasmid DNA and Lipofectin reagent within the range 
recommended by the manufacturer. The first experiment on NIMP-TH1 used 
50 jig of Lipofectin mixed with amounts of pRSVCAT ranging from 1 pg 
through to 10 jig (in 1 fig increments) diluted to 50 |il in sterile double distilled 
water; the 100 pi mixture was then added to 1 ml of cells (2xl06). 
Quantification of the conversion of 14C-chloramphenicol to the acetylated forms 
indicated that 4 pg of plasmid gave the highest CAT expression with 9.8% 
conversion (data not shown). However, precipitation occurred when higher 
amounts of plasmid were premixed with 50 pg of Lipofectin. In subsequent 
experiments precipitation was avoided by diluting plasmid DNA and 
Lipofectin separately in 750 pi of serum-free RPMI1640 medium before mixing 
to form the liposome-DNA complex (section 3.2.4.1). The next experiment used 
a range of amounts of Lipofectin, 40 pg, 50 pg, 60 pg and 70 pg each with 10 pg 
pRSVCAT (Figure 3.5.A). Quantification of the percentage conversion 
indicated 50 pg of lipofectin was optimal with 10 pg of plasmid (11.9% 
conversion). The third experiment used 50 pg of lipofectin with 10 pg, 12 pg, 14 
pg, 16 pg, 18 pg and 20 pg of pRSVCAT (Figure 3.5.B). There was no significant 
difference in CAT expression between 10 pg and 20 pg. The maximum 
expression obtained was 12-fold over the levels obtained with pSVOCAT.
Similar experiments were carried out with pRSVL using Lipofectin 
giving levels 13-fold and 18-fold over pSVOAL in duplicate experiments.
A.
-1, 3-diacetate CM
3-acetate CM 
1-acetate CM
•  •  •  •  •  CM
1 2 3 4 5 6
B.
1 2 3 4 5 6 7 8
Lane 1- negative control for CAT assay. 
Lane 2- 40 pg of lipofectin.
Lane 3- 50 pg of lipofectin.
Lane 4- 60 pg of lipofectin.
Lane 5- 70 pg of lipofectin.
Lane 6- positive control for CAT assay.
Lane 1-10 pg of pRSVCAT. 
Lane 2-12 pg of pRSVCAT. 
Lane 3-14 pg of pRSVCAT. 
Lane 4-16 pg of pRSVCAT. 
Lane 5-18 pg of pRSVCAT. 
Lane 6- 20 pg of pRSVCAT. 
Lane 7-15 pg of pSVOCAT. 
Lane 8-15 pg of pSVOCAT.
c.
1 2 3 4 5 6 7 8  9 10
Lanes 1 & 2- -547 unstimulated.
Lanes 3 & 4- -547 PMA stimulated.
Lanes 5 & 6- -547 (R.O) unstimulated. 
Lanes 7 & 8- -547 (R.O) PMA stimulated. 
Lane 9- positive control for CAT assay. 
Lane 10- negative control for CAT assay.
Figure 3.5 CAT activity from NIMP-TH1 cells following lipofectin-mediated 
transfection with pRSVCAT, pSVOCAT or mIL-5CAT constructs. NIMP-TH1 
cells were transfected with pRSVCAT, pSVOCAT or -547mIL-5CAT using the 
lipofectin procedure and CAT activity determined by thin layer 
chromatography as described in methods (section 3.2.5.1).
A. Different levels of lipofectin with 10 pg pRSVCAT. The different acetylated 
forms of chloramphenicol (CM) are indicated.
B. Different amounts of pRSVCAT with 50 pg lipofectin, pSVOCAT also shown.
C. Duplicate transfections with 15 pg mIL-5CAT constructs and 50 pg of 
lipofectin. R.O denotes reverse orientation of -547 bp in mIL-5CAT plasmid.
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Based on the conditions established in these initial control experiments, 
the -547mIL-5CAT reporter construct was tested in both orientations in 
Lipofectin-mediated transfection experiments with NIMP-TH1, with and 
without subsequent PMA stimulation. The -547mIL-5CAT construct showed 
low levels of constitutive expression, with a marginal increase upon PMA 
stimulation while the reverse orientation did not express above background 
(Figure 3.5.C). Later, the -3859mIL-5CAT construct was also tested in these 
Lipofectin-mediated transfection experiments with NIMP-TH1, however, this 
construct failed to express above background. These findings were consistent 
with more detailed studies subsequently carried out using electroporation (see 
below).
Attempts were also made to transfect pRSVCAT into the T cell clone 
D10.G4.1. Similar optimisation experiments were performed on D10.G4.1 as 
described above for NIMP-TH1. One extra variation was included and that was 
to substitute Optimem™  (BRL) for serum-free RPMI 1640 medium as 
recommended by the manufacturers. The only conditions that provided any 
sign of CAT expression were 40 pg of Lipofectin with 10 pg of pRSVCAT 
transfected in serum-free RPMI 1640 medium. However the level was only 
4-fold over background and much lower than the pRSVCAT expression 
achieved in NIMP-TH1 cells.
3.3.2.2 Transfection using electroporation
Electroporation conditions (270 V at 960 pF in PBS) had previously been 
established for NIMP-TH1 cells in this laboratory by Dr B. van Leeuwen. When 
these conditions were employed, good expression was achieved with 20 pg of 
pRSVCAT giving levels >50-fold over pSVOCAT (Figure 3.6). Under the same 
conditions, the -547mIL-5CAT construct gave low level constitutive expression 
and no expression was detected using -3859mIL-5CAT (Figure 3.6). The 
optimised conditions were also used with pRSVL electroporated into 
NIMP-TH1 cells in PBS giving 11-fold and 15-fold expression over pSVOAL in 
duplicate experiments.
pRSVL was also transfected into the T cell line EL4 using electroporation 
in PBS. A range of electrical parameters were tested in five different 
experiments. Although considerable variability was observed, a combination of 
250 V/500 pF gave the best results, with an average level of expression of 
10-fold over pSVOAL.
Luciferase constructs were also tested in the T cell clone D10.G4.1. In 
initial experiments D10.G4.1 was electroporated with pRSVL as a positive 
control to determine optimal electroporation parameters. A wide range of 
voltage and capacitance settings were tested around values known to work for 
other T-cell derived tissue culture cell lines. The cells were suspended in PBS at 
RT for electroporation at the settings shown in Table 3.2. Luciferase assays 
revealed the electroporations of D10.G4.1 were not very efficient giving a 
maximum level of four times pSVOAL.
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Table 3.2 Levels of luciferase activity following electroporation of pRSVL 
into D10.G4.1 in PBS medium.
50 V 100 V 200 V 220 V 240 V 260 V 280 V
125 pF 1 .0 a 1.0 1.6 N/Tb N/T N/T N/T
250 pF 1.9 4.0 1.1 1.3 1.7 2.2 1.4
500 pF 3.3 1.3 1.4 1.0 1.0 2.8 1.5
960 pF 1.4 2.5 4.0 1.3 1.2 1.2 1.2
a Values in table represent fold over pSVOAL of luciferase expression, 
b N /T  not tested.
3.3.3 Expression of IL-5CAT Reporter Constructs in NIMP-TH1 Cells
The control experiments showed that the luciferase reporter gene did not 
give any greater sensitivity in terms of levels of expression above pSVOAL than 
the CAT gene. The luciferase vector also gave greater variability in levels of 
expression than the corresponding CAT plasmid. The CAT reporter gene was 
therefore used in subsequent experiments. Similarly, more consistent data were 
obtained using electroporation than with Lipofectin.
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Six different mIL5CAT constructs were electroporated into NIMP-TH1 
and the levels of CAT were assayed by the butyryl CoA/LSC method. The 
constructs included -3859mIL-5CAT, -547mIL-5CAT, -458mIL-5CAT, 
-312mIL-5CAT, -140mIL-5CAT and -88mIL-5CAT. Each construct was 
electroporated into NIMP-TH1 in PBS with 270 V at 960 pF. Variability in 
electroporation efficiency between experiments was observed as seen 
previously. Nonetheless, the results showed a definite pattern, albeit at a low 
level of expression, which was reproducible (Figure 3.6).
Figure 3.6 Expression of 5' mIL-5CAT truncation constructs after transient 
transfection of NIMP-TH1 via electroporation. The graph shows an average of 
4 experiments (+/- the standard deviation). Cells were transfected as described 
(section 3.2.4.2), stimulated with PMA (10 ng/ml) for 16 hrs, and harvesting for 
CAT assay (section 3.2.5.2)
The largest construct, -3859mIL-5CAT, consistently gave background 
levels of l^ c  counts in the butyryl CoA/LSC assay, even lower than the 
negative control, pSVOCAT. The other five constructs showed varying levels of 
expression over pSVOCAT with -458mIL-5CAT expressing the highest levels.
However, none of these constructs showed the characteristic expression of the 
endogenous mIL5 gene, in that they gave constitutive expression with a slight 
decrease after PMA stimulation.
3.3.4 Expression of IL-5CAT Reporter Constructs in EL4 Cells
During the course of these experiments it was discovered that more 
reproducible levels of pRSVCAT expression were obtained when 
electroporation was carried out in normal tissue culture medium (RPMI 1640 
with 10% FCS) rather than in PBS which had been used previously. The six 
mIL-5CAT constructs were electroporated into EL4 cells giving much higher 
levels of expression relative to the positive control than achieved with 
NIMP-TH1 cells (Figure 3.7).
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Figure 3.7 Expression of 5' mIL-5CAT truncation constructs after transient 
transfection of EL4 via electroporation. The graph shows an average of 3 
experiments (+/- standard deviation). Cells were treated as described in the 
legend of Figure 3.6.
The pattern, however, was very similar to that obtained with NIMP-TH1. 
Expression was constitutive and -458mIL-5CAT expressed at the highest level. 
Once again it was noteworthy that expression of -3859mIL-5CAT was below 
background.
For later work, exonuclease III was used to generate additional 
truncation constructs of -3859mIL-5CAT (Chapter 4). Four of these constructs, 
with -965 bp, -912 bp, -698 bp and -409 bp of 5' mIL-5 sequence were also 
screened by transient transfection assay in comparison with -547mIL-5CAT and 
-458mIL-5CAT (Figure 3.8). This result further confirms the complete lack of 
expression from -3859mIL-5CAT and accentuates the high level constitutive 
expression from -458mIL-5CAT compared to -547mIL-5CAT. It is evident that 
-409mIL-5CAT retains the ability to express as well as -458mIL-5CAT while the 
three constructs with greater than 547 bp of 5' mIL-5 sequence were virtually 
inactive in this transient transfection assay.
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unstimulated EL4
E2  PMA stimulated EL4
Figure 3.8 Expression of 5' mIL-5CAT truncation constructs after transient 
transfection of EL4 via electroporation. Cells were treated as described in the 
legend of Figure 3.6.
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3.3.5 Expression of IL-5CAT Reporter Constructs in D10.G4.1 Cells
Since the previous levels of expression of pRSVCAT in the T cell clone 
D10.G4.1 had been rather low, further attempts were made to optimise 
electroporation in normal growth medium, as this had been successful with EL4 
cells. For this purpose the PCR construct pcEXV3-6.5kbmIL-5G(EcoRV) was 
used (see below). This construct carries the whole mIL-5 gene which has been 
modified to allow its expression to be distinguished from that of the 
endogenous gene. The gene is under the control of the SV40 early promoter 
and enhancer. The construct was electroporated into D10.G4.1 cells using a 
variety of different electrical parameters and its expression monitored using 
PCR. Optimum expression was obtained with 300 V at 500 pF (Figure 3.9.A).
The conditions identified as suitable for electroporating D10.G4.1 were 
used for five transient transfections of this murine T-cell clone with the first six 
5' mIL-5CAT truncation constructs and the control plasmids pRSVCAT and 
pSVOCAT which were previously transfected into NIMP-TF11 and EL4. Figure 
3.9.B shows that expression levels were low and constitutive for all 5' 
mIL-5CAT truncation constructs. The profile is different to NIMP-TH1 and EL4 
in that -547mIL-5CAT is the higher constitutive expresser instead of 
-458mIL-5CAT. Background counts are observed again for the largest 
construct, -3859mIL-5CAT, consistent with the situation in NIMP-TH1 and EL4. 
Constitutive expression in all 5’ mIL-5CAT truncation constructs was reduced 
upon stimulation of the transfected D10.G4.1 cells with Con A. This result is 
also consistent with the data for NIMP-TH1 and EL4.
3.3.6 Expression of Whole Gene Reporter Constructs in NIMP-TH1 
and EL4 Cells
Since the expression of none of the mIL-5CAT constructs carrying the 
upstream sequence regions of the gene showed the inducibility characteristic of 
the endogenous gene, a whole gene reporter construct was developed. It was 
considered possible that the regulatory elements responsible for inducibility 
may be located elsewhere in the gene such as in an intron or in the 3' 
untranslated region.
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Figure 3.9 Transient transfection of D10.G4.1 via electroporation in RPM I1640 
medium containing 10% FCS.
A. Agarose gel of PCR products showing expression from pcEXV3- 
6.5kbmIL-5G(EcoRV) after electroporation at the indicated voltage and 
capacitance. PCR reactions with primers PB19 & PB26 yielded a 587 bp product 
(see arrow). Lane 8 shows 300 V and 500 pF were the most effective 
parameters. B. Expression of 5' mIL-5CAT truncation constructs after transient 
transfection of D10.G4.1 using the conditions determined in A. The graph 
shows an average of 5 experiments (+/- standard deviation).
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The gene was modified by insertion of either an Mlul or an EcoRV linker 
into a unique restriction enzyme site (BstEII) in the 3' untranslated region 
(section 3.2.3.3) to create  pSP73-10kbm IL-5G (M /uI) and pSP73- 
10kbmIL-5G(EcoRV). A slightly shorter fragment of the gene carrying the same 
modifications was constructed in the SV40 based expression vector pcEXV3 
[Miller et al. 1985] to provide the corresponding positive controls pcEXV3- 
6.5kbmIL-5G(M/id) and pcEXV3-6.5kbmIL-5G(EcoRV). The modifications to 
the gene were designed so that its expression could be detected by PCR and 
distinguished from expression of the endogenous mIL-5 gene.
In order to verify the procedures used for mRNA preparation, cDNA 
synthesis and subsequent PCR amplification, two control primers were used. 
Primers MF74 and MF75 can amplify cDNA derived from endogenous mRNA 
as well as the whole gene reporter constructs. This primer pair gave the 
expected product of 507 bp after induction of NIMP-TH1 and EL4 cells 
verifying the methods used (Figure 3.10.A). The expected product was also 
obtained after induction of transfected NEMP-TH1 and EL4 cells.
The efficiency of the PCR primer pair combinations PB19/PB20 and 
PB19/PB26 which detected expression from the Mlul  and EcoRV reporter 
constructs, respectively, were tested using the positive control plasmids 
pcEXV3-6.5kbmIL-5G(M/wI) and pcEXV3-6.5kbmIL-5G(EcoRV). The construct 
carrying the EcoRV linker gave much higher levels of PCR product than that 
carrying the Mlul linker when transfected into NIMP-TH1 cells and EL4 cells by 
electroporation (Figure 3.10.B. and C., lanes 2-5). However, neither of the 
constructs in pSP73, which only carry the mIL-5 gene and do not have the SV40 
early promoter, gave detectable levels of expression when transfected into the 
two T cell lines (Figure 3.10.B. and C , lanes 7-10).
A. 1 2 3 4 5
507 bp
B * pcEXV3- pSP73-
6.5kbmIL-5G(M/uI) 10kbmIL-5G(M/uI)
1 ? 3 F T "  6 7 8 9 10
Lane 1- NIMP-TH1 unstimulated. 
Lane 2- NIMP-TH1 PMA stimulated. 
Lane 3- EL4 unstimulated.
Lane 4- EL4 PMA stimulated.
Lane 5-1 kb ladder (BRL).
Lanes 1 & 6 - 1 kb ladder (BRL)
Lanes 2 & 7- EL4 unstimulated.
Lanes 3 & 8- EL4 PMA stimulated.
587 bp
Lanes 4 & 9- N1MP-TH1 unstimulated. 
Lanes 5 & 10- NIMP-TH1 PMA stimulated
c.
pcEXV3-6.5kb pSP73-10kb 
mIL-5C(EcoRV) mIL-5G(EcoRV)
1 2 3 4 5 6 7 8 9 10 Lanes 1 & 6 -1  kb ladder (BRL)
Lanes 2 & 7- EL4 unstimulated.
Lanes 3 «Sc 8- EL4 PMA stimulated.
Lanes 4 «Sc 9- NIMP-TH1 unstimulated. 
Lanes 5 & 10- NIMP-TH1 PMA stimulated
587 bp
Figure 3.10 Agarose gels showing the products of PCR reactions on cDNA 
derived from normal and transiently transfected NIMP-TH1 and EL4.
A. Control for PCR methodology showing endogenous mIL-5 expression using 
PCR primers MF74 and MF75 which yield a 507 bp product (see arrow).
B. Expression from Mlu I linker modified whole gene reporter constructs, 
carried in either pcEXV3 or pSP73, after transient transfection via 
electroporation into EL4 and NIMP-TH1. PCR was carried out with primers 
PB19 and PB20 which yield a 587 bp product (see arrow).
C. Identical conditions to B except the EcoRV linker replaced the Mlul  linker 
and PCR was carried out with primers PB19 and PB26 which also give a 587 bp 
product (see arrow).
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3.4 Discussion
The aim of the work described in this chapter was to identify an mIL-5 
reporter gene construct that showed the inducible expression characteristic of 
the endogenous mIL-5 gene when transiently transfected into appropriate T cell 
lines. This was to serve as a starting point for a detailed analysis of the 
mechanisms regulating IL-5 gene expression.
Two different methods of transfection were tested and conditions 
optimised for the T-cell lines used. Although Lipofectin gave successful 
transfection, electroporation gave more consistent results particularly when the 
cells were electroporated in growth medium containing 10% FCS. Although T 
cell clones are generally very difficult to transfect, optimisation of conditions for 
D10.G4.1 did allow results to be obtained for these cells. This was considered 
important since D10.G4.1 is much closer to a normal T lymphocyte than the two 
continuous T cell lines (NIMP-TH1 and EL4) which were mainly used in this 
work.
Both CAT and luciferase were tested as reporter genes. Although the 
luciferase positive control gave similar levels of expression to pRSVCAT in 
relation to the relevant promoterless controls, it appeared to give greater 
variability and CAT was used as a reporter gene for subsequent work.
The initial low level constitutive expression data obtained for 
-547mIL-5CAT after transient transfection into NIMP-TH1 gave the first 
indication that mIL-5 may have different transciptional regulation 
characteristics to the other related cytokine genes studied to date (see 
Introduction of this chapter and Chapter 1). The constitutive expression shown 
by -547mIL-5CAT in NIMP-TH1 was not just peculiar to this hybridoma cell 
line. Later transfections of -547mIL-5CAT into EL4 and D10.G4.1 confirmed the 
weak constitutive promoter activity of this construct. Increasing the length of 5' 
flanking sequence to almost 4 kb did not improve reporter expression. In fact, 
not only did it fail to result in inducible expression but it consistently abolished 
the low level constitutive expression, suggesting the presence of a silencer 
element upstream of -547.
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Analysis of mIL-5CAT constructs carrying -547 bp, -458 bp, -312 bp, -140 
bp and -88 bp of 5’ flanking sequence showed the same pattern of constitutive 
expression in NIMP-TH1 and EL4 cells with the -458 bp construct giving the 
highest expression. In D10.G4.1 the pattern was similar but the -547mIL-5CAT 
expressed at the highest level.
A decrease in expression after stimulation was observed in all three T 
cell lines. Similarly, the cryptic promoter activity in pSVOCAT decreases after 
stimulation in all three T cell lines. In contrast, constitutive expression from 
pRSVCAT only decreases after stimulation in NIMP-TH1 and not in EL4 or 
D10.G4.1. This suggests the decrease after stimulation observed for the other 
constructs is a real phenomenon, although why it occurs is not clear.
Although inducible expression was not obtained with the 5' reporter 
constructs the possibility remained that sequences responsible for mIL-5 
transcriptional regulation might reside in areas of the gene other than the 5' 
region. The PCR seemed an ideal strategy for addressing this question because 
of its high sensitivity and because it obviated the need for interrupting the 
genomic sequence with a heterologous reporter gene. If quantification were 
required, the use of competitive PCR templates [Wang et al. 1989bl could 
provide a good approach. Constructs modified in the 3' region were used so 
that expression of the whole gene reporter could be distinguished from that of 
the endogenous gene. These constructs carried a 10 kb fragment of the mIL-5 
gene which included -3.9 kb 5' and ~1.8 kb 3' of the coding region of the gene. 
The various controls used verified that the PCR approach could readily detect 
expression of a whole gene reporter construct expressed from the SV40 early 
promoter. However, no expression of the modified mIL-5 gene was detected 
when the 10 kb whole gene fragment was carried in a neutral vector.
The failure to observe inducible gene expression with CAT reporter gene 
constructs carrying up to -3.9 kb of 5' sequence or with the 10 kb whole gene 
reporter construct was most unexpected. It distinguished the mIL-5 gene from 
other related genes such as IL-2 [Crabtree 1989], IL-3 [Mathey-Prevot et al. 1990; 
Shoemaker et al. 1990] and GM-CSF [Nimer et al. 1988,1989a and 1990] whose 
regulation had been studied to date. In these cases an inducible enhancer could 
be demonstrated within the first 400 bp of the 5' flanking region of the
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respective genes.
Formally, the results with the IL-5 gene could imply that the regulation 
was not at the level of transcription. This was not considered likely as nuclear 
run-on transcription assays in this laboratory have indicated significant 
transcriptional regulation in NIMP-TH1 [Wang et al. 1993] and, more recently, 
in EL4 and D10.G4.1 [H. Naora, unpublished results].
Alternatively the regulatory elements giving inducible expression of the 
mIL-5 gene in T lymphocytes could be outside of the 10 kb region studied in the 
present work or do not function out of their normal chromatin environment. 
The latter explanation was tested by stably incorporating the CAT-reporter 
constructs into the host genome and is described in Chapter 4.
CHAPTER 4
ANALYSIS OF mIL-5CAT REPORTER GENE CONSTRUCTS 
USING STABLE TRANSFECTION ASSAYS
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4.1 Introduction
The aim of the work presented in this chapter was to investigate the 
expression characteristics of mIL-5CAT reporter gene constructs in the 
chromosomal environment. The failure to identify a construct showing 
expression characteristics representative of the endogenous mIL-5 gene after 
transient transfection led to attem pts to perm anently transfect mIL-5CAT 
constructs into the T cell line EL4 and the T cell clone D10.G4.1.
4.1.1 Stable verses transient transfection
Stable transfection has the potential to overcom e some of the 
disadvantages associated with transient transfection. Integration of the 
exogenous DNA into the chromosomal environment may assist interaction 
with host transcription factors, it may change the methylation pattern of the 
exogenous DNA and the lower copy num ber of transfected DNA may also 
be important.
Integration into the host cell DNA places the exogenous DNA in a 
m ore favourable position for in teracting w ith nuclear proteins. As 
previously discussed (Chapter 3, Discussion), some critical t r a n s -acting 
factors may be incapable of interacting with plasm id DNA in transient 
transfection  and m ay only function  in their norm al chrom atin  
environment. Recently it has been shown that the configuration of binding 
for certain nuclear proteins on the MMTV prom oter differs depending on 
whether the exogenous prom oter is in chromatin or transiently transfected 
[Archer et al. 1992]. Integration may allow the exogenous DNA to interact 
with scaffold attachm ent proteins [Bode and Maass 1988; Klehr et al. 1991; 
Bode et  al. 1992]. The work of Klehr et al. [1991] on scaffold-attachm ent 
regions (SARs) of interferon ß is interesting in that SARs only enhance 
transcription when stably integrated in the chromosomal environment and 
have an antagonistic effect in transient transfection assays. It is also believed 
that DNA replication m ay facilitate the activation of a gene [Enver et al. 
1988].
The mIL-5CAT plasm id DNA has bacterial m ethylation on A or C
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residues from d a m  m ethylation (GATC) or d e m  m ethylation (C £W G G ); 
which may interfere with DNA binding of critical transcription factors. 
Once in tegrated  into the chrom atin of the host cell, the bacterial 
m ethylation pattern of the exogenous mIL-5CAT DNA will be lost after 
undergoing DNA replication during the host cell cycle [for example, 
Tasseron-de Jong et al. 1989; Shinar et al. 1989; Turker et al. 1991; ; Hasse et 
al .  1992]. If the bacterial m ethylation is replaced w ith endogenous 
methylation, i.e., at CpG dinucleotides, then the exogenous mIL-5CAT may 
not express as this form of methylation has been associated with promoters 
of transcriptionally inactive genes [Shinar et al. 1989; Tasseron-de Jong et al. 
1989; Holliday and Ho 1990; Bestor 1990; Bird 1992]. However, integrated 
exogenous DNA may also be hypomethylated [eg, Hsoltta et al. 1989; Shinar 
et al. 1989] which is commonly associated with transcriptionally active 
promoters [Bird 1992].
Another im portant feature of stable transfection is that fewer copies 
of the exogenous gene are present per transfected cell compared to the high 
concentration of supercoiled plasmid which can be achieved with transient 
transfection. This may be important when investigating the expression of a 
gene which occurs only as a single copy per haploid genome, as in the case of 
IL5 and other cytokines [reviewed in Arai et al. 1990]. It is conceivable that 
the appropriate trans-acting factor(s) may be present in limiting amounts as 
they are normally required at few binding sites at any one time, even if they 
function to regulate m ultiple host genes. As mentioned in section 3.1.3, the 
large am ount of plasm id DNA present in transient transfection would 
provide m any competing binding sites capable of selectively titrating low 
abundance t r a n s -acting factors. By way of precedent, Jaiswal et al. [1987] 
discussed copy num ber difference as an explanation for the disparity they 
observed between expression from transient and stable transfection of CAT 
constructs in their analysis of regulatory regions of a hum an P450I gene.
4.1.2 Interpreting stable transfection data
One aspect to be considered before embarking on stable integration 
experiments was on what basis to compare the expression of the transfected 
constructs. Previous work with cell lines [for example, Wigler et al. 1979;
Perucho et al. 1980; Robins et al. 1981; Hüttner et al. 1981; Folger et al. 1982; 
Bishop and Smith 1989] and with transgenic animals [eg, Gordon and 
Ruddle 1981; Palmiter et al. 1982; Palmiter and Brinster 1986] has indicated 
that in stable transfections, integration of DNA commonly occurs at one or a 
few random  chromosomal sites and that the integrated DNA forms arrays 
mainly consisting of head to tail repeating units of the introduced DNA. In 
addition, copy num ber and expression level are often uncorrelated in both 
tissue culture cells [eg, Novak and Rothenberg, 1986; Yoshimura and 
Chaffin, 1987; Bishop and Smith 1989] and transgenic mice [eg, Overbeek et 
al .  1986; Palm iter et  al. 1982; Palm iter and Brinster 1986; Davis and 
MacDonald 1988]. Differences in levels of expression are generally attributed 
to the structure of the integrated DNA array and the influence of the 
chromosomal region around the array [Wilson et al. 1990]. Neither of these 
variables can be controlled by the experim enter and there is no really 
satisfactory way of standardising stable transfection experiments. For the 
present work the cells were transfected and grown together in suspension 
which generated a polyclonal population. This approach helps m oderate 
variation in expression levels betw een individual transfectants, but to 
overcome the variation there appears to be no better alternative than to 
repeat critical experiments a number of times.
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4.2 Materials and Methods
4.2.1 Plasmid Manipulations:
4.2.1.1 Preparation of truncated constructs of -3859mIL-5CAT
Restriction endonuclease digestion was used to make the first three 
truncation constructs of -3859mIL-5CAT. Digestion of -3859mIL-5CAT with 
Nhel (Promega) removed a fragment of 2546 bp in length, and the product 
of digestion was re-ligated after a 1 in 10 dilution to yield -1313mIL-5CAT. 
Nhel/Sphl double digests were used similarly to create -1170mIL-5CAT. 
-3859mIL-5CAT was also passaged through E. coli strain JM110 to remove 
dam and dem methylation and the DNA digested with Bell to create 
-810mIL-5CAT.
Exonuclease III (ExoIII) was used to generate a comprehensive range 
of truncation constructs [Henikoff 1984] from -3859mIL-5CAT. The Promega 
Erase-a-base system was utilised for this purpose and the method followed 
was according to the manufacturer's protocol. Briefly, the template plasmid 
DNA was digested with two different enzymes, one to leave a 4 base 3' 
overhang to protect the vector from 3' to 5’ exonuclease digestion and the 
second to leave a 5' overhang (or blunt-end) as a substrate for ExoIII 
digestion. The digested DNA was extracted with phenol/chloroform, 
ethanol precipitated and resuspended in ExoIII buffer for ExoIII digestion. 
ExoIII digestion rates are known at a range of temperatures between 4°C and 
45°C allowing different temperatures to be selected according to the linear 
rate required. Samples were removed at one minute time points and mixed 
with SI nuclease to remove the single-stranded DNA remaining after ExoIII 
digestion. The low pH and Zn2+-containing SI nuclease buffer inhibited 
further ExoIII activity. SI nuclease was heat inactivated and the samples 
were neutralised before adding Klenow fragment of E. coli DNA polymerase 
I to ensure plasmid DNA ends were blunt and amenable to ligation by T4 
DNA ligase to re-circularise plasmids prior to transformation of competent 
E. coli cells.
Two ExoIII digestions were performed, one from -3656 and the second
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from -1483. In the first digestion 10 jig of -3859mIL-5CAT was digested with 
Sacl (site at -3726 in 5' mIL5 sequence) to generate a 4 base 3' overhang and 
Age I (site at -3656 in 5' mIL5 sequence) to provide a 5' overhang (substrate 
for ExoIII). Fifteen time points were taken from the reaction incubated at 
30°C (-210 bp/m inute) and the products of each time point were 
transformed into competent DH5a cells (section 2.2.1.1). Individual colonies 
were picked and grown up to prepare miniprep DNA (section 2.2.2.1) for 
screening by double digestion with Nhel and Xbal. Clones in the desired 
size range were grown up for large scale plasmid preparation (section 2.2.3) 
and each construct was sequenced to determine the 5' mIL-5 terminus 
(section 4.2.2).
The second round of ExoIII digestion was also performed on 10 fig of 
-3859mIL-5CAT except the template was prepared by a Sad-Bglll digest (Bg/II 
site is at -1483 in 5' mIL-5 sequence) and 16 time points were taken from the 
reaction incubated at 25°C (-90 bp/minute). This second round of 
truncations overlapped the first round, although the lower temperature 
during digestion meant that more colonies were obtained over the region of 
interest.
4.2.1.2 Preparation of internal deletions in mIL-5CAT
Seven internal deletions were generated from the -1016mIL-5CAT 
construct after digesting with the restriction endonucleases shown in Table 
4.1. The positions of each of these restriction endonuclease sites was 
indicated in Figures 2.1 and 2.4.
Table 4.1 Restriction endonuclease digests for internal deletions of 
-1016mIL-5CAT
Restriction Sequence deleted Sequencing prim era
endonuclease(s) after re-ligation
Accl and BspMl -457 to -409 PB8
Accl and Xbal -458 to -305 PB7
Accl and Nsil -457 to -138 RC37
BspMl and Xbal -416 to -314 PB7
BspMl and Nsil -406 to -138 RC37
Xbal and Nsil -310 to -138 RC37
EcoNl -465 to -87 RC37
a Primers used to confirm boundaries of deleted sequence. Sequencing primers PB7 and PB8 
bind to bases -125 to -109 and -356 to -340, respectively, of the mIL-5 gene (see Figure 2.1) and 
both extend back in the 5' direction. Figure 3.1 shows the binding site for RC37.
4.2.1.3 Preparation of mIL-5/mIL-3 hybrid construct
The mIL-5/mIL-3 hybrid construct contained a 620 bp mIL-5 fragment 
encom passing -1023 to -403 ligated in the correct orientation to the 
-208mIL-3CAT construct (kindly provided by Dr. B. van Leeuwen).
The 620 bp mIL-5 fragment (-1023 to -403) used in the mIL-5/mIL-3 
hybrid CAT construct was isolated from a BspMl digest of -1170mIL-5CAT 
on an agarose gel (section 2.2.7). This fragm ent was blunt-ended with 
Klenow fragm ent of E.coli DNA polym erase I (Promega) prior to gel 
isolation. The -208mIL-3CAT construct was linearised by digesting at the 
NdeI site which is at the 5' end of the mIL-3 5' sequence in this construct. 
The ends were then filled in w ith Klenow fragm ent of E.coli DNA 
polym erase I (Promega) and phosphatased w ith calf intestinal alkaline 
phosphatase (Boehringer-M annheim). The 620 bp mIL-5 fragm ent was 
ligated into the blunt-ended and phosphatased Nde I site of -208mIL-3CAT. 
Colonies (132) from the transformation were screened by single colony lysis 
(section 2.2.2.2). Four contained the correct size insert and after miniprep 
DNA was prepared  and digested, one was found to have the correct
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orientation.
4.2.1.4 Preparation of mutagenised mIL-5CAT constructs
Both the CTF/NFI site at -940 to-928 and IL-5/GM-CSF conserved 
sequence at -54 to -40 were mutated by oligonucleotide-directed in vitro 
mutagenesis (Kunkel et al. 1987) in the -1170mIL-5CAT construct. Figure 4.1 
shows the bases that were mutated. The subcloning, mutagenesis and initial 
mutant sequencing were performed by Mr David Mann in this laboratory. 
Briefly, a 1199 bp Sphl-EcoA7lll fragment of the 5' mIL-5 sequence was 
directionally subcloned into the Sphl-Smal cut polylinker of the phagemid 
pTZ18U (Bio-Rad). This construct was then transformed (section 2.2.1.1) 
into E. coli strain RZ1032 (dut", ung*) [Kunkel 1985]. Single stranded DNA 
(ssDNA), with uracil incorporated, was produced after co-infection with 
helper phage M13K07 (see section 2.2.9 for ssDNA preparation method). 
The mutagenic oligonucleotide was annealed to the uracil containing 
ssDNA template, extended with T4 DNA polymerase and ligated with T4 
DNA ligase. The resulting double stranded heteroduplex phagemid was 
transformed into E. coli strain MC1061.1 (dut+, ung+) [Rice et al. 1985]. 
Colonies were picked and miniprep DNA was prepared (section 2.2.2.1) for 
screening transformants by restriction endonuclease digestion. A Haelll site 
was lost in the CTF/NFI mutation and an EcoRI site was created in the 
IL-5/GM-CSF conserved sequence mutant. Mutations were confirmed by 
sequencing (section 4.2.2). Mutagenised fragments were then isolated from 
the pTZ18U mutagenesis vector by SflcI-HmdIII digestion, blunt ended with 
T4 DNA polymerase and cloned back into the blunt ended Hin dill cloning 
site of pSVOCAT (see Figure 3.1). After checking for orientation the plasmid 
was grown up and prepared as described in section 2.2.3. The plasmid DNA, 
ready for electroporation, was then sequenced again to confirm the mutants 
were as expected after subcloning back into the CAT vector.
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GAC
A 5'-TGGGTCAAGGCCA-3' 
-940 -928
CG A
B 5'-ATTATTCATTTCCTC-3'
-54 40
Figure 4.1 Mutations generated in the A, CTF/NFI site and B, IL-5/GM-CSF 
conserved region of mIL-5. Numbers beneath the sequence indicate base 
positions in the gene (see Figure 2.4.A) and underlined bases were changed 
to the bases shown above the sequence.
4.2.2 Sequencing of mIL-5CAT Constructs
All mIL-5CAT constructs including the mIL-5/mIL-3CAT hybrid 
construct were sequenced to confirm exact sequence boundaries. All 5' 
truncation constructs of -3859mIL-5CAT were sequenced from the primer 
RC44 (see Figure 3.2.1 for binding site). Internal deletions were sequenced 
from the primers indicated in Table 4.1. The mIL-5/mIL-3 hybrid construct 
was sequenced with primer RC44 to confirm the 5' end and primer RC37 
(see Figure 3.1 for binding site) to confirm the mIL-5/mIL-3 junction. The 
Applied Biosystems Inc. (ABI) PRISM™ dye terminator kit was used for all 
sequencing reactions which were carried out in accordance with the 
manufacturer's protocol for double stranded DNA sequencing with one 
modification, the addition of DMSO. Briefly, 1 pg of CsCl gradient purified 
plasmid DNA was deposited in an Eppendorf tube along with 3.2 pmol of 
the appropriate primer and 2 pi of DMSO. The volume was made up to 10.5 
pi with sddH2Ü before adding 9.5 pi of the PRISM™ dye terminator kit 
sequencing reaction pre-mix. The mixture was taken up in a capillary tube 
(Corbett Research CT-1000 capillaries) and transferred to a Corbett Research 
FTS-ls capillary PCR machine. The reaction conditions for the Taq 
polymerase sequencing reactions were a 2 minute pre-soak at 94°C before 25 
cycles of 94°C for 45 seconds, 43°C for 15 seconds and 60°C for 4 minutes. 
The 20 pi products of the sequencing reactions were returned to Eppendorf 
tubes and diluted to 100 pi with sddH20, extracted twice with 70%
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phenol/chloroform  (supplied by ABI) before ethanol precipitation (Note; 
sodium acetate at pH  5.2 was used to recover small sequencing products, 
personal communication from Dr Peter Milburn). All sequencing products 
were analysed on an Applied Biosystems 373A DNA sequencer operated by 
Mr Cameron McCrae and Dr Peter Milburn of the Biomolecular Resource 
Facility in the John Curtin School of Medical Research at the Australian 
National University.
4.2.3 Preparation of Plasmid DNA for Stable Transfection
mIL-5CAT constructs were grow n up for large scale plasm id 
preparation by the CsCl method (section 2.2.3). Table 4.2 shows the unique 
restriction endonucleases used to linearise the various constructs which 
were later used to prepare stable transformants in the T cell lines.
Table 4.2 Unique restriction endonucleases used for linearisation of plasmid 
DNA constructs prior to stable transfection.______________________________
Plasmid DNA
Linearising restriction 
endonuclease and 
source
Amount linearised for 
each stable transfection
pRSVCAT Psfl (NEB) 30 gg
pSVOCAT Bg/I (Progen) 30 gg
mIL-5CAT constructs B#/I (Progen) 30 gg
pM Clneo PolyAa Seal (Promega) 3ggb
mIL-5 /  mIL-3C AT Xmnl(NEB) 30 gg
-208mIL-3CAT X m n l  (NEB) 30 gg
a. pMClneo PolyA is described by Thomas and Capecchi [1987].
b. One tenth by mass of this selectable DNA marker was co-transfected in all stable 
transfections.
Plasmid DNA was checked on a 0.8% agarose gel to ensure complete 
linearisation  before phenol then chloroform  extractions and ethanol 
precipitation. The pellet was washed with 70% ethanol and dried under
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vacuum. The dried pellets were stored at -20°C or dissolved in RPMI 1640 
medium containing 10% FCS under sterile conditions. Thirty microgram 
quantities of reporter DNA constructs were dissolved in 180 jil and 
pMClneo Poly A was dissolved to a concentration of 3 fig per 20 fil.
4.2.4 Stable Transfection into Murine T Cell Lines
D10.G4.1 and H66 T cell clones were electroporated 9 to 11 days 
(inclusive) after allogeneic stimulation (section 3.2.1). D10.G4.1 and H66 
cells were resuspended at ~lxl06 cells/ml and EL4 clone 23 cells were 
resuspended at ~5xl05 cells/ml in fresh medium the day before transfection. 
Cells were counted and only transfected if greater than 90% were alive. Cells 
were pelleted and resuspended at lx l08/m l in their normal tissue culture 
medium and 200 fil was mixed with 180 fil (30 fig) of linear mIL-5CAT 
construct and 20 fil (3 fig) of linear pMClneo PolyA in a 0.4 cm Gene PulserR 
cuvette (Bio-Rad). Electrical parameters for electroporation of each cell line 
were identical to those for transient transfection (section 3.2.4.2) with H66 
being treated the same as D10.G4.1. Immediately after electroporation, cells 
were transferred to 30 ml of fresh medium in an 80 cm2 tissue culture flask.
The T cell clones D10.G4.1 and H66 cells were allogeneically 
stimulated (section 3.2.1, note: H66 was treated identically to D10.G4.1 except 
that Balb/c spleens were used for allogeneic stimulation) the day after 
electroporation and selection with the neomycin analogue G418 
commenced after a further 2 days incubation. The electroporated T cell 
clones were at a low number, estimated to be between 5x103 and lxlO4/flask 
by the time G418 had killed all the unelectroporated control cells (~8 to 10 
days). Different flasks from the same electroporation took between 2 and 4 
allogeneic stimulations to recover to levels sufficient (~2xl07) for a CAT 
assay (3 to 6 weeks).
EL4 cells were incubated for two days after electroporation before 
commencing G418 selection. The rapid growth rate of EL4 meant some cells 
had to be discarded during G418 selection in order to keep the number of 
flasks at a manageable level. The first incubation in medium containing 
G418 was for two days. Medium changes (with fresh G418) were required at
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two further two day intervals with 30% of the cells being discarded at the 
first change. After this period the unelectroporated control cells were all 
dead (~6 to 8 days). All flasks from the same electroporation recovered at a 
similar rate and cell numbers were around lx l06/m l by 10 days after 
selection. The G418 resistant EL4 cells were then diluted 1 in 30 and grown 
up in G418 free medium until sufficient numbers were present (-2x107) for a 
CAT assay. Then cells were diluted 1 in 30 a second time for a repeat CAT 
assay generally 3 days later.
Variation was found in the efficacy of various G418 batches from the 
same or different companies. In addition each cell line had a different 
susceptibility to G418, generally D10.G4.1 was the most sensitive at -400 
(ig/ml in the culture medium while EL4 and H66 required -800 pg/m l. 
G418 was dissolved at 500 mg/m l in 100 mM Hepes buffer, pH 7.3, and 
stored at -70°C for long term storage or -20°C for short term storage and each 
batch was titrated for each cell line.
4.2.5 Titration of Anti-D10.G4.1 T Cell Receptor Antibody, 3D3
Figure 4.2 shows a Northern blot that has been probed for expression 
of endogenous mIL-5 mRNA following stimulation using different levels of 
the D10.G4.1 T-cell receptor anti-idiotype specific antibody, 3D3 [Kaye et al. 
1983] (kindly provided by Dr. P. Hodgkin). It was apparent that a 1 in 1000 
dilution of the stock solution resulted in expression levels at least as good as 
a 1 in 100 dilution, or Con A at 5 pg/ml and this dilution factor was used for 
subsequent 3D3 antibody stimulations of D10.G4.1.
1 2  3 4
Lane 1- unstimulated D10.G4.1.
Lane 2- Con A (5 pg/m l) stimulated D10.G4.1. 
Lane 3- 3D3 antibody 1/100 dilution.
Lane 4- 3D3 antibody 1/1000 dilution.
Figure 4.2 Northern blot showing mIL-5 expression levels of D10.G4.1 after 
stimulation with Con A and 3D3 antibody. Cells were stim ulated with 
either Con A or 3D3 antibody for 6 hrs before harvesting total RNA and 
loading 20 jig per lane on a formaldehyde-agarose denaturing gel (section 
3.2.2). A blot was taken and probed with a 600 bp (HaeII to Acc\) mIL-5 
cDNA fragment which was 32P labelled by the random -prim er procedure 
(section 3.2.2.5). Following hybridisation the blot was w ashed before 
autoradiography (section 3.2.2.6) and the result is shown. mIL-5 mRNA is 
-1700 bp in length (position indicated by arrow).
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4.2.6 Chloramphenicol Acetyltransferase (CAT) Analysis
CAT expression was analysed around 12 days after electroporation for 
the first assay of EL4 and between 3 and 6 weeks for the T cell clones. Repeat 
assays were performed around three days later for EL4 and up to 2 weeks 
later for T cell clones (i.e., after another allogeneic stimulation). Cells were 
>90% viable (based on Trypan blue dye exclusion) at the time of assay. Cells 
were assayed by aliquoting lxlO7 cells into 20 ml of fresh medium in 80 cm2 
tissue culture flasks in duplicate. One flask was stimulated with either PMA 
(10 ng/ml), Con A (5 jig/ml) or 3D3 antibody for D10.G4.1, PMA (10 ng/ml) 
for EL4, or Con A (12 |ig/ml) for H66; all for 16 hrs. The butyryl coenzyme 
A / LSC CAT assay was used to assess CAT expression (section 3.2.5.2).
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4.3 Results
4.3.1 Analysis of mIL-5CAT Constructs Using Stable Transfection
The mIL-5CAT constructs previously used for transient transfection 
experiments were tested using the stable transfection approach. This 
involved cotransfection of cells with both the mIL-5CAT construct to be 
tested and the plasmid pMClneo polyA [Thomas and Capecchi 1987] which 
carries the neo gene under the control of the Herpes simplex virus 
thymidine kinase (HSV-tk) promoter. The mIL-5CAT constructs were used 
in ten-fold excess over pMClneo polyA on a weight basis to maximise the 
chance of their being incorporated into the genome. Stable transfectants 
were selected using G418. The electroporation conditions previously 
established for the transient assays were used for these experiments.
4.3.2 Demonstration of Inducible IL-5 Reporter Expression in Stable 
Transfectants
The first stable transfection experiments were carried out with 
D10.G4.1. The data shown in Figure 4.3, and in subsequent graphs with 
error bars, represents two separate stimulations performed three days apart 
(i.e., after a 1 in 30 dilution) on a polyclonal population of cells selected from 
the same stable transfection (+/- standard deviation).
The constitutive expression pattern of the five shorter constructs with 
547 bp, 458 bp, 312 bp, 140 bp and 88 bp of 5' mIL-5 sequence was similar to 
the pattern obtained with transient transfection. Reduced expression 
following stimulation was observed with these stably transfected constructs 
as seen in transient assays. The largest construct, -3859mIL-5CAT, however, 
gave clearly inducible expression. The relative expression of pRSVCAT is 
lower in stable transfection of D10.G4.1 than it was in transient transfection 
and appeared to increase on Con A stimulation.
It is interesting to note that in both transient and stable transfection 
experiments the -3859mIL-5CAT construct gave low levels of expression in 
unstimulated cells. This suggests that the ds-acting element(s) responsible
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Figure 4.3 Expression of 5' mIL-5CAT truncation constructs, pRSVCAT and 
pSVOCAT after stable transfection into D10.G4.1. Cells were incubated with 
Con A (5 |!g /m l) for 16 hrs before harvesting for CAT assay (section 4.2.6). 
The graph represents the average of two CAT expression assays from a 
polydonal transfectant population selected from the same experiment (+/- 
standard deviation).
for the constitutive expression seen in both cases with the -547mIL-5CAT 
construct is repressed by the presence of a silencer element(s) between -547 
and -3859. However, only when the -3859mIL-5CAT construct is in the 
chromosomal environm ent is the inducible expression characteristic of the 
IL-5 gene in T lymphocytes observed.
It was im portan t to see if the inducib le  expression of the 
-3859mIL-5CAT construct show ed the properties characteristic of the 
expression of the endogenous IL-5 gene. These include stimulation by Con 
A and the D10.G4.1 T cell receptor anti-idiotype specific antibody, 3D3, 
stim ulation by PMA, repression by dexam ethasone and resistance to 
cyclosporin A [Wang et al. 1993; H. Naora, unpublished results].
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The effect of dexam ethasone (0.1 jig /m l) on all constructs in the 
round 1 stable transfection of D10.G4.1 is shown in Figure 4.4. Clear 
repression is evident for the -3859mIL-5CAT construct. Interestingly, 
dexam ethasone did  not have a significant effect on the constitutive 
expression of the shorter constructs.
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Figure 4.4 Effect of dexam ethasone on expression of 5' mIL-5CAT 
truncation constructs stably transfected into D10.G4.1. Cells were incubated 
for 16 hrs with either Con A (5 |ig /m l) or dexamethasone (0.1 |ig /m l) or both 
before harvesting for CAT assay (section 4.2.6).
Figure 4.5 shows that the different stim ulation param eters of the 
largest mIL-5CAT construct correspond to those previously established for 
the endogenous gene. Con A (5 jig/m l), 3D3 antibody and PMA (10 ng/m l) 
all stimulated expression of CAT from this stably integrated construct and 
each type of stimulation was susceptible to repression by dexamethasone at 
0.1 |ig /m l. Cyclosporin A at 1 M-g/ml did not affect stim ulation by 3D3 
antibody. Thus the functional characteristics of IL-5 gene expression were 
retained with the -3859mIL-5CAT reporter construct when incorporated into
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the chromosomal environment.
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Figure 4.5 Stimulation characteristics of -3859mIL-5CAT stably transfected 
into D10.G4.1. Cells were incubated for 16 hrs with the indicated reagents 
before harvesting for CAT assay (section 4.2.6). Concentrations for each 
reagent were, Con A 5 )ig/ml, PMA 10 ng/ml, 3D3 antibody 1/1000 dilution 
(see section 4.2.5), dexamethasone 0.1 |ig/ml and cyclosporin A 1 pg/ml.
The same set of reporter constructs (-88mIL-5CAT to -3859mIL-5CAT) 
was also stably incorporated into EL4 cells (Figure 4.6). As with D10.G4.1, the 
shorter constructs showed constitutive expression with some differences in 
the relative levels of expression between EL4 and D10.G4.1 and between 
stable and transient assays with EL4. Once again the -3859mIL-5CAT 
construct gave tightly regulated inducible expression analogous to the 
behaviour of the endogenous IL-5 gene in EL4 cells.
The ease of handling EL4 cells relative to the difficulties of using 
D10.G4.1 led to the decision to use EL4 for most experiments.
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Figure 4.6 Expression of 5' mIL-5CAT truncation constructs after stable 
transfection into EL4. Stimulated cells were incubated with PMA (10 ng/ml) 
for 16 hrs before harvesting for CAT assay (section 4.2.6). The graph 
represents the average of two CAT expression assays from a polyclonal 
population of transfectants selected from the same experiment (+/- standard 
deviation).
4.3.3 Cell-Type Specific Expression of mIL-5CAT Constructs
It was important to demonstrate that the -3859mIL-5CAT construct 
did not express in the Th I class of T helper cell to show that this construct 
also exhibited the tissue-specific regulation characteristic of the mIL-5 gene. 
H66 is a Th I murine T cell clone and does not express IL-5 [Kaye et al. 1983]. 
The -3859mIL-5CAT construct was cotransfected with pMClneo PolyA 
under the same conditions used for D10.G4.1, and G418 resistant cells were 
obtained. Two separate stimulations were performed with Con A at 12 
pg/m l (this was the optimum concentration for Con A stimulation of H66 
as determined by Dr P. Hodgkin) and subsequent CAT assays revealed no 
CAT enzyme activity from these H66 transformants. Therefore the 
-3859mIL-5CAT construct appears to show cell type restricted expression.
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4.3.4 Minimum-Sized Reporter Construct for Inducible Expression
In order to try and determine the 5' boundary of the inducible IL-5 
enhancer a variety of truncation constructs were prepared using ExoIII 
digestion (section 4.2.1). An example of this kind of experiment is given in 
Figure 4.7. The excised fragment was not removed after the preparative 
digest of the -3859mIL-5CAT before ExoIII digestion but this was not found 
to be a problem when religating (to recircularise) ExoIII truncated mIL-5CAT 
constructs. The ExoIII approach yielded constructs with 5' ends ranging 
from -3530 to -271 (Table 4.3).
Five representative experiments are shown in which truncation 
constructs are compared for inducibility of expression with -3859mIL-5CAT 
or -3530mIL-5CAT as reference standards. Figures 4.8 A and B, 4.9 A and B 
and 4.10 summarise data which indicated that constructs shortened to -1016 
still give comparable inducible expression to -3859mIL-5CAT. The 
-1016mIL-5CAT construct was subsequently tested in a total of three 
experiments against -3859mIL-5CAT and the results support the conclusion 
that the basic elements of inducible IL-5 expression are contained in this 
fragment. Figures 4.9.A and 4.9.B suggest that further shortening of the 5' 
end of -1016mIL-5CAT to -965 impairs the level of expression. From -965 to 
-726 expression remains low although generally slightly inducible (Figures 
4.9.B and 4.10). -547mIL-5CAT repeatedly gave constitutive expression and 
generally at a lower level than -1016mIL-5CAT or -3859mIL-5CAT.
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 kb Size 
Standard (BRL) 
(base paizs)
1 2 , 2 1 6  
1 1 , 1 9 8  
1 0 , 1 8 0  
9 , 1 6 2  
8 , 1 4 4  
7 , 1 2 6  
6 , 108  
5 , 0  90 
4 , 0 7 2  
3 , 0 5 4  
2 , 0 3 6  
1 , 6 3 6  
1 , 0 1 8  
5 0 6 / 5 1 7  
3 9 6  
34 4  
298  
220  
201  
154  
134  
75
Figure 4.7 Agarose gel of ExoIII digestion products. The gel shows samples 
from each time point (1-16 minutes, corresponding to lane numbers) of an
ExoIII digestion of S a c l - B g l U  digested -3859mIL-5CAT (6145 bp) at 25°C
(section 4.2.1.1). The excised fragment (2243 bp) also degraded over the time 
course. Fragment sizes of the standards are shown on right (not aligned).
Table 4.3 Summary of 5' mIL-5CAT truncation constructs screened in stable 
transfection assays.
5'terminus of 
restriction enzyme 
generated 
truncations
5'terminus of 
ist ExoIII 
digestion 
generated 
truncations
5'terminus of 
2nd ExoIII 
digestion 
generated 
truncations
-3859 (HiwdlH) -3530 -980
-1313 (N/iel) -3502 -965
-1170 (SphI ) -3461 -952
-1089 (Tf/illlI) -3144 -929
-810 {Bell) -2634 -923
-547 (PCR product) -2300 -913
-458 (A c c l ) -1899 -898
-410 (BspMI) -1587 -667
-312 ( -1540 -643
-140 (Ns/I) -1472 -629
-88 (EcoN I) -1286 -581
-1016 -409
-912 -271
-864
-853
-808
-770
-749
-726
-698
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Figure 4.8 A and B both show inducible expression for 5' mIL-5CAT 
truncation constructs stably transfected into EL4. Each graph represents an 
independent experiment. Cells were treated as described in the legend of 
Figure 4.6.
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Figure 4.9 A and B show inducible expression for additional 5' mIL-5CAT 
truncation constructs stably transfected into EL4. Each graph represents an 
independent experiment. Cells were treated as described in the legend of 
Figure 4.6.
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Figure 4.10 Further 5' mIL-5CAT truncation constructs stably transfected 
into EL4. Cells were treated as described in the legend of Figure 4.6.
4.3.5 Heterologous Constructs with the IL-3 Gene Promoter
Recent work in this laboratory has demonstrated that the murine IL-3 
gene prom oter shows some overall similarities to that of the IL-5 gene in 
that the proximal region of the prom oter shows constitutive expression 
w hen tested in D10.G4.1 (Dr B. van Leeuwen, unpublished  results). 
However, when additional upstream  regions of the prom oter are included 
the expression becomes more tightly regulated and inducible. It was 
therefore of interest to test if the upstream  regions of the IL-5 gene, which 
appear to be responsible for inducible expression, could regulate the 
proximal region of the IL-3 gene promoter in heterologous constructs. The 
mIL-5/mIL-3CAT construct carried -1023 to -403 of the mIL-5 5' sequence 
ligated to -208mIL-3CAT.
C om parison  of -208mIL-3CAT expression  w ith  th a t of the 
heterologous construct in EL4 showed that expression in both cases was
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largely constitutive (Figure 4.11). Thus, within the limitations of this type of 
experiment it would appear that the upstream  regions of the IL-5 promoter 
are unable to confer tight regulation on the proximal region of the IL-3 
prom oter.
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Figure 4.11 Expression of -1016mIL-5CAT, the mIL-5/mIL-3 heterologous 
CAT reporter construct and -208mIL-3CAT after stable transfection of EL4. 
The mlL-5/mIL-3 heterologous CAT reporter construct contains -1023 to -403 
of the mIL-5 gene sequence ligated to -208mIL-3CAT (section 4.2.1.3). Cells 
were treated as described in the legend of Figure 4.6.
4.3.6 S tu d ies on  the Proxim al R eg ion  o f the IL-5 Prom oter
Reporter constructs carrying up to -547 of upstream  sequence 
regularly  show ed constitutive expression in EL4 cells. Full inducible 
expression was not shown until sequence was included up to -1016. The 
constitutive expression suggests basal prom oter activity in the absence of 
upstream  regulatory sequences conferring inducible expression. It was 
therefore of interest to test whether regions in the proximal region of the 
prom oter were im portant for inducible expression in the context of the 
whole reporter construct (-1016mIL-5CAT) and also to begin to identify
regions that were not required . Together with a deletion analysis of other 
regions this would eventually enable the generation of a minimal inducible 
promoter which could be tested for tissue-specific expression in transgenic 
mice.
4.3.6.1 Internal deletion constructs
Available restriction endonuclease sites (Figures 2.1 and 2.4) were 
used to prepare internal deletions covering the -87 to -465 region (Table 4.1). 
These constructs were compared in stable transfection experiments in EL4 
(Figure 4.12).
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Figure 4.12 Inducible expression levels for -1016mIL-5CAT internal deletion 
constructs stably transfected into EL4. Cells were treated as described in the 
legend of Figure 4.6.
In the absence of multiple repetitions, conclusions from this type of 
experiment need to be cautiously drawn. However, it seems clear from this
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experiment that the region from -310 to -138 is not required for inducible 
expression. In addition , significantly  reduced expression of four 
overlapping constructs in which the region -457 to -409 was missing suggests 
an important role for this region.
4.3.6.2 Site-directed mutagenesis
When the proximal sequence of the mouse IL-5 gene promoter was 
originally determ ined [Campbell et al. 1988] a short region of sequence 
imm ediately upstream  of the TATA box was detected which was highly 
conserved in the corresponding position of the hum an IL-5 gene (Figures 2.2 
and 2.4) and the mouse and hum an GM-CSF genes. Subsequent work has 
provided evidence that this region is im portant for hum an GM-CSF gene 
expression and has identified bases essential for the functioning of this site 
in a hum an GM-CSF-CAT construct [Nimer et al. 1990]. In this laboratory, 
gel shift assays with D10.G4.1 nuclear extracts have shown the presence of a 
DNA-binding protein in extracts from stimulated cells which binds to the 
relevant region of the m urine IL-5 gene (H. Naora, unpublished results). 
These experim ents also confirm ed that the sam e bases essential for 
functional activity in hum an GM-CSF were essential for binding to the 
equivalent mIL-5 sequence. In vitro m utagenesis of -1170mIL-5CAT was 
used to mutate the key bases (section 4.2.1.4) and the m utated construct was 
tested in six independent transfection experiments. The results of one of 
these experiments is given in Figure 4.13 which shows that the mutation of 
three bases in the IL-5/GM-CSF conserved region abolishes IL-5 expression.
104
H<U
<u
>*xs
’öJ
CsS
3 -
2 -
miwm
wm
-1170mIL-5CAT
unstimulated EL4 
PMA stimulated EL4
CTF/NFI mutation 
in -1170mIL-5CAT
IL-5/GM-CSF conserved 
region mutation in 
-1170mIL-5CAT
Figure 4.13 The effect of mutations in the CTF/NFI site and IL-5/GM-CSF 
conserved region on expression of -1170mIL-5CAT stably transfected into 
EL4. Each mutation was introduced into -1170mIL-5CAT by site-directed 
mutagenesis (section 4.2.1.4). Cells were treated as described in the legend of 
Figure 4.6.
4.3.7 Identification of a Cis-Acting Motif in the Distal Region of the
IL-5 Promoter
The 5' truncation experiments indicated that the region from -965 to 
-1016 was important for high level inducible expression. Just 3' of this 
general region of the promoter a consensus DNA binding site for the 
mammalian transcription factor CTF/NFI was detected (Chapter 2). This 
was present at -928 to -940 (Figure 2.4). Mutagenesis studies have shown 
previously which bases are critical for functioning of the CTF/NFI site [Jones 
et al. 1987]. Using this information, three bases of the consensus binding site 
in -1170mIL-5CAT were altered by site-directed in vitro mutagenesis to 
destroy the site (section 4.2.1.4). The mutated construct was then compared 
with the -1170mIL-5CAT in stable transfections in EL4 (Figure 4.12). 
Mutation of the CTF/NFI binding site had the very interesting result of 
converting the -1170mIL-5CAT construct to high level constitutive
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expression. This result was confirmed in six separate experiments. It would 
therefore appear that the CTF/NFI site is essential for the tight regulation of 
the IL-5 promoter.
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4.4 Discussion
This chapter presented data showing successful stable transfection of 
the murine T cell clone D10.G4.1 and the continuous murine T cell 
thymoma line EL4 with mIL-5 reporter gene constructs. In contrast to the 
transient transfection results described in Chapter 3 the -3859mIL-5CAT 
construct showed tightly regulated inducible expression. This allowed the 
achievement of the objective of investigating expression characteristics of 
mIL-5CAT constructs in the chromosomal environment and subsequent 
identification of two of the elements which play a major role in the 
regulation of mIL-5 gene expression.
4.4.1 Stable Transfection of D10.G4.1
Stable transfection of D10.G4.1 cells with the -3859mIL-5CAT construct 
provided a major advance in that significant levels of inducible expression 
were achieved. This result was in stark contrast to previous transient 
transfections performed with the same construct where no expression was 
detected. By comparison, the shorter constructs with 547 bp, 458 bp, 312 bp, 
140 bp and 88 bp of 5' mIL-5 sequence showed essentially the same profile of 
constitutive expression as in transient transfection although the level of 
expression was higher. This experiment clearly demonstrated that the DNA 
element(s) controlling inducible expression of the mIL-5 gene in T cells were 
between -547 and -3859 of the mIL-5 sequence, further upstream than had 
been found for related cytokines (Table 3.1). The constitutive expression of 
-547mIL-5CAT suggested the possibility of a silencer element(s) upstream of 
-547 to explain the loss of inducible regulation observed with this construct.
The -3859mIL-5CAT construct exhibited the same expression 
characteristics as the endogenous gene according to the criteria tested. These 
included induction by stimulation with Con A, or the anti-TCR antibody 
3D3 [section 4.2.8] or the phorbol ester PMA, sensitivity to repression by the 
glucocorticoid dexamethasone, and resistance to repression by cyclosporin A. 
In addition, the -3859mIL-5CAT construct did not express when stably 
transfected into H66, a murine T cell clone representative of the Th I class of 
T helper cells (which do not express IL-5) suggesting that the -3859mIL-5CAT
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construct exhibits cell type-specific expression. The sensitivity to repression 
by dexamethasone was not evident for the shorter constructs indicating that 
the dexamethasone sensitive element(s) is between -547 and -3859. The lack 
of sensitivity of the shorter constructs also acts as a control to demonstrate 
that the cells survive the exposure to dexamethasone. This is important to 
establish because dexamethasone is known to induce apoptosis in 
thymocytes [Cohen and Duke 1984].
The stable transfection procedure developed in the present work for 
the T cell clone D10.G4.1 should be generally applicable to other T cell clones 
and allow the functional analysis of other cytokine-reporter gene constructs 
to be carried out in such cells. This would allow results previously obtained 
with various continuous T cell lines (section 1.5.5) to be tested in cells more 
closely related to normal T lymphocytes.
4.4.2 Stable Transfection of EL4
The eight constructs stably transfected into D10.G4.1 were also 
electroporated into the faster growing EL4 mouse T cell thymoma line. The 
largest construct -3859mIL-5CAT was inducible and tightly regulated, 
although the level of expression was generally lower than in D10.G4.1. 
-547mIL-5CAT was constitutive and expressed as well as -3859mIL-5CAT. 
Essentially, the EL4 stable transfection results reinforced the data obtained in 
D10.G4.1. The lower level of inducibility for -3859mIL-5CAT in EL4 
presumably reflects the large difference in the level of endogenous mIL-5 
expression between these two cell lines shown previously by Northern blot 
in Figure 3.4.
EL4 was used for subsequent experiments aimed at localising 
upstream enhancer(s) and silencer(s) because it allowed faster screening of 
-3859mIL-5CAT truncation constructs, that is, around 2 weeks from 
electroporation to CAT assay as opposed to an average of 4-5 weeks for 
D10.G4.1.
The localisation of the inducible enhancer within the 3859 bp of 
upstream sequence was studied by progressive truncations at the 5' end.
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These experiments showed that the -1016mIL-5CAT construct consistently 
gave comparable levels of expression to -3859mIL-5CAT. Further truncation 
at the 5' end from -1016 gave a gradual decline in inducibility between the 
-1016, -980 and -965 mIL-5CAT constructs until only slight inducibility was 
observed for constructs from -965 bp down to -913 bp (Figure 4.9 A and B). A 
possible explanation for these results is that the enhancer mechanism 
involves several protein-DNA interactions in the region between -965 and 
-1016. As binding sites are removed in the 5' truncation constructs the 
potential for cooperative action between the tra7is-acting factors would 
diminish and the enhancer would function less efficiently.
The results with inducible reporter gene constructs (Figure 4.8A and 
B, 4.9A and B and 4.10) also show that, in practice, position effects such as 
anomolous expression due to insertion of the exogenous reporter constructs 
near strong endogenous enhancers, were not a problem. In general all 
constructs w ith mIL-5 5' flanking sequences of at least 1016 bp in length 
exhibited tightly regulated inducibility, w ith the possible exception of 
-1170mIL-5CAT (Figure 4.8A) which, although inducible, showed a higher 
background expression than was normally the case.
A computer search (Chapter 2, Figure 2.4) located a consensus binding 
site for the mammalian transcription factor family, CTF/NFI, (-928 to -940) 
near the region believed to contain the mIL-5 enhancer. Three bases of the 
consensus sequence of this site were m utated to prevent binding of the 
C T F/N FI transcrip tion factor [Jones et al. 1987]. The resulting m utant 
showed relatively high level constitutive expression after stable transfection 
into EL4, suggesting that the CTF/NFI site is involved in tightly regulated 
inducible expression of the mIL-5 gene.
CTF/N FI is generally associated w ith enhancer activity [Jones et al. 
1987] a lthough  it is possible the C TF/N FI fam ily contains as yet 
uncharacterised member(s) which may function as repressors [Roy et al 
1992]. A duplicity of function has already been reported for at least five 
other transcriptional activators. In these examples activators are converted 
into repressors by rem oval of a functional dom ain through differential 
splicing or m odified translation processes [for review  see Foulkes and
Sassone-Corsi 1992]. Considering some of the established features for 
CTF/NFI, a similar mechanism could be proposed for this family of trans­
acting activator proteins. CTF/NFI is noteworthy because transcripts from 
this gene family are known to undergo differential splicing during mRNA 
processing and as a result create different proteins from the one transcript 
[Santoro et al. 1988; M eisterernst et al. 1988]. The CTF/NFI proteins have 
also been show n to have functionally distinct domains. The N-terminal 
region is highly conserved and accounts for both the common DNA binding 
specificity of the family and DNA replication activity, as m easured by 
initiation of adenovirus replication in  v i tro . The proline-rich C-terminal 
region functions as the transcriptional activation dom ain [Mermod et al. 
1989]. In view of the m odularity of functional domains dem onstrated for 
CTF/NFI it seems possible that differential splicing could generate a variant 
of CTF/NFI that retains the N-terminal DNA binding domain but lacks part 
of or the complete C-terminal transcriptional activation domain. Such a 
variant could act as a silencer if its binding to the CTF/NFI site disrupted the 
binding or function of adjacent or nearby positive acting factors. If this 
mechanism for CTF/NFI as a silencer is valid it may explain why the IL-5 
upstream region was not able to regulate the IL-3 heterologous promoter. If 
the silencer activity is due to the binding of a variant of CTF/NFI that lacks a 
frajis-activating functional domain then the silencing action may be specific 
to IL-5 because it only interferes with locally binding positive factors and 
cannot silence at a distance as w ould be required in the heterologous 
construct. Of considerable interest to the present work is a recent report by 
Roy et al. [1992] describing the identification of a new m em ber of the 
CTF/NFI family of transcription factors that binds to a proximal negative 
regulatory element in the rat growth horm one gene. This protein has a 
molecular weight of 45 kd which is at the lower end of the molecular weight 
range previously determined for the CTF/NFI family of proteins, i.e., 52 kd 
to 66 kd [Jones et al. 1987]. The lower molecular weight of this protein may 
be due to the absence of a domain of the characterised proteins. If this is the 
case then this protein may be a product of differential splicing and thus may 
represent the first example of a CTF/NFI variant acting as a silencer by the 
mechanism outlined above.
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Experiments were also designed to localise sequences of the mIL-5
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proxim al region im portant for inducible expression. Seven internal 
deletion constructs were m ade from the -1016mIL-5CAT construct and 
preliminary results suggested the region from -310 to -138 was not necessary 
for inducible expression, whereas sequences between -457 and -409 are 
im portant for inducible expression. Figure 2.4 showed the location of 
putative regulatory sequences which were identified by a computer search. 
Although this search identified two sites within the region -310 to -138, a 
potential Spl site and a site originally discovered as a binding site for a yeast 
mating factor type protein which had also been shown to bind a hum an 
homeobox protein in lym phoid cells (Table 2.2), it seems neither are 
important for mIL-5 expression. Of more interest is the site for the octamer 
transcription factor (ATTTGAAT, -454 to -447) which was found in the 
region of potential importance, -457 to -409. This site closely resembled the 
consensus sequence of the octamer motif (ATTTGCAT) [Singh et al. 1986] 
and as mentioned in Chapter 2 this variant octamer motif has been shown 
to compete with the consensus site for binding of nuclear factors from T 
lymphoma cell lines [Staudt et al. 1986]. Further work, such as site-directed 
or deletion m utagenesis, is required to establish w hether this site is 
functionally involved in IL-5 transcriptional regulation.
In  vitro  mutagenesis was also used to assess the involvement of a 
more proximal mIL-5 promoter sequence (-54 to -40) in inducible expression. 
This sequence was designated IL-5/GM-CSF conserved region for this work 
since it is conserved in both genes in hum an and mouse. As mentioned 
previously, Nim er et al. [1988 and 1990] had shown the importance of this 
site in hum an GM-CSF expression by DNase I footprinting and CAT 
reporter data. A three base mutation in the IL-5/GM-CSF conserved region 
abolished inducible expression of the -626hGM-CSF-CAT reporter construct 
into which it was introduced. In this laboratory the same m utation was 
tested along with the mIL-5 wild-type sequence in gel mobility shift assays 
using nuclear extracts from the murine T cell clone D10.G4.1 and the results 
confirmed that the same m utation abolished the gel shift observed for the 
wild-type sequence [H. Naora, unpublished results]. Transient transfection 
data from Chapter 3 had indicated that this site was insufficient for inducible 
expression in mIL-5CAT reporter constructs although it appeared to confer 
low level constitutive expression (see expression for the -88mIL-5CAT
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construct in Figures 3.6, 3.7, 3.9, 4.3 and 4.6). Nonetheless, it was decided to 
investigate the possible involvement of this site as a mediator of induction 
within the context of a larger inducible construct and the results presented 
in this chapter, where expression was abolished (Figure 4.12), confirmed a 
role for this site as a proximal mediator of mIL-5 gene expression.
Miyatake et al. [1991] have studied this region in more detail with 
respect to mouse GM-CSF regulation in the human Jurkat T cell leukemia 
line. The authors have demonstrated involvement for this site in 
PMA/calcium ionophore induced expression of a mGM-CSF-CAT construct 
and shown binding of two proteins, NF-CLEOa and NF-CLEOb, to the 
IL-5/GM-CSF conserved region in mobility shift assays. NF-CLEOa binds to 
the 3' end (bases -42 to -49) and NF-CLEOb binds to the 5' end (bases -46 to 
-53) of the IL-5/GM-CSF conserved region, respectively (Note: numbering is 
identical between mouse IL-5 and GM-CSF in this region). Consequently 
both sites overlap at the central TCAT residues in the IL-5/GM-CSF 
conserved region (Figure 4.14). Functional activity was also assigned to each 
protein, with NF-CLEOa corresponding to the region required for induction 
by PMA/calcium ionophore and the NF-CLEOb binding site corresponding 
to bases associated with inhibitory activity in mouse GM-CSF-CAT reporter 
constructs. Mutations made in the region -46 to -49 inhibited binding of 
both NF-CLEOa and NF-CLEOb factors and abolished activity in mGM-CSF- 
CAT reporter constructs. As Figure 4.14 shows the mutations made in 
-1170mIL-5CAT corresponded to the same region (-46 to -49) and so would 
preclude binding of both NF-CLEOa and NF-CLEOb factors. According to the 
work of Miyatake et al. [1991] the disruption of the NF-CLEOa binding site 
may be sufficient to explain the loss of expression in the mutant made for 
the present work if NF-CLEOa is also involved in mIL-5 expression.
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a . 5'-AATTATTCATTTCCTC-3'
b . 5'-AATTATCGAATTCCTC-3'
C . 5'-AWWTATN CAT-3'
d. 5'-TMANTCA-3 '
Figure 4.14 IL-5/GM-CSF conserved region. NF-CLEOa and NF-CLEOb 
binding locations are indicated in the key. Three other sites are aligned to 
show the overlap between the mutated bases (underlined in b) and the 
overlapping sites (see key) in the proximal region of mIL-5.
a. wild-type IL-5/GM-CSF conserved region from -54 to -40 which 
binds NF-CLEOa (-42 to -49) and NF-CLEOb (-46 to -53), see text.
b. the same site showing the bases mutated in -1170mIL-5CAT.
c. consensus site for Pit-1 (on the positive strand).
d. consensus site for AP-1 (on negative strand).
It is also worth noting that within the IL-5/GM-CSF conserved region 
there are at least two other candidate regulatory sites, Pit-1 [Rosenfeld et al. 
1988; Ingraham et al. 1988] and AP-1 [Lee et al 1987], which also overlap the 
mutated bases in the -1170mIL-5CAT construct (Figure 4.14). Although Pit-1 
is a pituitary-specific factor it is a member of the POU family [Ruvkun and 
Finney 1991], along with the Oct factors, and thus may have additional 
representatives in lymphoid cells. The putative AP-1 site is of interest 
because of its demonstrated involvement in phorbol ester induction of 
transcription in many genes [Angel et al. 1987]. With respect to AP-1, the 
results of point mutations within the IL-5/GM-CSF conserved region on 
expression are of interest [Miyatake et al. 1991]. Point mutations at -50 (T to 
C) and -52 (T to G) upregulated basal and induced expression, while 
mutation at -51 (A to C) upregulated basal but not induced expression. AP-1 
may tolerate the -50 and -52 mutations as they are in less well conserved 
locations of the consensus site, but -51 corresponds to a critical base in the 
AP-1 consensus sequence. Thus it is possible AP-1 may play a role in the 
PMA-induced increase in transcription observed for mGM-CSF-CAT 
constructs although other factors, responsible for conferring low 
background, may also interact with this site.
The mIL-3 gene also appears to have a similar functional organisation 
to mIL-5 with a distal upstream enhancer and a proximal promoter region
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[Dr B. van Leeuwen, unpublished results]. In an experiment designed to test 
the utility of the upstream  regulatory region of mIL-5, a fragment covering 
the putative enhancer and silencer domains was ligated to a CAT construct 
carrying the proximal prom oter region of the related mIL-3 gene. This 
heterologous construct was made to test whether the IL-5 enhancer could 
confer tightly regulated inducible expression on the normally constitutive 
-208mIL-3CAT construct. In unstim ulated cells, the heterologous construct 
expressed almost as well as in stim ulated cells, thus it seems the mIL-5 
enhancer was not able to regulate the mIL-3 gene prom oter. This 
prelim inary result suggested that the mechanism(s) controlling IL-5 gene 
expression are specific for IL-5 although further investigation of this 
possibility is needed. To this end, the proximal region of GM-CSF may be 
more compatible with the IL-5 upstream  regulatory elements because it has 
at least one common element in the proximal region, i.e., the IL-5/GM-CSF 
conserved region d iscussed  above. A nalysis of an IL-5/GM -CSF 
heterologous construct may shed some light on the mechanisms involved 
in the mIL-5 enhancer a n d /o r  silencer function. If the various upstream  
elements interact with different proximal elements then such interactions 
may be more easily dissected in the heterologous construct particularly if not 
all proximal elements are present in the GM-CSF heterologous promoter. 
Such an approach may help focus mutagenesis of the mIL-5 proximal region 
and allow more rapid localisation of critical proximal elements.
In conclusion, the problems encountered with transient transfection 
assays w ere overcom e w hen the IL-5 reporter gene constructs were 
integrated into the chromatin by stable transfection. Thus a system has been 
established for ongoing analysis of mIL-5 regulatory regions.
CHAPTER 5
GENERAL DISCUSSION
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5.1 An overview of the project
The first step towards an understanding of the mechanism of 
transcriptional regulation of the inducible mIL-5 gene required 
identification of the general DNA regions in or around the gene which 
influence transcription of the gene in appropriate mIL-5 expressing cells. 
Cis-acting DNA regions exert their effect by binding specific trans-acting 
factors which may in turn function via direct or indirect interactions with 
the basic transcription factors of the preinitiation transcription complex at 
the promoter. Thus further and more specific delineation of the DNA 
sequences of cis-acting motifs within the general regulatory regions was the 
next step along the path leading to identification of the cognate trans-acting 
factors which are ultimately responsible for the transcriptional mechanism.
The work described in this thesis has established that the 5’ flanking 
region of the mIL-5 gene contains as-acting regions important for inducible 
expression of mIL-5 in a murine T cell clone. T cell clones are the closest 
analogue of a normal T lymphocyte available in tissue culture and thus are 
the best system for regulation studies of cytokine genes in vitro. T cell 
clones are difficult to grow and transfect and one important advance in the 
present work was the development of a successful stable transfection 
procedure for a murine T cell clone. A major finding which followed the 
successful transfection of the T cell clone was that the 5' flanking sequence 
of the mIL-5 gene only confers inducible expression on a linked CAT 
reporter gene when stably incorporated into a native chromatin 
environment. Subsequent analysis aimed at delineating the DNA 
sequences of cis-acting motifs was performed using the stable transfection 
assay in a T lymphoma line because it allowed more rapid screening of 
modified mIL-5-reporter gene constructs than was possible with the T cell 
clone. A distal enhancer region was initially localised between -965 and 
-1016. A more detailed study identified specific sites which were 
functionally important cis-acting motifs. These were a CTF/NFI site (-928 to 
-940) and a proximal promoter region containing a conserved sequence (-40 
to -54) which is common to the IL-5 and GM-CSF genes.
5.2 T cell clones are a better model for the study of cytokine
gene expression than continuous T cell lines
One of the limitations of using tumour-derived continuous T cell 
lines for regulation studies is that these cell lines do not retain the full 
complement of T lymphocyte cell surface receptors and thus have to be 
stimulated in an artificial manner [Weiss et al. 1986]. The continuous T cell 
lines may also have alterations in their signal transduction pathways 
relative to normal T cells [Niemeyer et al. 1989; Granelli-Piperno and Nolan 
1991]. Recent work investigating the signalling pathways which connect 
stimulation at the cell surface with altered transcriptional activity in the 
nucleus has highlighted the importance of the stimulating signal [Ullman et 
al. 1990; Koretzky et al. 1991; Fraser et al. 1991; Fraser and Weiss 1992; 
Schwartz 1992]. It has become apparent that cytokines can be differentially 
expressed in T lymphocytes depending on the particular signalling pathway 
invoked by stimulation [Bohjanen et al. 1990; Sander et al. 1991]. In the 
present work, the development of a stable transfection system for the study 
of cytokine gene regulation in T cell clones provides a good model for 
investigating the c/s-acting DNA elements which respond to particular 
signalling pathways invoked by the stimulation of different cell surface 
receptors.
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5.3 Stable transfection allows gene regulation to be studied in the
chromatin environment
Introducing regulatory DNA sequences of a gene into a cell in the 
form of a soluble supercoiled plasmid, i.e., by transient transfection, was an 
early method established for studying promoter regions but now seems a 
very artificial approach for investigating the activity of DNA sequences 
which normally function within the highly intricate structure of native 
chromatin. Nonetheless this technique has been successful in identifying 
c/s-acting DNA elements involved in the induction of transcription of 
many cytokine genes. However this project has clearly demonstrated that 
the transient transfection procedure was unsuccessful in the search for c/s- 
acting regions involved in the induction of the mIL-5 gene, even though 
basal transcriptional activity from the proximal promoter sequences and
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putative upstream silencer activity appeared to be functional.
The requirement for the chromatin environment and a relatively 
large amount of 5’ flanking sequence for inducible expression appears to set 
the mechanism for mIL-5 regulation apart from the related cytokines 
studied to date. Regulation studies on the most closely related cytokine 
genes, such as IL-2 [Hentsch et al. 1992], IL-3 [Park et al. 1993] and GM-CSF 
[Sugimoto et al. 1990; Nimer et al. 1990], have indicated that c is-acting 
regulatory elements capable of conferring inducible transcription are located 
within the first -400 bp of the transcription initiation site. Generally the 
regulatory mechanisms of IL-2, IL-3 and GM-CSF have been studied in 
continuous T cell lines by transiently transfecting supercoiled plasmids 
containing 5’ flanking sequences of the cytokine gene ligated to a reporter 
gene and stimulating the transfected cells with agents such as phorbol esters 
in conjunction with phytohemagglutinin or a calcium ionophore. A 
puzzling feature of these transient assays is that longer 5' flanking sequences 
actually cause a decrease in expression even under inducing conditions. 
The use of transient transfection has identified many c is -acting DNA 
elements, which function outside the native chromatin environment and 
are involved in the inducible mechanism of cytokine expression. Many of 
the cognate trans-acting factors have been characterised in detail [Ullman et 
al. 1990] some have also been cloned such as NF-kB. Most of the trans-acting 
factors are ubiquitous (e.g., AP-1, AP-3, Oct-1, NF-kB) and do not show cell 
type-restricted distribution although some are restricted to lymphoid cells 
[e.g., Oct-2, NFAT-1]. The mechanism of tissue-specific expression of the IL-2 
gene has been postulated to rely on particular interactions between 
combinations of both ubiquitous and cell type-restricted trans-acting factors 
[Hentsch et al. 1992]. In light of the finding that mIL-5 5' flanking sequences 
confer a different expression profile on a linked reporter gene depending on 
the type of transfection assay, it will be interesting to compare the transient 
expression data obtained for the related cytokine genes in continuous T cell 
lines with expression from stable transfection assays in cells more 
representative of T lymphocytes, i.e., T cell clones.
The stable transfection approach to regulatory DNA sequence analysis 
may overcome some of the difficulties encountered in the study of IL-4
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regulation. Regulatory data for IL-4 has been difficult to obtain because of 
limited availability of transfectable tissue culture cell lines which produce 
IL-4. The only regulatory data published to date for this cytokine has been 
obtained for the human IL-4 gene in the Jurkat human T cell leukemia cell 
line [Arai et al 1989; Li-Weber et al 1992; Abe et al 1992]. However, Jurkat is 
a poor model for studying inducible expression of IL-4 because the 
endogenous IL-4 gene expression in these cells is only detectable by PCR, not 
Northern blot, and is not tightly regulated, showing low level constitutive 
expression with only slight induction upon stimulation with PMA and 
calcium ionophore [Li-Weber et al 1992]. In the search for hIL-4 enhancer 
activity one group utilised a heterologous mGM-CSF promoter in their 
hIL-4-reporter gene construct [Abe et al 1992]. This approach may have the 
problem that there can be cytokine specific interactions of the enhancers and 
proximal promoter regions of the cytokine genes; an example of this was 
provided by the results obtained with the mIL-5/mIL-3 heterologous 
reporter construct tested in the present work. Hence the regulatory data 
obtained for hIL-4 needs to be verified in more appropriate cell models and 
with more complete IL-4-reporter gene constructs. The increasing 
availability of human T cell clones capable of expressing IL-4 [Umetsu et al 
1988; Parronchi et al 1991] may allow the establishment of a stable 
transfection system analogous to the one established in the present work for 
mIL-5.
5.4 Why is there a difference in expression between transient and
stable transfection assays of mIL-5-reporter gene constructs?
Despite trying a range of transfection techniques and different 
reporter systems no cis-acting DNA sequences capable of conferring 
inducible expression were detected when up to 10 kb of mIL-5 genomic DNA 
was tested in transient transfection assays. There were several possible 
explanations for this result:
i) The sequences responsible for conferring inducible transcription of 
the mIL-5 gene were outside the regions of the gene already tested or were, 
in the case of the PCR whole gene reporter construct, interrupted by the 
modification to the gene.
ii) The mIL-5 gene was transcribed constitutively and posttranscriptional
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regulation was responsible for controlling the expression of this cytokine.
iii) Too many copies of the enhancer DNA binding region were present 
in the nucleus of transiently transfected cells and this resulted in 
sequestration of the enhancer binding protein(s) which may normally be 
present only in low abundance [Jaiswal et al. 1987].
iv) Although RNA polymerases are believed to be able to transcribe DNA 
that is assembled into nucleosomes, initial access of the transcription 
complex to the promoter may be impeded by the core histone octamers 
[Kornberg and Lorch 1991; Felsenfeld 1992]. Nucleosomes may present a 
similar impediment for the tra n s-acting factors responsible for enhancer 
function. Thus there may be a requirement for the ordered positioning of 
nucleosomes within a given regulatory region [Hayes and Wolffe 1992]. The 
mIL-5 regulatory region may have such a requirement for positioned 
nucleosomes. However, transiently transfected supercoiled plasmid DNA 
constructs may be assembled into anomalous minichromosomes where 
misplaced nucleosomes prevent enhancer binding proteins from interacting 
with their cognate DNA recognition sequence(s) .
v) The free supercoiled plasmid DNA was not able to interact correctly 
with appropriate nuclear proteins. For example, nuclear matrix attachment 
regions have been proposed to function by targeting intervening DNA for 
transcription [van Driel et al. 1991; Bonifer et al. 1991]; however the plasmid 
DNA may be too small or not flexible enough to engage in such interactions.
vi) Commitment toward inducible tissue-specific gene expression may 
occur at the time of DNA replication. It is conceivable that events such as 
phased nucleosome positioning or hierarchical and coordinated assembly of 
DNA binding proteins may be critical for committing a gene for expression 
within a particular cell lineage. Such events may be restricted to occuring 
just after the replication fork has passed through a promoter or enhancer 
region allowing important DNA binding proteins to bind to the new 
daughter strands [Wolffe 1992; Felsenfeld 1992]. The transiently transfected 
nonreplicating plasmid DNA may not be able to take part in these 
potentially critical stages of the cell cycle.
Since inducible expression was observed for 5' mIL-5-reporter gene 
constructs of appropriate length after stable transfection, possibilities (i) and 
(ii) seem unlikely, and other work in this laboratory has also provided
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strong evidence that the IL-5 gene is transcriptionally regulated. The 
requirem ent for the chrom atin environm ent m eans that the relative 
contributions of the other possible explanations cannot be assessed at 
present as all would be overcome by stable integration followed by 
replication along with the host genome. Further studies of nucleosome 
positioning and matrix attachment sites may give information as to why 
this chromatin environm ent is important.
5.5 The emerging regulatory anatomy of the mIL-5 gene
5' truncations, in te rnal dele tions and site-d irec ted  in vitro 
mutagenesis were all employed to analyse the mIL-5 5' flanking sequence in 
constructs stably transfected into the thymoma line EL4. Inducible enhancer 
activity was found in the region -965 to -1016. A definite cut-off for 
enhancer activity was not found using truncation analysis, suggesting that 
the enhancer does not act via a single cis-acting motif. Two cis-acting sites 
were identified as playing important roles in the transcriptional regulation 
of the mIL-5 gene and were located more exactly. One of these, the CTF/NFI 
site at -928 to -940, was important for tightly controlled inducible regulation 
of transcrip tion, a role not previously a ttribu ted  to this family of 
transcription factors. A question arising from this result is whether the 
CTF/NFI site suppressor activity is due to the binding of a variant member 
of this transcription factor family which is devoid of a functional enhancer 
domain. The other cis-acting site identified in the present work was the 
IL-5/GM-CSF conserved region at -54 to -40 which was essential for 
expression. A lthough further work is required to identify the exact 
sequences constituting the mIL-5 enhancer and the proteins which mediate 
the activities at the CTF/NFI site and IL-5/GM-CSF conserved region, a 
pattern for the arrangem ent of mIL-5 cis-acting regulatory sequences has 
emerged. Figure 5.1 summarises this arrangement showing a distal region 
containing enhancer activity with a nearby silencer and a proximal element 
which mediates the distal activities.
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Distal Region Proximal Region
Enhancer region IL-5/GM-CSF conserved region
-1016-965 -54 -40
ü
-942 -930 
CTF/NFI 
Silencer element
Figure 5.1 Summary of the arrangement of czs-acting regulatory sequences 
in the 5' flanking region of the mIL-5 gene. The arrow represents the start 
site of transcription.
This arrangement of upstream enhancer sequences acting through 
proximal sequences that are part of or closely associated with the basic 
promoter region lends further support to the DNA looping models which 
have been suggested previously to explain enhancer action [Ptashne 1988; 
Mitchell and Tjian 1989]. In addition, modularity within enhancer regions 
appears to be common [Dynan 1989] with the SV40 enhancer being one of 
the earliest and best characterised [Zenke et al. 1986; Fromental et al. 1988].
An interesting corollary can be made between the spacing 
arrangement of the regulatory regions of the mIL-5 gene and those of the rat 
[Rosenfeld et al. 1988], bovine [Wolf et al. 1990] and human [Peers et al 1990] 
prolactin genes. All three prolactin genes have potent distal (>~1 kb 5' of the 
transcription initiation site) regulatory regions (-200-450 bp in size), which 
are comprised of multiple binding sites, and these distal regions require 
proximal elements to mediate their effect on transcription. An important 
feature of prolactin transcriptional regulation which may have some 
significance for IL-5 expression is that a highly conserved member of the 
POU family of transcription factors [for review see Ruvkun and Finney 
1991], Pit-1, is responsible for pituitary-specific expression of prolactin genes 
[Radovick et al. 1992]. The IL-5 sequence was also shown to contain a POU 
site in the IL-5/GM-CSF conserved region and this site was very similar to 
Pit-1. Although Pit-1 is found specifically in anterior pituitary cells the 
binding site may be recognised by Oct-2 and mutation of only two bases in a 
Pit-1 site carried in a reporter gene construct has been shown to convert the 
reporter construct to lymphoid-specific expression [Elsholtz et al. 1990].
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Thus investigation into the involvement of POU transcription factor family 
members in the tissue-specific inducible expression of IL-5 will be of 
considerable interest.
The work described in this thesis provides a foundation for further 
interesting studies on the transcriptional mechanism of the mIL-5 gene. 
The next step will involve testing to see if the ds-acting sequences identified 
by regulation studies in EL4 also function in D10.G4.1. Ultimately transgenic 
mice will be the best model for answering the question of whether there are 
additional mIL-5 genomic sequences required for tissue-specific expression.
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